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Abstract
Leptin is a 16-kDa protein that is primarily secreted by adipose tissue. It affects body 
mass regulation by constituting part of the adipostat, that acts to alert the brain of the 
body’s stored energy levels. Additional roles in immune function, reproduction and 
inflammation are known.
Genetic studies of single nucleotide polymorphisms (SNPs), that exist in the 
extracellular domain of the leptin receptor gene, were undertaken in a population of 
European Caucasian postmenopausal women to investigate associations with 
indicators of adiposity. Homozygosity of the G allele of the LYS109ARG SNP was 
associated with lower mean fat mass levels and BMI. Furthermore, linkage 
disequilibrium was detected between this SNP and GLN223ARG, which in previous 
studies was also associated with indicators of adiposity. No associations were found 
between the LYS656ASN SNP and the tested phenotypes.
To complement genetic studies of the leptin receptor, cDNA constructs representing 
different combinations of the alleles for SNPs in the leptin receptor were generated and 
subsequent expression of protein variants was conducted in COS-7 cells. Using a 
radioactive ligand-binding assay, labelled leptin was shown to specifically bind to the 
LYS109ARG223 and GLN223ARG protein variants, thereby testing the effect of the 
GLN223ARG mutation on LBA Preliminary data, suggest that the ARG allele 
appeared to bind less leptin than the GLN.
Genetic studies were carried out on polymorphisms in related candidate genes. A 
promoter polymorphism (G -2548 A) in the leptin gene was associated with lower 
mean BMI and leptin levels in a cohort of European Caucasian postmenopausal 
womea
Individuals who lacked the 2 repeat allele of the variable number tandem repeat 
(VNTR) polymorphism present in intron two of the interleukin 1 receptor antagonist 
gene had an association with lower leptin levels but not BMI or fat mass. This suggests 
a potential feedback and / or cross-talk mechanism between leptin and members of the 
IL-1 family of cytokines in processes other than adiposity. Immunity and inflammation 
are processes where the interleukin one receptor antagonist protein has a prominent 
role and in which the function of leptin is increasingly being investigated, therefore an 
interaction between the two cytokines may be specific for these conditions.
The TNF alpha (G -308 A) SNP was also investigated but no associations were 
observed between this SNP and the phenotypes in the postmenopausal cohort.
To investigate the influence of the leptin receptor gene in conditions at the opposite 
end of the body weight spectrum to obesity, a case-control association study was 
undertaken to compare allele frequencies of the LYS109ARG, GLN223ARG and 
LYS656ASN leptin receptor SNPs between anorexic women and controls. No 
significant differences were observed in allele or haplotype frequencies.
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1.1 Adiposity
Adiposity is the level of fat present in the body. The opposing processes of energy 
intake and energy expenditure set this level. Precise and definite mechanisms are 
employed to measure and hence regulate levels of adiposity. Any elements which lead 
to a dysregulation of this system will affect body composition and health status.
1.1.1 Obesity
Obesity is one of the most common and serious health problems faced by industrialised 
societies. In essence, it becomes manifest when energy intake (via food) exceeds 
energy output over a period of time. The epidemic of obesity is most striking in the 
USA with 63% of men and 55% of women being classified as overweight (Must et al, 
1999) and figures are rising.
It has been associated with many diseases such as coronary heart disease, type 2 
diabetes mellitus, and osteoarthritis. Although the exact mechanism for the association 
with these conditions has not been established, the associated life expectancy, quality 
of life and health cost issues are a relevant and major cause for concern.
Obesity is accompanied by complications such as hypertension and atherosclerosis, 
which can lead to heart failure. An analysis of the relationship between adiposity and 
incidence of heart failure was undertaken by Kenchaiah et a l (2002) in the 
Framingham Heart study. In this study, a graded increase in the risk of heart failure 
with increasing obesity was highlighted among the 5881 participants.
A study of more than 11,000 women carried out in the US showed that measurements 
of increasing obesity were the dominant predictor of type 2 diabetes (Colditz et al,
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1995) although unequivocal medical evidence explaining the relationship is not yet 
known.
Skeletal systems may be affected by increased weight bearing. Hip and knee 
osteoarthritis is most common in white Europeans compared to other groups with 
approximately 7-25% of Caucasian individuals over 55 years of age suffering from the 
disorder in the hip. Felson and colleagues (1998) identified strong epidemiological 
evidence that increasing levels of obesity lead to susceptibility of knee osteoarthritis 
and a more moderate influence on osteoarthritis of the hip.
Fat distribution has different characteristics associated with gender. This is anecdotally 
observable with men tending to have more abdominal fat ('apple-shape') whereas 
women tend to have more fat on their hips and buttocks ('pear-shape’). Furthermore, 
changes in body fat distribution occur in women through reproductive cycling and 
childbearing (For review see, Legato, 1997). The different distribution of adipose 
tissue between sexes may have unique health implications.
It is difficult to associate many benefits with obesity. Yet it has been hypothesised that 
natural selection favoured a thrifty genotype in human history where a lower rate of 
energy expenditure and / or hyperphagia would lead to increased fat stores during 
times of food surplus. Body fat reserves would then be advantageous during times of 
food shortage (Heel, 1962). Unfortunately, in modem western societies where food is 
plentiful and physical exercise in the general population is on the decline this 
adaptation would no longer be beneficial resulting in marked obesity.
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1.1.2 Underweight
At the other end of the body composition spectrum is the underweight phenotype. 
Underweight is associated with a variety of health issues including loss of reproductive 
function, depressed immunological responses and starvation (Hsu, 1980)
One of the most distressing manifestations of underweight is that of anorexia nervosa 
(AN). Classification criteria include maintenance of bodyweight at 85% or less of 
normal weight adjusted for age and height, amenorrhoea in female sufferers and an 
intense fear of weight gain. Indeed, behavioural patterns encompassing perfectionism 
and obsessionality are common amongst AN sufferers (Bulik et al, 2003). In addition, 
AN can be further classified into restricted eating and binge/purge sub-types. As being 
underweight is a criteria for AN, individuals suffer the physiological consequences of 
starvation, and mortality figures approaching 16% have been recorded after a 20 year 
follow up study (Crisp et al, 1992).
1.1.3 Measurements of adiposity
There are several methods of measuring indicators of adiposity, which are used in 
studies, with each method having associated drawbacks and benefits. A frequently used 
indicator is body mass index (BMI), where the weight of an individual in kilograms is 
divided by the square of their height in metres. This is a simple measurement to carry 
out but does not differentiate between fat mass and lean mass (Table 1.1 highlights 
World Health Organisation weight classifications taken from epidemiological data).
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BMI kg/m2
<18.5
18.5-24.9
25-29.9
30-39.9
>40
WHO classification 
Underweight
Grade 1 overweight 
Grade 2 overweight 
Grade 3 overweight
Popular description 
Thin
Healthy, normal
Overweight
Obese
Morbidly obese
Table 1.1: Classification of weight based upon BMI measurements
Another frequently used measurement is skinfold thickness, which can be carried out 
using callipers at multiple surface sites on the body. Specifically the SF8 value 
measures the sum of skinfold thickness at eight different points of the body but is 
unable to measure abdominal or intramuscular fat.
Bio-impedance measurements determine conductance of an electrical impulse through 
the body based on the principle that lean mass conducts better than fat mass. This is a 
simple and effective device, but is no more accurate than the previous tests. Variation 
in measurements can result from the point during the day at which readings are taken 
and also hydration levels at time of measurement.
Dual energy x-ray absorptiometry (DEXA) measurements afford accurate 
determination of fat and lean mass but require specialised equipment and handling 
making them impractical in field measurements.
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1.1.4 Heritability of body composition
The role of heritability in the susceptibility to obesity and AN has been examined. Twin 
studies of adults from industrialised nations have resulted in heritability estimates 
varying between 50 and 80% using BMI as an indicator of obesity (Stunkard et al, 
1986, Allison et al., 1994, and Borecki et al., 1998), with lower values for family 
studies (For review, Comuzzie and Allison, 1998). Such variation is thought to come 
from age-specific effects of genes on BMI, as well as gender specific differences 
(Korkeila et al, 1991). Twin studies in children show the highest heritability, with 
about 80% for BMI (Pietilainen et al, 1999).
Results of twin studies of eating disorders, including AN, have been less consistent 
than studies of obesity. Observations of higher concordance rates for AN amongst 
monozygotic twins versus dizygotic twins (differentiating between shared genes and 
environment versus shared environment) was not observed by Walters and Kendler, 
(1995) using a general twin registry. However, Treasure and Holland (1994) found a 
higher level of AN amongst monozygotic twins versus dizygotic in a more targeted 
study using twin registries, advertisements and clinical populations. As such, the 
genetic and environmental contribution to eating disorders requires clarification and 
new twin studies are in progress.
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1.2 The Adipostat
Located in the brain, the hypothalamus is the central mediator of regulation of body 
composition. To fulfil this role, it is able to detect the level of adiposity via a factor 
secreted by adipose tissue into the blood stream After which, this factor is able to 
interact with the hypothalamus and activate specific downstream signals which 
moderate food intake and energy expenditure. This concept was historically termed as 
the adipostat (Kennedy, 1953).
1.2.1 Main players of the Adipostat
There are three distinct pathways that contribute to the adipostat as a whole. Neural 
mechanisms, that are activated as a result of gut distension following food intake, are 
undoubtedly involved in restricting further food intake by stimulating the appropriate 
areas of the brain (Tack et al, 2002). Also gut hormones (for example PYY 3-36), 
which are released postprandially from the gastrointestinal tract in proportion to the 
calorie content of the meal, reduce food intake (Batterham et al., 2002).
Thirdly, cytokines that are secreted from adipocytes (fat cells) into the blood stream in 
direct relation to the body’s fat reserves and level of food intake.
Leptin is a 16 kilodalton (kDa) cytokine, which is primarily expressed by adipocytes, 
which secrete the protein into the blood circulation. When food is scarce, the 
adipocytes secrete less leptin into the bloodstream It is also released from the 
adipocytes (above basal levels) a period of time after food intake.
Leptin is able to cross the blood brain barrier and specifically bind to leptin receptors 
within the arcuate nucleus region of the hypothalamus of the brain. The hypothalamus
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is crucial in maintaining body weight control and the main area where leptin exerts its 
actions by informing the brain about the status of energy reserves. Hence, it is the 
blood borne factor, first postulated by Kennedy (1953). There are two specific cell 
types within the arcuate nucleus region of the hypothalamus that have a high 
concentration of leptin receptor and to which leptin binds. These cell types are able to 
express the pro-opiomelanocortin (POMC), agouti-related protein (AGRP) and 
neuropeptide Y (NPY) hormones. Cells that release NPY (a 36 amino acid peptide) 
stimulate food intake via the hormone binding to a sub-set of cells called the 
paraventricular nucleus activating specific downstream signals (Stephens et al, 1995). 
Stephens and colleagues (1995) demonstrated that administration of recombinant leptin 
to lean and ob/ob mice suppressed food intake by having an inhibitory effect on the 
amount of NPY released. This was experimentally determined because the area of the 
arcuate nucleus, that stained positive for an antisense ribonucleotide probe specific for 
NPY messenger RNA, was decreased after leptin delivery.
Various POMC-derived melanocortin peptides including a-melanocortin stimulating 
hormone (a-MSH) are able to act on a cell sub-set within the lateral hypothalamic 
area, inhibiting food intake (Fan et al, 1997, Elias et al, 1999).
At the molecular level, the binding site for a-MSH is the melanocortin 4 receptor 
(Mc4R). a-MSH behaves as a high affinity agonist, initiating downstream anorexigenic 
responses to this receptor. Using similar techniques to those that were used on the 
NPY pathway, leptin binding was shown to have a stimulatory effect on this pathway 
in rats (Schwartz et a l, 1997).
The agouti related protein (AGRP) is a potent antagonist of Mc3R and Mc4R 
(Ollmann et a l, 1997). Levels of this protein are reduced subsequent to leptin
administration and ubiquitous expression of human AGRP in transgenic mice results in 
obesity. By competing with the same receptor sites as POMC derived hormones, 
AGRP inhibits the satiety effects of leptin.
Evidence suggests that pathways involving NPY, POMC and AGRP participate in an 
integrated system within the hypothalamus, contributing to the adipostat mechanism. 
Considering the combined affects of leptin on this pathway, leptin can be described as a 
satiety factor in that it reduces the desire to keep eating after food intake (Gibbs et al., 
1973) and so plays a key role in regulating the bodies’ energy balance. Table 1.2 lists 
several neurotransmitters that affect feeding behaviour.
Stimulatoiy Inhibitory
Neuropeptide Y 5 -hy droxytiyptamine
Orexin Corticotrophin releasing factor (CRF)
Melanin concentrating hormone CART
Agouti-related protein a-melanocyte stimulating hormone
Galanin Glucagon-like peptide 1
Table 1.2 Neuropeptides that affect feeding behaviours
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1.3 Leptin and the Leptin Receptor
1.3.1 Identification and organisation of the ob (leptin) gene
There are at least five strains of mice that show an obese phenotype. The autosomal 
recessive, obese strain of mice {ob) identified in the 1950s is associated with obesity 
and type II diabetes (Ingalls et al., 1950) (see figure 1.1).
Parabiosis is a technique that can be used to investigate such phenotypes by employing 
surgical techniques to cross-circulate blood between mutant and wild type mice. This 
procedure demonstrated a deficiency in a blood-bome factor that regulated food intake 
and metabolism by virtue of the fact that cross-circulation ameliorated the ob mouse 
phenotype (Coleman et al., 1978). However, the blood-bome factor was not actually 
identified until 1994, when a positional cloning approach to locate and identify the 
mouse obese gene was undertaken. To achieve this, a genetic and physical map of the 
region was obtained followed by isolation of the gene and detection of the causative 
mutation (Zhang et al., 1994). For the positional cloning, a yeast artificial chromosome 
(YAC) contig was generated spanning a region on mouse chromosome 6 known to 
contain the gene due to preliminary localisation by RFLP analysis. The Critical region 
containing the gene was further refined, and DNA from the critical region cloned into 
exon-trapping vectors. Putative exons were screened against corresponding RNA in 
northern blotting experiments and one particular exon hybridised to a 4.5kb RNA 
species from white adipose tissue only. This transcript was absent in ob/ob mice. 
Subsequent isolation of cDNA clones (mouse leptin cDNA sequence is available at 
http://www.ncbi.nlm.nih.gov via the GenBank database, accession number 
NM008493) revealed a 167 amino acid open reading frame (ORF)
10
Figure 1.1: Picture of ob mouse compared to wild type mice (Picture 
from front cover of Nature, volume 372, issue 6505)
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which in ob/ob mice contained a C to T base change at codon 105 coding for a 
premature stop codon. The human genome organisation (HUGO) subsequently named 
the mouse gene Lep. They proceeded to hybridise the mouse Lep cDNA to a human 
adipose tissue cDNA library, isolating homologous clones with 84% amino acid 
identity in the ORF between the two species (human leptin cDNA accession number 
NM000230). Leptin protein delivered intraperitoneally to ob/ob mice reduced feeding 
and body weight (Weigle et al., 1995), proving that the gene caused the ob phenotype. 
Following the breakthrough of locating the gene, He and colleagues (1995) determined 
its genomic organisation and promoter activity. The gene comprised a maximum of 4 
exons (a minority of the Lep mRNA accommodated an extra untranslated exon) with 
the coding sequence present in exons 2 and 3 (see figure 1.2). Using successive 
deletion mutants of the promoter sequence (cloned into a luciferase reporter vector to 
analyse changes in promoter activity), the 762-bp promoter was shown to have a 
minimal promoter region of 161bp. The minimal promoter contained Spl and 
CCAAT/enhancer-binding protein (C/EBP) motifs.
The human homologue (named by HUGO as LEP) spanned 20kb, with 3 exons 
separated by 2 introns (10.6kb and 2.3kb respectively), and the promoter region 
contained a TATA box-like sequence and several cis-acting regulatory elements 
including C/EBP motife but also an AP-2 binding site and GC boxes (Isse et al., 1995). 
Moreover, Isse and colleagues (1995) assigned the chromosomal position of the 
human LEP gene by fluorescence in situ hybridisation using probes specific for the ob 
gene, these hybridised at position 7q31.3. This agreed with comparative mapping of 
mouse chromosome 6, containing the LEP gene, to a syntenic portion on human 
chromosome 7q that was later refined to position 7q31.3 by genetic mapping (Green 
et al., 1995).
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1.3.2 Leptin protein structure
Leptin is a 16-kDa protein expressed and secreted by the adipose tissue. Using X-ray 
crystallography, Zhang et al., (1997) determined the structure of the protein (see figure 
1.3). For this, they took advantage of an introduced glutamine to tryptophan amino 
acid substitution at codori 100 that dramatically improved the ability of the protein to 
crystallise whilst still maintaining its biological activity. Cysteine residues at codons 96 
and 146 were shown to form a disulphide bond and mutation of either rendered the 
protein biologically inactive. This indicates that disulphide formation is important for 
structure folding and receptor binding. An overall four-helix bundle structure was 
revealed that is shared with members of the long-chain helical cytokine family such as 
G-CSF, LIF and IL-6. These structures consist of four antiparallel alpha-helices 
arranged in a twisted helical bundle forming a hydrophobic cylindrical core. The 
similarity of these ligands and the sequence similarity of their receptors are suggestive 
of similar mechanisms of ligand receptor interaction.
1.3.3 Identification and organisation of the leptin receptor gene
Upon discovery of the leptin gene, the tools became available to locate its native 
receptor. Tartaglia and colleagues (1995) generated a series of leptin-alkaline 
phosphatase (AP) fusion proteins and initiated a binding survey of cell lines and tissues. 
Leptin binding sites were located to the mouse choroid plexus. Using this piece of 
information, a cDNA expression library was constructed from the tissue, screened with 
a leptin-AP fusion protein and a leptin receptor gene identified
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Figure 1.3: Three dimensional model of the human leptin protein structure containing 
four anti-parallel alpha helices (red, blue, green and turquoise) which form a barrel 
structure with a hydrophobic core (Picture derived from Zhang et al., 1997).
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(mouse leptin receptor accession number NM146146 and classified as Lepr by 
HUGO). By hybridising the mouse cDNA to a human cDNA library, a human 
homologue was found (accession number NM002303 and named LEPR by HUGO). It 
was syntenically mapped, in relation to the db locus in mice, to chromosome lp.
In an effort to identify the gene responsible for the mouse db/db phenotype (which 
exhibits obesity, hyperphagia and insulin insensitivity), Lee and colleagues (1996) 
generated refined physical and genetic maps at the db locus.
Furthermore, they utilised exon trapping and cDNA selection from mouse 
hypothalamus to identify candidate genes from the db region. Several cDNA clones 
contained sequence identical to the extracellular domain LEPR sequence. Some of 
these clones varied in their C-terminal sequences beyond the point of the 
transmembrane domain suggestive of splice variants coding for varying length 
cytoplasmic tails and were designated Ob-Ra to Ob-Re. The study identified that RT- 
PCR products from hypothalamic RNA in db/db mice had a longer fragment length of 
Ob-Rb whilst sequencing of these products indicated a 106-bp insertion between a 
splice donor site at codon 889 and acceptor site at codon 890. A G—»T mutation 108- 
bp downstream from codon 890 was shown to result in the creation of a splice donor 
site enabling incorporation of the 106-bp sequence. This inserted sequence coded for a 
termination codon five amino acids after the splice, junction and so the mutant protein 
lacked most of the cytoplasmic region in db/db mice. This indicated a lack of 
downstream signalling following leptin binding and provides an explanation for the 
obese phenotype seen in db/db mice.
The Zucker (fa) rat is another rodent model of obesity that has a mutation located in 
the leptin receptor gene. Chua and colleagues determined that the gene responsible for
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the fa  rat phenotype was the same gene responsible for the db mouse by a combination 
of genetic mapping, and genomic Southern blot analysis of fa  and db rodent DNA with 
a mouse extracellular domain leptin receptor cDNA probe.
The fa  rat was subsequently shown to be homozygous for an A to C DNA base 
missense mutation that introduces a glutamine to proline amino acid substitution at 
codon 269 (Philips etal., 1996, White etal., 1997).
In humans, Chung and colleagues (1996) developed a refined genetic map of human 
chromosome lp in the region of LEPR by radiation hybrid mapping. Using a panel of 
individuals from a family, 18 polymorphic markers were genetically mapped to 
chromosome lp31 relative to LEPR with the aim of identifying new markers for the 
analysis of human pedigrees segregating with obesity.
1.3.4 Leptin receptor protein structure
The murine leptin receptor was classified as a single membrane-spanning receptor. A 
mature extracellular domain of 816 amino acids (minus a putative 22 amino acid signal 
sequence for peptide secretion) was determined from the cDNA sequence followed by 
a predicted 23 amino acid transmembrane domain (Tartaglia et al., 1995).
The amino acid sequence is most closely related to the gpl30 signal-transducing 
component of the IL-6, receptor with conservation of the characteristic cysteine and 
Trp-Ser-X-Trp-Ser motifs (Tartaglia et al., 1995). Sequence comparison places the 
receptor within the class I cytokine receptor family together with the IL-6 receptor and 
growth hormone receptor (GH-R). The extracellular regions of these receptors are 
characterised by the presence of multiple domains including the cytokine receptor 
(CK), Ca2+binding fold (C2) and fibronectin type III (F3) domains (see figure 1.4).
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High-resolution structures for GH-R provide good evidence for a ligand-binding 
region within a combined CK-F3 domain (Wells and de Vos, 1996). Although the 
crystal structure for the leptin receptor has not been determined, the extracellular 
domain contains two repeat CK-F3 domains highlighting potential ligand binding sites. 
Using COS-7 cells, Liu et al. (1997) expressed and characterised a soluble human 
leptin receptor containing the extracellular domain only. Immunoprecipitation of the 
receptor revealed a product with a molecular mass of approximately 130-150 kDa, 
which is higher than the 92-kDa protein predicted from the coding sequence alone. 
This suggests a high level of post-translational modification. Indeed, Haniu et al,
(1998) purified a human leptin receptor from Chinese hamster cells and detected N- 
glycosylation approximating 36% of the total protein mass by digesting the receptor 
with the enzyme iV-glycanase. Alternatively O-glycosylation, as detected by O- 
glycanase treatment was minimal.
In humans and mice, there are several isoforms of the leptin receptor with identical 
extracellular domains and varying length intracellular domains. In humans, differentially 
spliced transcripts have been observed with one 'long' and three variant isoforms of the 
receptor containing the complete extracellular domain and transmembrane domain, but 
varying sizes of the intracellular domain (Barr et al., 1999). The different forms of the 
leptin receptor are termed as ObRa through to ObRe. The longest form (ObRb) 
contains a 303 amino acid tail, including two 12 amino acid JAK box domains that are 
required for JAK dependent signalling. The three variant isoforms have much shorter 
intracellular tails of 34 (ObRa), 44 (ObRc) and 96 (ObRd) amino acids each and only 
contain one JAK box domain. The fifth isoform is the soluble isoform, which is the 
extracellular domain alone (Lee et al., 1996). Unlike mice, humans do not have 
mRNA coding for the soluble form, instead it is generated by proteolytic cleavage of
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membrane-anchored leptin receptors by a metalloprotease (Maamra et al., 2001). It is 
the only isoform, which is present systemically. In the blood it is able to bind to leptin 
and may play a role in modulating receptor signalling by competing for ligand binding 
and it may also reduce leptin degradation and clearance in serum (Huang et al., 2001). 
It has been stoichometrically demonstrated that leptin binds to its receptor in a 2:2 
ratio (Devos et al, 1997), i.e. two leptin molecules bind to two receptor molecules.
This suggests a similar binding mode to that of granulocyte-colony stimulating factor 
(G-CSF) with its receptor (also a member of the class 1 cytokine receptor family). 
Hiroike and colleagues (2000) used the tertiary structure of G-CSF to build a 
computer model of the complexed leptin: leptin receptor structure in order to 
determine aspects of ligand binding. The model demonstrated a major and minor 
interface for both 1:1 leptin: leptin receptor complexes. The model also showed that 
site-directed mutations incorporated into the leptin protein (Verploegen et al., 1997, 
Imagawa et al., 1998, Boganet et al., 1998) which were present within these interfaces 
led to reduced binding activity. These experimental and modelling results could 
therefore contribute to a rational drug design.
1.3.5 Leptin receptor signalling
Belonging to the class I cytokine receptor family, the leptin receptor lacks intrinsic 
tyrosine kinase activity. As such, it requires the recruitment and activation of receptor- 
associated kinases to initiate signal transduction pathways by phosphorylating tyrosine 
residues present in the receptors' cytoplasmic domain. Of the several isoforms, the 
long and short membrane-bound forms are the most predominant in tissues and are 
conserved between humans and mice, with the long form but not the short form having 
signalling capacity for most signalling pathways. To initiate specific down-stream
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signalling, ligand binding to the extracellular domain is necessary. Yet it is interesting 
to note that several papers (Devos et al, 1997, White et a l, 1999) indicate a ligand- 
independent ability of the receptors to homo-oligomerise. Specifically, White and 
colleagues demonstrated that pre-formed leptin receptor complexes were formed 
following receptor immunoprecipitation from human embryonic kidney (HEK) 293 
cells transfected with vectors encoding the long form of the protein. Ligand treatment 
of these cells minimally altered levels of oligomerisation. This would suggest that 
ligand binding is not essential for receptor oligomerisation but would presumably be 
required for alteration of signalling capacity. More recently, Couturier and colleagues 
(2003) used bioluminescence resonance energy transfer techniques to show that leptin 
receptors exist as constitutive dimers but that leptin induces conformational changes in 
the pre-existing receptor dimers.
A signalling pathway that the leptin receptor is able to activate is the JAK/STAT 
pathway. Leptin binding leads to a conformational change in the intracellular domain of 
the receptor enabling juxtaposition of JAK proteins, which phosphoiylate each other 
and specific tyrosine residues of the receptor. Then, signal transducer and activator of 
transcription proteins (STATs) interact with the phosphoiylated residues, are 
activated, forming hetero- or homodimers and translocate to the nucleus where they 
modulate transcription of target genes including c-fos and c-jun.
Both the fa/fa rat and db/db mouse have mutations that affect JAK/STAT signalling 
and analysis of these models stimulated investigation of the pathways involved. The 
mutation in db/db mice dramatically reduces expression of the long form of the 
receptor. Using electrophoretic mobility shift assays (EMSA), in which STAT proteins 
bind to specific DNA sites and exhibit reduced mobility on PAGE gels, Ghilardi and
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colleagues (1996) showed that STAT 3, 5 and 6 were activated in normal mice but 
not in the case of db/db mice.
Expression vectors containing the leptin receptor with the fa  point mutation in the 
extracellular domain, were able to constitutively activate transcription via STAT 1 and 
3 independently of ligand binding (White et a l, 1997). STAT5B was not, however, 
constitutively activated and ligand-induced STAT5B activation was greatly reduced 
compared to the wild type receptor. Taken as a whole, these results suggested that the 
mutation induces a conformational change that partially mimics the ligand-bound state, 
enabling ligand-independent activation of ST ATI and 3 but not STAT5B.
The long form of the receptor contains the largest number of sequence elements that 
recruit JAKs. Having two conserved box motifs (which specifically recruit JAK 
proteins) compared to only one for the other isoforms (Baumann et a l, 1996, Ghilardi 
etal., 1997).
Using site-directed and deletion mutagenesis strategies towards different isoforms of 
the murine leptin receptor, both Kloek and colleagues (2002) and Bahrenberg and 
colleagues (2002) reported that loss of the box 1 domain and immediate surrounding 
residues terminated JAK2 phosphorylation. Although the shorter forms of the receptor 
contain the box 1 domain, they lack these critical surrounding residues and fail to 
signal via the JAK2 kinase family.
In vitro studies have shown that activated JAKs, phosphorylate tyrosine residue -1138 
on the long form of the murine receptor enabling recruitment of STAT3, and tyrosine 
residue 985 which recruits the SH2 domain containing protein, SHP-2 (Li et al, 
1999). Banks et al (2000) presented data suggesting that SHP-2 controls activation of 
extracellular factor-regulated kinases (ERKs), a set of serine/threonine kinases 
involved in regulation of gene transcription and cellular physiology. The methods used
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to measure this relied upon detection of phosphorylated proteins, in this instance from 
the ERK pathway, whilst specific accumulation of mRNA transcribed from the c-fos 
gene was detected as well. Interestingly, in the same study mRNA accumulation of 
suppressor of cytokine signalling 3 (SOCS3) mRNA was detected after STAT3 
activation suggesting that at least one function of STAT3 activation is to inhibit 
signalling by increasing levels of SOCS3. SOCS proteins have been shown to inhibit 
cytokine signalling. They contain a central SH2 domain that may inhibit signalling by 
binding to phosphorylated JAK proteins and/or by occupying phosphorylated residues 
on the receptor and indeed SOCS3 is recruited by the tyrosine residue at position 985 
(Banks etal., 2000, Bjorbaek etal., 2000).
In vivo and in vitro studies in mice have shown that following leptin treatment, the 
tyrosine phosphatase, protein tyrosine phosphatase IB (PTP1B) attenuates signalling 
by dephosphorylating JAK2. This subsequently blocks STAT3 phosphorylation and 
STAT3 induction of gene transcription (Cheng et al, 2002, Kaszubska et al, 2002, 
Zabolotny et al, 2002). By reducing the expression of genes that are up regulated by 
leptin indicates that PTP1B negatively regulates leptin signalling. Inhibitors of PTP1B 
may therefore reduce leptin resistance, making it a potential target for drug therapies 
against obesity.
Chinese hamster ovary (CHO) cell lines expressing the short or long form of the rat 
leptin receptor were shown to have enhanced levels of tyrosine phosphorylation of 
STAT3, in long form expressing cells only, and mitogen-activated protein kinase 
(MAPK), in long and short form expressing cells. The data suggests that the short 
form is actually able to transmit signals via the MAPK pathway (Yamashita et al, 
1998). MAPKs are known to be stimulated by several growth factors and in turn
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phosphorylate many transcription factors and cytoplasmic proteins involved in a 
number of cell functions.
The involvement of leptin signalling in biological processes other than weight 
regulation has become apparent. Recent studies in mice by Bates and colleagues 
(2003) demonstrated that substitution of an intracellular tyrosine residue, which is 
required for STAT3 signalling led to targeted disruption of STAT3 signalling in the 
long form of the receptor. The mice were obese but fertility was maintained. This 
result provided evidence for different biological effects resulting from different 
signalling pathways.
Such insights into the regulation and types of leptin receptor signalling will 
undoubtedly be explored further as studies continue and could highlight any potential 
dysregulation involved in various conditions (see figure 1.5 for overview of leptin 
receptor signalling).
1.3.6 Leptin and leptin receptor levels in humans
Leptin is expressed and secreted by adipocytes into the blood stream A circadian 
rhythm (Sinha et al, 1996) for leptin has been observed with circulating levels peaking 
at midnight and the early hours that could help to suppress appetite during the night. 
Gender is another factor which affects leptin levels, with women having higher levels 
for a given fat mass compared to men (Schwartz et al., 1996). This difference is likely 
to be influenced by sex hormone variation between the sexes and indeed a reduction in 
leptin levels is observed after the menopause (Rosenbaum et al, 1996) possibly 
reflecting the reduction of female sex hormones. Gender specific differences in leptin 
mRNA expression have also been observed, with females having a higher ratio of 
subcutaneous to intra-abdominal leptin mRNA expression (Montague et al, 1997a).
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Figure 1.5: Schematic representation of model of signalling for the long form of the 
leptin receptor containing the two conserved box motifs required for interaction with 
JAK2. Upon ligand stimulation, JAK2 phosphorylates tyrosine residues on the receptor. 
These residues recruit STAT 3, which is tyrosine phosphorylated by JAK2, whereupon 
it translocates to the nucleus to mediate transcription of socs3, c-jun and other genes. 
SOCS3 protein ultimately feeds back by inhibiting JAK2 and binding to the 
phosphorylated tyrosine residue at position 985.
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Leptin levels increase proportionally with increasing BMI and percentage body fat 
(Considine et al, 1996). Basal levels of leptin are markedly increased in obese 
individuals. This state of 'leptin resistance' is characteristic of obesity and suggestive of 
a lack of signalling response despite the high levels of leptin. Brain perfusion studies in 
mice have established that leptin transport into the brain is a saturable mechanism 
(Banks et al., 2000, Maness et al, 2000). At high serum leptin levels, saturation of the 
transport mechanism may impart a rate limiting effect which may limit the cytokines 
satiety effects in the brain contributing to leptin resistance (Banks, 2003).
Soluble leptin receptor levels, as detected by enzyme linked immunosorbent assay 
(ELISA), are inversely correlated with percentage body fat (Ogier et al, 2002, Van 
Dielen et al, 2002) with soluble receptor levels being lower in obese and over-weight 
individuals. Individuals in Ogier’s study undertook a three-month low calorie diet and 
an increase of soluble receptor levels with concurrent loss of fat mass were detected. 
One possible explanation of these results that requires investigation is that higher 
circulating levels of leptin down-regulate soluble leptin receptor release whilst high 
receptor levels may enhance leptin action in lean subjects.
Interestingly, in the same study an increased soluble receptor level was seen in men 
when compared to women, but not only in the obese state. On the other hand, Quinton 
et al (1999) noticed no sex difference in leptin binding activity as determined by a 
radioactive leptin-binding assay of serum samples from a sample in which a range of 
BMI was represented. It is possible that the combination of lean and overweight 
individuals in this study design may explain the discrepancy with the results obtained by 
Ogier and colleagues.
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1.3.7 Other activities of the leptin system
Leptin has been shown to be expressed from a range of tissues other than adipose 
tissue. These include the stomach (Breidert et al, 1999), skeletal muscle (Wang et al, 
1998) and umbilical cord (Akerman et al, 2002). As a result, research has opened up 
into the peripheral activities of leptin distinct from its role in the central regulation of 
appetite.
1.3.8 Reproduction
A major focus area of research aside from weight regulation is the involvement of 
leptin in reproductive function. An indication of this comes from the observation that 
leptin deficient ob/ob mice are infertile. Administration of exogenous leptin to the 
hypothalamus, causes maturation of the reproductive system and restoration of fertility 
(Weigle et al, 1996). In humans, expression of leptin and the leptin receptor has been 
detected in the ovaries (Loffler et al, 2001) and placenta (Hauguel-de Mouzon, 2003). 
It is suggested that leptin’s ability to regulate the female’s level of adiposity is 
important within the context of attaining long-term energy stores which are essential 
for reproduction. The availability of nutrients for fetal growth and development require 
substantial energy stores and indeed women who have BMI levels below a certain level 
will tend to be infertile. Furthermore, the onset of puberty is linked to fat storage, with 
pioneering studies by Kennedy and Mitra (1969) proposing that signals from fat were 
responsible for hypothalamic regulation of ovarian activity. In the ob mouse model, 
progression to puberty was rescued by administration of exogenous leptin. In humans 
with mutations in the leptin and leptin receptor, failure to progress through puberty 
was also observed (Strobel et al., 1998, Clement et al., 1998). Quinton and colleagues
(1999) determined that leptin binding activity in serum was high in pre-pubertal years
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in both boys and girls and fell during puberty. They postulated that the fall in leptin 
binding activity reflected a reduction in soluble leptin receptor (which is able to bind to 
leptin in the circulation) enabling more leptin to be available to the full-length leptin 
receptor causing the biological signal of leptin to be transmitted.
1.3.9 Leptin and the cytokine network
As has been demonstrated with many cytokines, leptin is able to interact within the 
cytokine network in several different situations in an overlapping and complementary 
manner.
For example, Santos-Alvarez et al (1999) reported that by increasing production of 
the cytokines, IL-2 and interferon gamma (IFN-y), leptin enhances the activation and 
proliferation of circulating T lymphocytes in humans. Considering that the db/db 
mouse has reduced levels of T and B lymphocytes (Bennett et al, 1996), these results 
suggest that by regulating other cytokines, leptin could have an important role in 
lymphopoiesis and is necessary for the proinflammatory immune response.
Another piece of evidence suggestive of a role for leptin in the immune response was 
recognised when administration of the endotoxin, lipopolysaccharide (LPS) in hamsters 
up- regulated leptin gene expression in adipose tissue and protein serum levels 
(Grunfeld et al, 1996). These compounds can potently induce cytokine production in 
vivo, with leptin induction apparently mediated via release of IL-1 and TNF-a. (Sarraf 
et al., 1997). Indeed, LPS fails to increase leptin levels in IL-lp knockout mice 
(Faggioni et al, 1998) whilst ob mice exhibit attenuated levels of serum TNF-a and 
IL-6 in response to LPS.
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The results of these studies suggest that leptin could interact with other cytokines to 
modulate responses to infection and inflammation which are associated with reduced 
food intake and weight loss.
Further evidence of the specific interaction of leptin with IL-1 has been seen in rats, 
Luheshi and colleagues (1999) observed that injecting leptin into the brains of normal 
rats increased IL-lp levels in the hypothalamus and, the central injection of IL-1 
receptor antagonist (IL-lra) inhibited the satiety action of leptin.
Leptin has been shown to induce the secretion of IL-lra in human monocytes (Gabay 
et al, 2001). Recently, the molecular mechanism of activation of the IL-lra promoter 
via the long form of the leptin receptor was discovered (Dreyer et al, 2003). It 
involves signalling through a MAPK pathway with binding of p42/44 MAPK protein 
and an uncharacterised complex of transcription factors to a nuclear factor kB/PU. 1 
site in the IL-lra promoter region Considering that MAPK pathways are usually 
proinflammatory, an overall inflammatory action of leptin has been postulated which is 
in keeping with the clinical observation of local inflammatory reactions after 
subcutaneous administration of leptin in humans (Heymsfield et al, 1999).
1.4 Genetic Concepts and Methods
Although the genetic material is very alike in humans, throughout the human genome 
there are numerous variations at specific positions between individuals.
These sites of variation, or polymorphisms, are present in duplicate because the human 
genome is comprised of pairs of matched chromosomes. Each copy (allele) is inherited 
from an individual's parents and passed on to their offspring.
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As a generalisation, DNA variants present in >1% of the population are termed 
polymorphisms. A particularly deleterious DNA variation is usually present in less than 
1% of the population. However, as common polymorphisms can contribute to disease, 
the delineation between the two is becoming less clear. Genetic studies of diseases 
such as obesity/anorexia involve the analysis of such DNA variations, used as genetic 
markers.
1.4.1 Single Nucleotide Polymorphisms (SNPs): a type of genetic variation
SNPs are the most common form of DNA variation in the human genome occurring on 
average once every 0.3-1 kilobase of DNA (Schork etal., 2000).
This form of DNA variation involves variation in a single base. Substitutions can occur 
within coding DNA sequence and, as such, may result in a substitution of one amino 
acid for another. If this is the case, the substitution may be conservative, whereby one 
amino acid is substituted for another amino acid with similar charge and size 
properties. Alternatively, a non-conservative change may take place involving the 
incorporation of an amino acid with different properties which may alter the protein’s 
conformation and, perhaps, activity. A nonsense SNP substitution will code for one of 
the three stop codons resulting in the formation of a truncated protein. A 'silent' change 
may also occur whereby the substitution maintains the same amino acid. SNPs that are 
present in the third base of a triplet codon are an example of a silent polymorphism as 
any one amino acid can be coded for by different triplet codons, each one varying in 
the third base only. This degeneracy of the genetic code was described by Crick (Crick, 
1966). SNPs can reside in non-coding sequences and therefore may have a minimal 
functional effect unless they are situated in conserved regions that influence gene
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expression, such as the promoter sequences, or at splice recognition sites which are 
required for correct splicing of RNA transcription products.
The base change at any one SNP may generate or abolish a restriction site for a class II 
endonuclease enzyme. If so, then DNA amplified over this region can be conveniently 
digested using the appropriate enzyme, the products subjected to electrophoresis and 
individuals typed for the particular SNP. Recent advances in technology, including 
real-time PCR and denaturing high performance liquid chromatography have increased 
automation and sample throughput. The high frequency of SNPs, rapid screening 
characteristics and the potential to have a functional effect on gene expression or on 
the protein itself, makes SNPs desirable to study. This is because there are enough of 
them in and around genes to represent candidate polymorphisms (individually or in 
unison) some of which may influence a disease/disease trait. Such advantages coupled 
with the ease of typing for the SNP in individuals and the relative stability of SNPs 
over generations has led to international efforts to generate maps of SNPs spanning the 
human genome, one example being the NCBI SNP database 
(http://www.ncbi.nlmnih.gov/SNP).
1.4.2 Linkage disequilibrium
A phenomenon observed through studies of genetic variability is that of linkage 
disequilibrium In a population, it has been described as the co-occurrence of specific 
alleles from more than one marker at a higher frequency than would be predicted by 
random chance (Genetics Home Reference database at the U.S. National Library of 
Medicine website, http://ghr.nlmnih.g0v/ghr//page/H0me). This may be because the 
alleles are physically close so that the chance of being disrupted by recombination at 
meiosis is low and they are inherited together over successive generations. These
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are inherited together over successive generations. These combinations of alleles are 
described as haplotypes, and changes in frequency at one allele may reflect /  cause 
changes in the others. Therefore, the knowledge of whether a cluster of SNPs is in 
linkage disequilibrium is beneficial for two reasons, firstly, as analysis of any one SNP 
may represent the functional effects of a neighbouring SNP or secondly, a combination o f 
SNPs represented by their alleles in a conserved haplotype may be contributing to a 
disease state.
1.4.3 Linkage analysis
Linkage studies have been classically used to analyse the co-segregation of DNA markers 
with a particular monogenic disease in family pedigrees. This methodology, in its 
simplest form involves studying pairs of affected siblings, but larger multiplex families 
are also used.
Unlike this qualitative classification which is based on the presence or absence of a 
disease, many diseases can be defined by an underlying quantitative trait, such as 
percentage body fat or BMI in obesity. This approach is commonly used when linkage 
studies are applied to multifactorial diseases, which may result from the combined effects 
of more than one gene and where patterns of hereditary are usually more complex than 
those of single-gene disorders. These traits provide a measure of disease severity and the 
trait itself may be affected by a smaller number of factors compared to the variety of 
genetic and environmental factors that lead to the presence or absence of the disease 
itself Such features can enable the quantitative variable to have a stronger correlation 
with variants of one particular gene amongst the several genes which contribute to the 
disorder, improving the identification of causative susceptibility variants.
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contribute to the disorder, improving the identification of causative susceptibility 
variants.
1.4.4 Association studies
The comparison of allele and genotype distribution between patients and controls is a 
strategy for the detection of disease susceptibility genes. Any observed difference in 
frequencies between the two groups may arise from a functional effect of the allele 
under investigation. Alternatively, the allele may be in linkage disequilibrium with a 
nearby susceptibility locus. The original SNP may therefore be a marker of 
susceptibility to a disease without having a causal role.
Such case control studies require careful matching. For example, maintaining the same 
ethnicity between cases and controls is important because different ethnic populations 
may have different frequencies for a particular allele, which could be mis-construed as 
a significant difference in an association study.
The confounding effect of population stratification on association studies is also a 
concern. In this scenario, a population is assumed to be homogenous with respect to 
allele frequencies for a particular marker but in reality is composed of several 
subpopulations each with different allele frequencies. If the subpopulations have 
different risks of disease then an association between the candidate gene and disease 
may be spuriously assigned.
Another consideration is cohort size as the greater its size, the more statistically 
significant the results will be. This may be of importance if the frequency of the variant 
allele, which is hypothesised to make individuals susceptible to a disease, is low 
(Schork, 2002).
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1.4.5 Transmission disequilibrium test
This test detects association in the presence of linkage. It involves a statistical 
comparison between candidate susceptibility alleles transmitted or not transmitted to 
affected offspring from parents who are heterozygous for the DNA variant being 
studied. These studies circumvent the issue of needing to find carefully matched 
controls as analysis is based within a family.
1.5 Genetics of Leptin and the Leptin Receptor in Humans
Following the discovery of the leptin and leptin receptor genes and their involvement in 
obesity deduced from rodent models, these genes became obvious candidates for the 
condition in humans.
In obese humans, very few mutations have been discovered which affect obesity.
A rare example is described by Montague and colleagues (1997b) who demonstrated 
severe early-onset obesity in two children, from a highly consanguineous family of 
Pakistani origin, caused by a frameshift mutation at codon 133 in the LEP gene. This 
resulted in a mutant truncated leptin protein with an aberrant C-terminus, that was not 
secreted normally from cells (Rau et al, 1999).
Another study by Clement and colleagues (1998) uncovered a homozygous mutation at 
a splice site, which causes deletion of exon 18 from the mature mRNA, forming a 
truncated leptin receptor lacking the transmembrane and intracellular domain. This 
results in morbid obesity for the affected individuals from a family of Kabilian origin. 
Such null mutations that lead to morbid obesity have rarely been found in humans. This 
led researchers to believe that generally, obesity does not result from a single gene
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defect and is probably a complex disorder with a combination of several genes and 
environmental factors likely to contribute or predispose to the disorder. Searches for 
common polymorphisms within key genes were mounted to determine whether they 
make a more modest contribution to regulation of obesity.
Sequencing of the LEP gene reported an A to G substitution in the untranslated exon 
one (Hager et al, 1998) and a G to A base change at nucleotide position -2548 in the 
promoter region (Mammes etal, 2000).
Location of these SNPs in the LEP gene enabled association studies to be conducted 
within normal populations and between obese and normal weight groups (as 
determined by obesity indicators such as BMI, percentage fat mass etc). This requires 
comparison of allele frequencies and distribution for each polymorphism separately and 
in combination (haplotype analysis).
Studies on the LEP gene have identified that the G-allele of the A to G base change in 
exon 1 is associated with lower leptin leptin levels (Hager et al, 1998) in obese 
individuals. Examples of SNPs in the coding region of the gene are few (this may 
reflect the fact that the LEP gene is substantially smaller than the LEPR gene). Several 
SNPs were located in the 5' flanking region of the LEP gene, three of which were 
found to differ in allele frequencies between obese and non-obese women (W-D, Li et 
al, 1999) The most significant difference was observed for the G to A -2548 base 
change SNP. In a separate study, Mammes and colleagues (2000) reported that the G 
allele was associated with lowered leptin levels and obesity in men only.
Studies by Considine and colleagues (1996), Gotoda and colleagues (1997) and 
Thompson and colleagues (1997) involved sequencing of the LEPR gene in obese 
individuals from Pima Indians, British and French populations. Pima Indians are a 
North American tribe who split several centuries ago into two geographical groups.
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The Arizona Pimas who eat a high-fat, westernised diet have the highest incidence of 
obesity in the world, whilst their Mexican kindred are on average 26kg lighter, 
participate in extensive physical labour and live on a limited diet (Gibbs, 1996).
Several coding and non-coding polymorphisms were discovered. More than one SNP 
was identified in the sequence coding for the extracellular domain of the leptin 
receptor. An adenine (A) to guanine (G) base change generating the LYS109ARG 
amino acid substitution (both of which have a basic charge (+ve) at pH 6-7). Another 
A to G base change codes for the GLN223ARG substitution (resulting in a change 
from an uncharged amino acid to one with a basic (+ve) charge at pH 6-7 at that 
codon). A silent thymine (T) to cytosine (C) base change at codon 343 was located 
which maintains the presence of a serine residue (See figure 1.6 for location of leptin 
receptor SNPs).
Association studies of the LEPR gene by Gotoda and colleagues (1997) did not detect 
any difference in allele frequencies for any of the polymorphisms between obese and 
lean white British males. Thompson and colleagues (1997) observed that two 
polymorphisms in the non-coding region of the LEPR gene were present in obese Pima 
Indians but not normal weight Pima Indians. Due to the small sample size (twenty 
individuals) however, the significance of this result is unclear.
Since these initial investigations, many more studies have been undertaken in different 
ethnic groups with varying study designs. Some have reported an association whilst 
others have not. Positive associations of the GLN223ARG SNP with measures of 
adiposity have been detected in several studies (Chagnon et al, 1999, Chagnon et al, 
2000, Yiannakouris et al, 2001 and Quinton et al, 2001) (see table 1.3) where the 
presence of the arginine residue is associated with an increase in such indicators of 
adiposity as BMI and fat mass. In contrast, other studies have failed to reveal an
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association of any of the common SNPs with measures of adiposity (Echwald et al, 
1997, Matsuoka et al, 1997, Silver et al, 1997) (see table 1.3). These conflicting 
results may not be surprising due to the complex aetiology of obesity where different 
combinations of genes combined with environmental factors may contribute to the 
same phenotype (obesity) in different individuals. In such a condition, the effect of 
individual polymorphisms is harder to detect and also because different ethnic groups 
were studied, it is unsure whether a certain polymorphism is having a specific influence 
on a particular ethnic group. Gender and age differences are additional confounding 
factors that are known to influence leptin levels, with one example being that leptin 
levels fluctuate during the menstrual cycle (Shimizu et al, 1997). Some studies have 
attempted to control for such problems. For example, Quinton et al. (2001) looked at a 
cohort of postmenopausal women only (Table 1.3). Heo et al. (2001) initiated a meta­
analysis to increase numbers and, therefore, the power of the results by combining the 
data from several association studies of the leptin receptor gene. They concluded that 
there was no statistically compelling evidence that any of these alleles were associated 
with BMI or waist circumference in the general population. It is interesting to note, 
however, that the majority of their data was pooled from studies originally having a 
negative result and that they also concluded that certain genotypic effects could be 
population-specific.
Linkage analysis measuring co-segregation of the 24 hour respiratory quotient 
quantitative trait (a predictor of weight gain as determined by Ravussin and Swinbum, 
1993) with obesity, found strong linkage at chromosome Ip31-p21.
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LyslG9Arg Gln223Aig Scr543Ser Ser492TTir LysfiKAsn
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Figure 1.6: Schematic representation of the extracellular and transmembrane domains 
of the human leptin receptor protein and also the relative position o f the LEPR gene 
exons and SNPs. Adapted from Matsuoka et al. (1997).
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1.6 Aims of the study
There were three main aims of the studies described in this thesis:
1. to identify and further characterise any associations between leptin receptor SNPs 
and measures of adiposity in:
a) a postmenopausal female European Caucasian population;
b) a female European Caucasian anorectic population
2. to identify associations between other relevant cytokine polymorphisms and 
measures of adiposity in a postmenopausal female European Caucasian population
3. to generate leptin receptor protein variants (representing the DNA polymorphisms), 
functionally characterise them, with the aim of comparing activity to determine if 
the SNPs have a functional effect.
These studies should enhance our understanding of the role of genetic variation in 
eating disorders and disease, whilst enabling functional analysis of these variations.
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Chapter 2 
Materials and Methods
41
2.1 Anthropometrical measurements
To determine height and weight, subjects were barefoot and lightly clothed. The BMI 
was calculated as the body weight (kilograms) divided by the square of the height 
(metres2).
To determine fat and lean mass values, whole body scans were performed under a dual 
energy x-ray absorptiometry (DEXA) machine. By determining the varying levels of 
absorbance by the different anatomical structures of the body, a quantitative 
measurement (grains) of lean and fat mass was obtained.
2.2 Genotyping
2.2.1 Polymerase Chain Reaction (PCR) of SNPs in the human leptin receptor 
gene (LEPR)
The LEPR polymorphisms investigated were, LYS109ARG, GLN223ARG and 
LYS656ASN. PCR was carried out using either purified genomic DNA or DNA from 
dried blood spots as a template.
Primers used to amplify these regions of the leptin receptor are described by Echwald 
et al, (1997) and Gotoda et al, (1998).
PCR reactions were carried out in a 25 pi volume. A negative control (whereby the 
DNA template was replaced with an equal volume of water) was included in each 
batch of PCR
For all reactions, the Taq DNA polymerase (recombinant from Thermus aquaticus), 
deoxynucleotides (dNTPs), magnesium chloride (MgCl) and IOXNH4 reaction buffer 
were supplied by Bioline. The primer oligonucleotides were supplied by Invitrogen.
The PCR reactions were conducted on an MJ research PT-225 thermal cycler.
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Reaction components, conditions and primer sequences are presented in tables 2.1, 2.2 
and 2.3.
Template DNA was supplied as either dried blood spotted onto standard neonatal 
blood cards (carried out by Professor EastelTs research group, Northern General 
Hospital, Sheffield) or purified DNA solutions extracted by Helen Eastwood at the 
Yorkshire Centre for Eating Disorders (Leeds).
LYS109ARG GLN223ARG LYS656ASN
DNA solution1 2pl 2pl 2pl
MgCh (Bioline) 2mM 2.5mM ImM
lOxNH* buffer 2.5 pi 2.5pl 2.5pl
dNTPs (Bioline) 0.2mM 0.2mM 0.2mM
Forward primer 0.4pM 0.6pM 0.6pM
Reverse primer 0.4pM 0.6pM 0.6pM
Taq polymerase 2.5 units 2.5 units 2.5 units
Sterile H20 To a final volume of 25pl to volume of 25 pi To volume of 25 pi
Table 2.1: Table of components for PCR mixture for LYS109ARG, GLN223ARG and 
LYS656ASN genotyping PCRs. Reaction volumes stated were the optimum reaction 
volumes observed following PCR optimisation.1 Where the template is dried blood, 
DNA solution is replaced by 1mm2 of card containing dried blood and the final reaction 
volume of 25pi is maintained by adjusting the sterile water volume.
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2.2.2 LEPR SNPs PCR product digestion
Digestion of the LYS109ARG, GLN223ARG and LYS656ASN polymorphisms were 
undertaken using the restriction enzymes Hae III (Promega), Msp I (Promega) mdAcc 
II (Amersham Biotech) using the reaction components and conditions presented in 
table 2.4.
LYS109ARG GLN223ARG LYS656ASN
PCR product lOpl lOja.1 lOpl
Enzyme lpl (10 units) lpl lpl
Enzyme buffer 2pl 2|il 2pl
Sterile water (to a final volume of) 20pl 20 pi 20pl
Incubation time and 16 hours at 37°C (water 16 hours at 37°C 16 hours at 37°C
temperature bath)
Table 2.4: Reaction components and conditions for LYS109ARG, GLN223ARG and 
LYS656ASN restriction digest genotype reactions.
After digestion, the samples were electrophoresed on 3% Nusieve agarose gels (BMA 
products) for the LYS109ARG and LYS656ASN polymorphisms and 2.5% agarose 
gels (Sigma) for the GLN223ARG polymorphism in order to visualise the different 
genotypes (Figure 6.1 in chapter 6).
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2.2.3 PCR of SNPs in the LEP, TNF-a and EL1RN genes
PCR was carried out using DNA from dried blood spots as a template. The reaction 
conditions for the LEP G-2548A promoter SNP were carried out using the PCR 
conditions and primers reported by Mammes and colleagues (2000). The TNF- a  G- 
308A SNP PCR conditions are essentially based upon those used by Fernandez-Real 
and colleagues (1997) and the ILRN variable number tandem repeat (VNTR) PCR 
used the PCR and primer conditions published by Tarlow et al, (1993).
Reagents and equipment used were the same as described in section 2.2.1.
Reaction components, conditions and primer sequences are presented in tables 2.5, 2.6 
and 2.7. The LEP G-2548A and TNF a  G-308A SNPs were subsequently digested by 
restriction enzymes to visualise the different alleles for each SNP. Each allele present in 
individuals for the IL1RN VNTR was specifically amplified during the PCR reaction 
and detected by running the PCR products on a 2% agarose gel.
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LEP  G -2548 A SNP TNF-a -308 SNP IL1RN VNTR
DNA bloodspot 1mm2 1mm2 1mm2
MgCl2 (Bioline) 2mM 1.5mM 1.5mM
lOxNHLt buffer 2.5pl 2.5 pi 2 .5 j l l 1
dNTPs (Bioline) 0.2mM 0.2mM 0.2mM
Forward primer 0.4pM 0.6pM 0.5pM
Reverse primer 0.4pM 0.6pM 0.5pM
Taq polymerase 2.5 units 2.5 units 2.5 units
Sterile H20 To a final volume of 25 pi to volume of 25pl To volume of 25pl
Table 2.5: Table of PCR components used for the LEP G-2548 A SNP, TNF-a -308 
SNP and IL1RN VNTR PCRs. Reaction volumes stated were the optimum reaction 
volumes observed following PCR optimisation.
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2.2.4 LEP  G -2548A and TNF-a G-308A SNP PCR product digestion
Digestion of the LEP G-2548A SNP and TNF a-308 SNP PCR products were 
undertaken using the restriction enzymes Cfo I (Promega) and Nco I (Promega) 
respectively. The reaction components and conditions presented in table 2.8.
LEP  G-2548A TNF a  -308
PCR product lO i^l lOpl
Enzyme lptl (10 units) lfll
Enzyme buffer 2pl 2 pi
Sterile water (to a final volume of) 20pl 20pl
Incubation time 16 hours at 37°C (water 16 hours at 37°C
and temperature bath)
Table 2.8: Reaction components and conditions for the LEP G-2548A and TNF a  - 
308 restriction digests.
After digestion, the LEP G-2548A samples were subjected to electrophoresis in 3% 
Nusieve agarose gels to visualise the different genotypes. The TNFa G-308A samples 
were subjected to electrophoresis on 9% polyaciylamide (PAGE) gels (Sigma) to 
visualise the different genotypes (See chapter 5, figures 5.1 and 5.2).
2.2.5 IL1RN VNTR genotyping
Following PCR, the IL1RN VNTR PCR products were applied directly to a 2% 
agarose gel. As each allele differs by 86bp, scoring of the different alleles can be 
determined directly from visualising size differences on an ethidium-stained gel (see 
chapter 5, figure 5.3).
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2.3 Nucleic acid purification techniques
2.3.1 Plasmid purification from bacterial cultures
Inoculated bacterial cultures were incubated overnight in an orbital shaker (New 
Brunswick Scientific model G25) at 200 revolutions per minute (rpm) at a temperature 
of 37°C in 17x100mm tubes (Falcon) containing 3ml (LB) broth and lOOpg/ml of the 
appropriate selective antibiotic. Subsequently, 1.5ml of culture was centrifuged in an 
Eppendorf tube for 5 minutes at 11,500 x g (Eppendorf 1615 centrifuge) to pellet the 
cells. The supernatant was removed and the pellet re-suspended in 100pl of solution 1 
(50mM glucose, lOmM ethylenediamine-tetraacetic acid (EDTA) and 25mM Tris. 
hydrochloric acid (HC1) pH 8). To this was added 200pi solution 2 (0.2M sodium 
hydroxide (NaOH), 1% w/v sodium dodecyl sulphate (SDS) and the tube placed on ice 
for 5 minutes. Afterwards, 150pl ice-cold solution 3 (5M potassium acetate and glacial 
acetic acid) was added, the tube inverted slowly several times and then stored on ice 
for 5 minutes. The tube was centrifuged for 10 minutes at 11,500 x g at 4°C; the 
supernatant collected and transferred to a new tube. 400pl phenol: chloroform (24:1) 
was added to the supernatant, vortexed and centrifuged for 2 minutes at 11,500 x g. 
The supernatant was transferred to a new tube and 700pl ethanol added. The tube was 
incubated for 5 minutes on ice and then centrifuged for 5 minutes at 11,500 x g at 4°C. 
The supernatant was removed, and 1ml 70% ethanol added to the tube, which was 
then centrifuged for 5 minutes at 11,500 x g at 4°C. The supernatant was discarded 
and the DNA pellet air-dried, followed by resuspension in 50pl sterile water containing 
5pg/ml RNAse A (Sigma).
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2.3.2 DNA purification from agarose gel (Gene Clean protocol)
The DNA band of interest was excised from ethidium bromide-stained agarose gels 
over a UV transilluminator. The excised band was weighed to determine the 
approximate volume of the gel slice (O.lg approximately equals lOOpl) and placed in a 
1.5ml Eppendorf tube. Subsequently, the GeneClean DNA purification kit was used 
(BiolOl). Four and a half volumes of a sodium iodide solution (BiolOl) was added to 
the gel slice along with a half volume of TBE (Tris-Borate EDTA) modifier solution 
(BiolOl). The mixture was incubated at 45-55°C in a water bath for 5 minutes to melt 
the gel. Five pi of EZ-glass milk silica suspension (BiolOl) was added to the melted 
agarose and incubated for 5 minutes at room temperature with occasional mixing. The 
silica matrix was pelleted by spinning the Eppendorf tube for 5 seconds at 11,500 x g 
(Eppendorf 1615 microcentrifuge) and the supernatant discarded. The pellet was 
washed by resuspending the pellet in 400pl of New wash (BiolOl), followed by 
centrifugation for five seconds at 11,500 x g and removal of supernatant. The wash 
step was carried out three times in total. To elute the DNA, the pellet was resuspended 
with lOpl of water and the suspension centrifuged for 30 seconds at 11,500 x g. The 
supernatant containing the DNA was transferred to a new tube.
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2.3.3 Assessment of DNA concentration and purity
The concentration of DNA was estimated by measurement of absorbance at a 
wavelength of 260 nanometres (nm) (GeneQuant spectrophotometer). DNA samples 
were diluted 1:100 in sterile water and placed in a 1cm pathlength quartz cuvette 
(Amersham Biotech) and the absorbance measured at 260nm Under such conditions, 
an absorbance unit of one is measured from a solution containing 50pg/ml DNA 
Subsequently the concentration of the test sample can be calculated.
The purity of the DNA sample was assessed by measurement of the absorbance at 
280nm as well as 260nm followed by calculation of the ratio between the two 
absorbance readings. A ratio of 1.8 was considered free of impurities. Samples 
typically gave ratios of 1.75 to 1.85.
2.3.4 RNA purification techniques
Extraction of total RNA from cultured cells was performed using a guanidinium 
thiocyanate-phenol-chloroform method first described by Chomczynski and Sacchi 
(1987). The presence of Tri reagent (Sigma) maintains the integrity of the RNA during 
and following disruption of cells.
2.3.5 Preparation of cultured cells for RNA extraction
Human embiyonic kidney (HEK) 293 cells were provided as confluent monolayers.
The medium was removed and the cells washed twice in 10ml of lx phosphate- 
buffered saline (PBS) (Sigma). Subsequently, 1ml of TRI reagent was added per 10cm2 
of flask area. The liquid was pipetted vigorously to dislodge and lyse the cells after
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which the samples were transferred to chilled 1.5ml Eppendorf tubes. Following 
incubation on ice for 5 minutes, lOOpl of ice-cold chloroform (per ml of Tri reagent) 
was added to the tubes, mixed and incubated on ice for 10 minutes. The tubes were 
then centrifuged at 11,500 x g (Eppendorf 1615 microcentrifuge) for 15 minutes at 4° 
C. The top aqueous layer (approximately 500pl) was removed and placed into a fresh 
Eppendorf tube with an equal amount of ice-cold isopropanol. This mixture was 
incubated on ice for one hour. The centrifugation was then repeated at 11,500 x g for 
15min at 4°C, the supernatant was discarded and the pellet resuspended in 250pi of 
80% ethanol. The resuspended pellets were centrifuged at 11,500 x g for 5min at 4°C 
and the supernatant removed. The pellets were air-dried for 10 minutes and 
resuspended in 20-5Opl of sterile H20.
2.3.6 Assessment of RNA concentration and purity
The RNA concentration for each sample was calculated by measuring the optical 
density of a diluted sample, at a wavelength of 260nm (GeneQuant 
spectrophotometer). In a lcm-pathlength quartz cuvette, an absorbance reading of 1 
unit at 260nm is equal to 40pg/ml single-stranded RNA The original samples were 
then appropriately diluted to obtain an RNA concentration of approximately lpg/pl.
The ratio of the absorbance at 260nm: 280nm was also calculated. This value reflected 
the purity of the RNA in the sample, with a value of 2.0 considered relatively free of 
impurities.
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2.4 Reverse Transcriptase-PCR (RT-PCR)
2.4.1 First strand cDNA synthesis
Using the enzyme AMV (avian myeloblastosisvirus) reverse transcriptase (RT) 
(Gibco), first strand cDNA was synthesised using mRNA as a template.
For each RNA sample, a 36pl reaction mix was made containing 8 pi of 5 x RT buffer, 
(500mM Tris-HCl, (pH 8.3), 50mM MgCl2, 50mM DTT) (Gibco), 8pl of KC1 
(250mM), 16pl of dNTPs (containing equi-molar amounts of dGTP, dATP, dCTP and 
dTTP), 1.2pl of Oligo (dT)i2.i8 primer (0.5mg/ml in diethyl pyrocarbonate treated 
water) (Gibco), 1.2pl (3units) reverse transcriptase and 1.6pl of sterile H20. This 
mixture was added to 4pl of RNA (lpg/pl). Two controls were run parallel to each 
sample. The first contained only sterile H20  in replacement of RNA (negative control) 
and the second contained sterile H20  in replacement of the RT enzyme (no RT 
control). The mixture was then overlaid with 40pl of mineral oil, to prevent 
evaporation, and placed in a MI research PT-225 thermal cycler for the following 
reaction (table 2.9).
Step Duration Temperature
cDNA synthesis 1 hour 37.5°C
Enzyme denaturation 5 minutes 99°C
Holding temperature 00 4°C
Table 2.9 First strand synthesis reaction conditions 
The samples were then removed and stored at -20°C.
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2.4.2 PCR of LEPR extracellular domain
PCR was used to amplify the cDNA for the extracellular domain of LEPR. Using the 
following primers designed specifically for this study:
Forward primer 5'-GGA TCC AAC TTG TCA TAT CCA ATT ACT CCT TG-3’
Reverse primer 5'- A CCT GCA TCA CTC TGG TGT TT-3’
The PCR reaction mix consisted of a 20pl master mix containing 15.5pl sterile water, 
2.5pl 10 x NH4 reaction buffer (Bioline), 0.5ptl 50mM MgCl2 (Bioline), 0.5pi of 20pM 
forward primer, 0.5pi of 20pM reverse primer (Invitrogen) and 2.5 units of Taq 
polymerase (Bioline). The reaction was conducted on an MJ research PT-225 thermal 
cycler using the following program (table 2.10).
PCR cycle step Duration (seconds) Temperature
DNA denaturation 1 180 96°C
DNA denaturation 2* 60 94°C
Primer annealing* 60 56.5°C
DNA strand synthesis* 150 72°C
Synthesis completion 480 72°C
Holding temperature 00 4°C
Table 2.10: Conditions for extracellular LEPR PCR * The steps, DNA denaturation 2 
through to DNA strand synthesis were repeated for 35 cycles before proceeding to the 
synthesis completion step.
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2.5 Recombinant DNA techniques
2.5.1 pGEM-T cloning
The extracellular LEPR cDNA obtained from the RT-PCR was cloned into the pGEM- 
T vector (Promega).
This plasmid is supplied pre-cut at a specific position, with thymine bases added at 
both ends of the cut site, forming single base overhangs. The termini of the RT-PCR 
products have adenine base overhangs added by Taq polymerase, facilitating 
complementary base pairing and ligation between the product and plasmid.
The insert and plasmid DNA were joined using T4 DNA ligase (Promega) in the 
following reaction mixture of 5pi 2x ligation buffer (Promega), 5Gng of pGEM-T 
vector, 150ng of PCR product, lpl of T4 DNA ligase (3 weiss units/pl) and sterile 
water to a final volume of lOpl. The reactions were incubated overnight at 4°C.
2.5.2 pCMV-Tag 2B cloning
The extracellular LEPR cDNA insert present in the pGEM-T vector was digested, 
agarose gel purified by the gene-clean method, and sub-cloned into the pCMV-Tag 2B 
expression vector (Stratagene). The insert and plasmid DNA were ligated together 
using T4 DNA ligase (Promega) in the following reaction mixture of 5 pi 2x ligation 
buffer (Promega), lOOng of vector, 40Qng of LEPR insert, lpl of T4 DNA ligase (3 
weiss units/pl) and sterile water to a final volume of lOpl. The reactions were 
incubated overnight at 4°C.
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2.5.3 Site-directed mutagenesis
Site-directed mutagenesis was employed to engineer mutations in the LEPR cDNA 
insert in the pCMV vector at the sites corresponding to the LYS109ARG and 
GLN223ARG polymorphisms using the Stratagene quick-change mutagenesis kit.
For the first step of the process, DNA amplification occurred using the recombinant 
pCMV-Tag 2B vector as template and mismatched primers to incorporate the desired 
mutation. The site-directed mutagenesis amplification reactions were identical for both 
the LYS109ARG and GLN223ARG with the exception of the different primer 
sequences required for each. The reaction components comprised 5pil of lOx reaction 
buffer (Stratagene), 5ng of plasmid template, 125ng of oligonucleotide primer 1 and 2 
(Invitrogen), lpl of dNTP mix (Stratagene), lpl of PfuTurbo (high fidelity) DNA 
polymerase (2.5 units pet pi, Stratagene) and sterile water to a final volume of 50pl. 
The reactions were conducted on an MJ research PT-225 thermal cycler using the 
following cycle parameters (table2. l l )  and primer sequences (table 2.12).
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Amplification step Duration (seconds) Temperature
Plasmid denaturation 1* 30 95°C
Plasmid denaturation 2* 30 95 °C
primer annealing * 60 55°C
DNA strand synthesis 960 68°C
Table 2.11: Conditions for amplification of mutant pCIVl[V-Tag 2B plasmids. * The
steps, plasmid denaturation 2 through to DNA strand synthesis were repeated for 16 
cycles.
Forward primer sequence Reverse primer sequence
LYS-»ARG 
(codon 109)
5'-gcagacaacattgaaggaaG*ga 
CATTTGTT -3’
5'-GAAACAAATGTCC*TTCCTTCAA 
TGTTGTCTGC -3'
ARG->GLN 
(codon 223)
5’-GGTGGAGTAATTTTCCA*GTCAC 
CTCTAATGTCAG -3'
5'-CTGACATTAGAGGTGACT*GGA 
AAATTACTCCACC -3'
Table 2.12: Primer sequences used to generate and amplify mutant pCMV-Tag 2B 
plasmids. *Bold case highlights the mis-matched base incorporated into the amplified 
products.
After plasmid amplification, the methylated parental plasmid DNA was digested with 
the enzyme Dpnl which targets methylated DNA only. Firstly, the samples were 
incubated on ice for 2 minutes and then lpl (10U/pl) of Dpnl restriction enzyme 
(Stratagene) added. The samples were digested for 1 hour at 37°C in a water bath. The 
remaining, nicked, non-methylated daughter plasmids were subsequently available for 
transformation
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2.5.4 Transformation
Following ligation reactions and/or site-directed mutagenesis reactions, bacterial cells 
were transformed with the relevant plasmid. The cells were supplied with growth 
media and an antibiotic selection agent for the recombinant plasmid, allowing 
replication and propagation of the cell colonies containing the recombinant plasmid on 
agar plates.
2.5.5 Cell transformation with the pGEM-T vector
Initially, 2pl of the ligation mixture was added to 50pi of JM109 competent bacterial 
cells (Promega) in an Eppendorf tube. The tube was placed in ice for 20 minutes and 
then placed in a water bath at 42°C for 45 seconds. The tubes were removed and 
returned to ice for 2 minutes after which 950ul of LB growth media added to them 
The tubes were incubated at 37°C for 1.5 hours on an orbital shaker to enable the 
plasmid to sufficiently express its ampicillin resistance gene (New Brunswick Scientific 
model G25) at 200rpm and then plated out onto LB agar plates containing 0.5mM 
IPTG (Sigma), 80pg/ml X-Gal (Sigma) and lOOpg/ml ampicillin (Sigma). The plates 
were incubated overnight at 37°C and colonies analysed the following day.
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2.5.6 Cell transformation with the pCMV plasmid
5pi of the ligation mixture was added to 50pl of XL-10 gold competent bacterial cells 
(recA, endAl phenotype) (Stratagene) in an Eppendorf tube. The tube was placed on 
ice for 20 minutes and then placed in a waterbath at 42°C for 45 seconds. The tubes 
were removed and returned to ice for 2 minutes and then 950pl of LB growth media 
added. They were subsequently incubated at 37°C for 1.5 hours on an orbital shaker 
(New Brunswick Scientific model G25) at 200rpm so that the kanamycin resistant gene 
contained within the plasmid was adequately expressed. The media was subsequently 
plated onto LB agar plates containing 50pg/ml kanamycin antibiotic (Sigma). The 
plates were incubated overnight at 37°C. Colonies were analysed the following day.
2.5.7 Cell transformation with site-directed mutant pCMV plasmids
One pi of the Dpn I-treated nicked plasmid DNA was added to a 17 x 120mm tube 
(Falcon) containing 50pl of XLl-Blue cells (Stratagene) and placed on ice for 30 
minutes. After which, the reactions were incubated at 42°C for 45 seconds in a water 
bath. 0.5ml of NZY+ broth was added to each tube and the transformations incubated 
at 37°C for 1 hour in an orbital shaker (New Brunswick Scientific model G25) at 
200rpm. 250pl of the transformation mixture was plated onto LB agar plates 
containing lOOpg/ml kanamycin antibiotic (Sigma) and incubated overnight at 37°C. 
Colonies were analysed the following day.
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2.5.8 DNA sequencing
For DNA sequence analysis of plasmid DNA, lpg of plasmid DNA, at a concentration 
of 250ng/pl, was mixed with 12pmol of sequencing primer and delivered to the 
Advanced Biotechnology Centre (Imperial College London) for automated sequencing.
2.5.9 Plasmid digestion
DNA cloned into vectors was digested using appropriate type II restriction enzymes to 
cleave the insert DNA from the vector. The products were applied to 0.8% agarose 
gels, containing ethidium bromide, and subjected to electrophoresis. The products 
were visualised using a UV transilluminator. A typical digestion reaction included 
500ng of plasmid DNA, 2pi of reaction buffer (Promega), lpl of restriction enzyme 1 
(10 units/pl) (Promega), lpl of restriction enzyme 2 (10 units/pl) (Promega) and sterile 
water to a final volume of 20pl. The reactions were incubated at 37°C for 4 hours.
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2.6 Electrophoretic Techniques applied to DNA samples
2.6.1 Agarose gel electrophoresis
Agarose gel electrophoresis was used to visualise PCR, PCR digest, RT-PCR and 
restriction enzyme digestion products.
Agarose gels were prepared by adding the appropriate amount of agarose (Sigma) to 
100ml of lx Tris borate EDTA (TBE) buffer (e.g. 1 gram per 100ml gives a 1% gel). 
TBE was diluted in water from a lOx concentrate solution (Invitrogen). The agarose 
was dissolved by heating in a microwave. The agarose solution was allowed to cool 
and 2pi of ethidium bromide (Sigma) (stock solution lOmg/ml in water) was added. 
The agarose was left to set in the gel apparatus (Biometra). Samples were mixed with 
TBE loading dye (1% bromophenol blue in 10% sucrose in 50ml lx TBE) in a ratio of 
4:1 v/v. The appropriate molecular weight markers were loaded and gels 
electrophoresed for 1 hour at 80-100V. The DNA bands were visualised and images 
captured on a dual intensity ultraviolet gel analysis system (UVP Ltd).
2.6.2 Polyacrylamide gel electrophoresis (PAGE)
For detection of the TNF-a -308 digestion products, PAGE gels were utilised. Gels of 
a final acrylamide concentration of 9% were made by mixing 5.5ml of a 40% 
Aciylamide:Bisacrylamide solution (29:1 ratio) (Sigma) with 14.5ml of lx  TBE 
buffer. 25% ammonium persulphate (APS) (Sigma) was made up fresh each day a 
PAGE gel was required. 65pi APS and 35pi of TEMED (Sigma) were added last to 
the gel mixture in order to crosslink the acrylamide/bisacrylamide solution permitting 
polymerisation to occur. The PAGE gel system used to electrophorese the gels was the
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Mini-PROTEAN III cell system (Bio-Rad). The apparatus was assembled according to 
manufacturers instructions and the gels allowed to polymerise for 40 minutes. Samples 
(mixed with TBE loading dye) were loaded onto the gel and electrophoresis carried 
out for 1 hour at 120 volts. Visualisation of bands was achieved by bathing the gels in 
50ml of lxTBE running buffer containing 2p,l of ethidium bromide (lOmg/ml stock 
solution) subsequent to electrophoresis. Gel images were captured using a dual 
intensity ultraviolet gel analysis system (UVP Ltd).
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2.7Cell culture methods
2.7.1 COS-7 Cell culture methods
For recombinant protein expression studies, the mammalian COS-7 cell line (ECACC, 
Porton Down) was used. The cells originate from African green monkey kidney cells 
transformed with the SV40 virus.
2.7.2 Cell feeding
Adherent cells were grown in 6ml complete Dulbeccos modified Eagles medium 
(DMEM) media (10% foetal bovine serum (FBS) and 2mM glutamine) (Sigma) in a 
37°C incubator at 5% CO2 levels in 25cm2 tissue culture flasks (Coming). Cells were 
fed 3-4 days by removal of the media and replacement with 5ml fresh complete media.
2.7.3 Cell counting
For accurate and reproducible cell densities, viable cell numbers were obtained by 
carrying out a trypan blue exclusion assay. Trypan blue is a dye which is taken up by 
dead cells but not viable cells. A haemocytometer was used to count the cells. This is a 
glass slide which contains 2 chambers of known volume. Each chamber contains a 
series of 1mm x 1mm squares. Viable cells were counted within each of these squares 
and the mean number of cells per square was calculated. Twenty microlitres of cells in 
complete media (Sigma) was mixed 1:5 with trypan blue (Sigma) and a small amount 
pipetted onto a haemocytometer, allowing a viable cell count to be made. The 
concentration of viable cells in the tissue culture flasks was subsequently calculated.
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2.7.4 Sub-culturing
When the COS-7 cells reached 70-80% confluency in the tissue culture flasks, they 
were diluted 1:10 to obtain cell densities of approximately 10,000 cells / cm2. Firstly, 
the cell media was discarded and the cells washed twice with 2ml PBS solution 
(Sigma). Subsequently, the cells were dislodged using 1ml of lx trypsin / EDTA 
solution (Sigma) per flask. The cells were incubated at 37°C for 10 minutes and 5ml 
complete media added. The cells were resuspended by shaking and a small aliquot 
removed for cell counting. The appropriate amount of complete media was then added 
and the cells plated out into a suitable number of 25 cm2 tissue culture flasks to obtain 
the correct cell density.
2.7.5 COS-7 cell transfection
Transfection of the COS-7 cell line with recombinant pCMV-TAG2b vector (and site- 
directed mutant derivatives) was required to facilitate production of the extracellular 
domain leptin receptor protein. Transfection was carried out using The TransIT COS 
transfection reagent (Mirus Corporation). This reagent consists of a mixture of 3:1 
wt:wt ratio of cellular protein and cationic polyamine which forms a complex with the 
vector DNA enabling the DNA to enter the target cells by an endosomal pathway.
24 hours prior to transfection, COS-7 cells were split into the appropriate number of 
25cm2 tissue flasks in complete media to obtain approximately 60-70% confluency the 
following day.
In a sterile 17 xl20mm tube (Falcon), 8pi of TransIT- COS reagent (Mirus) was 
added dropwise to 200pl of serum-free DMEM media and mixed thoroughly by
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vortexing. The mixtures were incubated at room temperature for 15 minutes. 4jil of 
COS Boss reagent (Mirus) was added to each mixture and subsequently incubated for 
15 minutes at room temperature. 2pg of pCMVtag2b plasmid DNA, and each of the 
site-directed mutant plasmids, were each added separately to a TransIT -COS / COS 
Boss reagent mixture and incubated for 15 minutes at room temperature. Each 
TransIT -COS/COS Boss/DNA complex mixture was added dropwise into its own 
25cm2 tissue culture flask and incubated for 72 hours at 37°C with a 5% C02 
atmosphere.
2.8 Protein purification and analysis
2.8.1 Imimmoprecipitation
The FLAG epitope tagged proteins produced after transfection of the COS-7 cells with 
recombinant pCMV vector can be affinity purified using highly specific antibodies 
raised against the epitope. This is the basis of the immunoprecipitation method carried 
out using the Sigma FLAG tagged protein immunoprecipitation kit containing 
monoclonal antibodies attached to an agarose resin. Immunoprecipitates were pooled 
from groups of tissue culture flasks, each group bemg transfected with a specific 
recombinant vector coding for one of the leptin receptor protein variants.
2.8.2 CeU lysis
The COS-7 cells were lysed to release the recombinant protein. The growth medium 
was removed and the cells washed twice with 5ml of lx PBS buffer (Sigma). 1ml
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lysis buffer (50 mM Tris-HCl, pH 7.4, 150mM NaCl, ImM EDTA, 1% Triton X-100) 
(Sigma) containing lOpl protease inhibitor cocktail (Sigma) (to inhibit protease 
degradation of the target protein) was added per 25cm2 tissue culture flask. After 
which, the flask was incubated for 30 minutes on a shaker at 4°C. The cells were lifted 
using a sterile cell scraper (Nunc) and collected into a 1.5ml tube. The cells were 
centrifuged for 10 minutes at 12,000 x g (Eppendorf 1615 centrifuge) and the 
supernatant transferred to a fresh tube.
2.8.3 Flag fusion protein immunoprecipitation
40jil resuspended agarose resin (Sigma) was added to an empty 1.5ml tube. The resin 
was centrifuged for 5 seconds at 10,600 x g. The supernatant was subsequently 
removed. The packed gel was washed 4 times with 0.5ml of 1 x wash buffer (0.05 M 
Tris-HCl, pH 7.4, 0.15 M NaCl) (Sigma) and after the last wash, 1ml of cell lysate was 
added. Samples were agitated overnight at 4°C allowing the antibody to bind to the 
FLAG epitope. The following day, the resin was centrifuged for 5 seconds at 10,600 x 
g and the supernatant discarded. The resin was washed three times with 0.5ml 1 x 
wash buffer.
2.8.4 Elution of the FLAG-fusion protein
Elution of the FLAG epitope tagged protein was carried out under native conditions by 
competition with a FLAG peptide. 150ng/pl FLAG peptide solution (Sigma) was 
added to the resin in each tube. The samples were incubated with gentle shaking for
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30 minutes at 4°C to facilitate displacement of the target protein. Subsequently, the 
resin was centrifuged for 5 seconds at 10,600 x g. The purified, target protein was 
transferred to a fresh tube and stored at -20°C until further use.
2.8.5 Leptin receptor enzyme-linked immunosorbent assay (ELISA)
A double monoclonal sandwich enzyme immunoassay (Abeam) was used for the 
quantitative measurement of human leptin receptor to determine the concentration of 
the recombinant human leptin receptor protein variants. This was achieved by 
incubating leptin receptor standards and the samples in a microtitration plate coated 
with monoclonal human leptin receptor antibody. A second anti-human leptin receptor 
antibody, labelled with horseradish peroxidase (HRP), was added and incubated with 
the immobilised antibody-leptin receptor complex. Addition of the HRP substrate, 
comprising of tetramethylbenzidine containing H2O2, produced a colour reaction which 
was measured spectrophotometrically at a wavelength of 450nm The absorbance is 
proportional to the concentration of the leptin receptor and by plotting the absorbance 
values versus the concentration of the leptin receptor standards; a standard curve was 
generated from which the concentration of the samples was determined.
50pl of each purified protein sample was diluted 1:3 with dilution buffer (Abeam). 
lOOpl of standards and diluted samples were pipetted in duplicate into the 
microtitration plate wells. The plate was incubated at room temperature for one hour. 
Subsequently each well was washed 3 times in 350pl of wash solution (Abeam). lOOpl 
of conjugate solution, containing the labelled antibody (concentration not provided in 
literature) (Abeam), was added and the plate incubated at room temperature for one
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hour. Then the wells were washed four times in 350jil of wash solution after which 
lOOfil of HRP substrate solution was added (concentration not provided in literature). 
The plate was incubated in the dark for 10 minutes at room temperature, after which 
the colour development was stopped by adding lOOpl of stop solution (Abeam). 
Finally the absorbance was read at 450nm by a UV spectrophotometer (Dynatech 
MRX).
2.8.6 Leptin receptor protein deglycosylation
Purified leptin receptor products were deglycosylated with the amidase enzyme 
PNGaseF (New England Biolabs) which cleaves a wide range of oligosaccharides that 
are linked to asparagine residues in the protein sequence (N-linked oligosaccharides). 
The protein was denatured in lx glycoprotein denaturing buffer (0.5% SDS, 1% p- 
mercaptoethanol) (New England Biolabs) for 10 minutes at 100°C. Subsequently, the 
sample was incubated in lx G7 reaction buffer (50mM sodium phosphate) (New 
England Biolabs), supplemented with 1% NP-40 (New England Biolabs), for 2 hours 
at 37°C.
2.8.7 Measurement of leptin binding activity
This procedure is based upon the method of Quinton and colleagues (1999) and is used 
to determine the specific binding of the recombinant human leptin receptor protein 
variants towards a radioactive ligand (leptin).
50[_il of serum (control sample) and 0.5 units (1 unit equals 2ng of human leptin 
receptor) of purified recombinant human leptin receptor samples were each incubated
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with 150|xl of assay buffer (0.01M phosphate buffer pH 7.4, 0.18M MgCl2, 1% BSA) 
and lOOpl of 125 iodinated leptin (135pCi/pg) (Linco research Co) in the absence of 
excess cold leptin (in order to measure total binding of leptin to all possible binding 
sites within the sample) or presence of excess cold leptin (lp.g) (R&D systems). The 
cold leptin displaced the radioactive leptin from specific sites leaving the radioactive 
leptin bound to non-specific sites, providing a non-specific binding measurement. 
Duplicate reaction samples were prepared for samples containing the cold leptin and 
also for those.lacking the cold leptin. The samples were then incubated for 16 hours at 
4°C. The bound and unbound fractions were separated by adding a charcoal slurry 
(2% charcoal (Norit), 0.2% dextran T-70 (Pharmacia) in assay buffer) which will bind 
to any free leptin. The assay tubes were mixed, incubated on ice for 10 minutes and 
centrifuged at 10,000 x g for 12 minutes at 4°C so that any leptin bound to the dextran 
would be pelleted. The supernatant was removed to a fresh tube and counted on an 
automatic y-counter (Wallac).
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2.8.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
For size analysis, proteins were resolved by molecular weight using one-dimensional 
SDS-PAGE. This technique uses discontinuous chloride and glycine ion fronts to form 
moving boundaries that stack and then separate SDS-coated polypeptides by molecular 
weight (Laemmli, 1970).
2.8.9 Sample preparation for SDS-PAGE
17pl sample was diluted with 33pl sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% 
SDS, 25% glycerol, 0.01% bromophenol blue, 5% 2-mercaptoethanol) and heated at 
95°C for 5 minutes before being applied to a pre-prepared gel.
2.8.10 Gel preparation and running conditions
The Mini-Protean III cell system from Bio-Rad Laboratories was used. Two 4-15% 
Tris-HCl gradient gels (Biorad) were utilised per cell system, in 400ml of lx  running 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS). Electrophoresis conditions 
consisted of a constant voltage of200V for 45 minutes.
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2.8.11 Protein Silver staining
This protein staining method is a modification of Blum's rapid silver stain procedure 
(Blum et ah, 1987). The chemical basis for the image development relies on the 
differential reduction of silver ions bonded to amino acid side chains enabling protein 
visualisation. The method is reversible and sensitive with reported limits of detection of 
l-5ng protein per band.
Each gel was placed in fixative (10% acetic acid v/v, ethanol 30% v/v) for 2 hours and 
rinsed in 20% v/v ethanol for 20 minutes followed by a 10 minute rinse in distilled 
water. Subsequently the gel was soaked in sensitiser solution (0.02% w/v sodium 
thiosulphate) for 1 minute and then rinsed three times in distilled water. Then the gel 
was soaked in silver nitrate solution (0.2% w/v silver nitrate) for 45 minutes, rinsed in 
distilled water and soaked in developer solution (0.3% w/v sodium carbonate, 0.025% 
v/v formaldehyde and 0.004% v/v sodium thiosulphate) until the intensity of the bands 
was adequate. To stop gel development, the gel was soaked in stop solution (5% w/v 
Tris Base) for 5 minutes. The gel image was captured using a Sony MVC-FD75 digital 
camera.
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2.9 Statistical Analysis
2.9.1 Hardy-Weinberg equilibrium
The frequency of genotypes observed from a polymorphic locus should remain 
constant from generation to generation assuming random mating has occurred. If this 
is so, then the population is in Hardy-Weinberg equilibrium for that locus. Two alleles 
of a biallelic locus, for example, Aj and A2, are observed at a frequency p  and q 
respectively. As such, p  + q -  1 and the expected genotype frequencies can be 
calculated as,
Frequency Ai Ai = p  2 x sample size (n)
Frequency Aj A2 = 2pq x n 
Frequency A2 A2 = q2 x n 
And p  2 +2pq + q2 = 1.
Subsequently, a chi-squared analysis (%2 ) (with 1 degree of freedom) is used to 
determine if the expected genotype frequencies determined from this equation differ 
significantly from those values observed experimentally. If there is no statistically 
significant difference then the observed balance of genotypes does not differ from that 
expected of a population in Hardy-Weinberg equilibrium If there is a difference then 
the cohort studied may have incorrectly assigned genotypes.
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2.9.2 Chi- squared (%2) analysis of contingency tables
%2 analysis enables measurement of the extent to which observed numbers in a 
contingency table deviate from the expected values. %2 distribution tables then show if 
the observed value deviates by a greater amount than would be expected by chance 
alone based on a null hypothesis that postulates no difference between observed and 
expected distributions. 2 (column) x 2 (row) contingency tables were used to compare 
alleles between different groups (i.e. control versus anorexic individuals).
The x2 value is obtained by the equation: %2 = E (o-e)2/ e 
Where o = observed number and e = expected number
The number of degrees of freedom for %2 is given by (number of columns -1) x 
(number of rows-1). The null hypothesis is rejected and the test statistic considered 
significant if it is assigned a p (probability) value which is less than 0.05. Such a value 
indicates that the probability of the findings occurring by chance is less than 5%.
An example of a 2x2 contingency table to calculate %2 is demonstrated in table 2.13.
Variable 1
0 1 Total
Variable 2 0 a b a+b
1 c d c+d
Total a+c b+d a+b+c+d
Table 2.13: An example of a 2x2 contingency table.
Subsequently, y2 can be calculated by the following equation: 
X2 = (ad-bc)2 (a + b + c + d) / (a + b) (c + d) (b + d) (a + c)
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2.9.3 Carriage rates
The frequency of an allele in a population can be increased by the presence of many 
homozygotes. To assess whether having one copy of a particular allele is sufficient for 
susceptibility to a disorder, carriage rates are determined. The carriage rate of an allele 
is the proportion of a population who carry at least one copy of that allele.
2.9.4 Haplotype analysis
The frequency of specific haplotypes in control and patient samples was calculated 
using the EH program (Xie and Ott 1993), including the assignment of haplotypes with 
unknown phase by a permutation function in the program. The FAS TEH software 
(Zhao and Sham, 2002) was employed to obtain a p-value via the %2 statistic, 
comparing the distribution of haplotype frequencies between case and control 
individuals. The null hypothesis that there was no significant difference in haplotype 
frequency between groups was rejected if p<0.05.
2.9.5 Coefficient of linkage disequilibrium (D’)
Using a biallelic example at two loci (ai, a2 and bi, b2), D is measurement of the 
departure from linkage equilibrium as determined by the following calculation:
D = PaibiP a2b2 - P a ^ P  a2bi (where P equals frequency)
The 2LD program used the haplotype frequencies obtained from the EH program and 
calculated D' which is a ratio between the actual value of D, and the maximum value it 
could possibly be for the given allele frequencies.
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2.9.6 Tests for normality
The Normal distribution represents the phenomenon whereby continuous variable data 
(i.e. data for which there an infinite number of values the variable can take) are 
distributed via a bell-shaped curve, symmetric about the mean, so that the mean equals 
the median value. Data that are distributed in this fashion can be subjected to parametric 
statistical tests. Data which are not distributed in this way, may be analysed by non- 
parametric tests. Continuous variable data were tested to determine whether the data were 
normally distributed. The Normal Probability Plot (Normal plot) was constructed by 
ranking observations into ascending order (e.g. of B3VH values) and then plotting this 
ranked data against the corresponding Normal Score (which is the number of standard 
deviations above or below the mean that we would expect the observations to lie if the 
data were Normally distributed). Graphically, the straighter the Normal plot, the more 
closely it follows a Normal distribution. The Shapiro-Wilk and Kolmogorv-Smimov tests 
were used to assess the straightness of the Normal plot. The test calculates the probability 
that the data were normally distributed. The null hypothesis for the test being that the 
distribution is normal, and a p-value of less than 0.05 rejects the null hypothesis. Figure
2.1 demonstrates an example of a Normal plot in which the data were found not to be 
normally distributed.
N o rm a l  P l o t o f B M I
- 2 -
40302010
Observed BMI kg/m2
B.
Tests of Normality
Kolmogorov-Smimov3
Statistic df Sig.
VAR00001 .095 97 .030
a* Lilliefors Significance Correction
Figure 2.1: A. Normality plot of BMI data constructed by ranking observed BMI values 
and plotting them against the corresponding Normal score (the number of standard 
deviations above or below the mean value that each data point would lie if it was 
normally distributed). B. Kolmogorov-Smimov test result for normality of plotted BMI 
data detailing the test statistic value of 0.095 and p-value of 0.03. Therefore the 
variable is not normally distributed.
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2.9.7 Mann-Whitney U test
The Mann-Whitney U test was used to compare the mean values between two 
independent samples of continuous data which were not normally distributed (for 
example the mean BMI values between two genotype groups for a particular SNP). 
The null hypothesis for testing such cases stipulates that there is no significant 
difference in means between the two samples. A p-value of less than 0.05 leads to 
rejection of the null hypothesis.
2.9.8 Box and whisker plot
Graphical representation and comparison between groups of a particular continuous 
variable (e.g. BMI between different genotype groups for a particular SNP) was 
achieved using a box and whisker plot. This consists of a box whose ends correspond 
to the interquartile range, i.e. the 25th and 75th centiles. A line inside the box marks the 
median. The length of the two straight lines (whiskers) drawn outwards from the ends 
of the box represent 1.5 times the interquartile range rolled back to where there is data. 
The ends of the whiskers are named as the lower and upper fences. Data points outside 
the fences are plotted individually and may be regarded as outlier (open circle) and 
extreme (star) values. Box and whisker values more accurately represent the spread 
and concentration of data points compared to scatter plots. If values of a continuous 
variable (for example BMI) are identical between different individuals they are simply 
superimposed on top of each other on a scatter plot. See figure 2.2 for an example of a 
box and whisker plot.
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N = 40
AA
33
GA
7
GG
Figure 2.2: Box and whisker plot o f leptin levels between genotype groups of 
the LYS109ARG leptin receptor SNP. The Shaded boxes represent the 
interquartile range for each data set and the region between the upper and 
lower fences represent 1.5 x the interquartile range. Open circles represent 
outlier data points and stars represent extreme value data points.
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Chapter 3 
Genetic studies of SNPs in the LEPR 
gene in relation to indicators of
adiposity
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3.1 Introduction
Single nucleotide polymorphisms (SNP) are the most common and evenly distributed 
genetic variations in the human genome, occurring as frequently as one every 300- 
lOOObp (Schork. etal, 2000).
In fact it has been estimated that 85% of all exons are within 5kb of at least one SNP 
(The International SNP Map Working Group 2001). Such a level of frequency and the 
ability to alter protein structure or expression levels as an end result of their sequence 
variation makes SNPs a potential source of susceptibility factors for disease. 
Furthermore, via linkage disequilibrium, they may act as 'beacons' for nearby disease- 
causing genetic targets.
Linkage disequilibrium occurs when a combination of alleles of a group of linked 
genetic markers (a haplotype), occurs at a frequency that differs significantly from that 
normally expected in a population. This phenomenon indicates that the alleles have 
been inherited together, because the physical distance between the loci is small 
reducing the likelihood for recombination to occur within that regioa An allele for a 
particular SNP may be associated with a particular phenotype. This SNP may be in 
linkage disequilibrium with alleles of other markers (including SNPs). Indeed, a 
particular haplotype may be associated with the phenotypic change. One or more of 
these alleles may have a functional effect on the phenotype or reflect linkage 
disequilibrium with nearby polymorphisms that are having a functional effect. In the 
case of SNPs in the LEPR gene, it may be that a certain SNP is associated with 
indicators of adiposity or is in linkage disequilibrium with another SNP in the gene that 
is exerting an effect or indeed that more than one SNP in a haplotype is involved.
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Inter-individual differences in BMI are highly heritable (Austin et a l, 1997, Rice etal., 
1999), and this could be due, in part, to variation in the LEP and LEPR receptor genes. 
Several SNPs have been discovered throughout the LEPR gene (Considine et al, 1996, 
Gotoda et al. 1997, Thompson et al. 1997). Studies have been undertaken to determine 
whether these SNPs are implicated as indicators of adiposity. The GLN223ARG SNP 
has been linked to fat mass in Caucasians (Chagnon et al., 1999). Homozygosity of the 
G allele for the GLN223ARG SNP has been associated with fat mass and BMI in 
middle-aged men and post-menopausal women (Chagnon et al, 2000, Yiannakouris et 
al, 2001 and Quinton et al., 2001). The LYS656ASN SNP has been associated with 
waist circumference in postmenopausal overweight females (Wauters et al., 2001) and 
the LYS109ARG SNP has been linked to BMI and fat mass in Caucasians (Chagnon et 
al., 2000). This study expands upon the initial work by Quinton et al (2001) by 
analysing the LYS109ARG and LYS656ASN SNPs (in addition to the GLN223ARG 
SNP) for associations with adiposity in a population of postmenopausal women from 
the Sheffield area (ages ranging from 59.2 to 70.1 years old).
It has been observed that there are differences in the leptin system between males and 
females. Women have higher leptin levels than men even after adjustment for fat mass 
(Hickey et al., 1996, Saad et al., 1997). Leptin levels also vary significantly during the 
menstrual cycle (Hardie et al., 1997). Therefore limiting the study cohort to 
postmenopausal women only, may limit hormonal effects.
Any associations found with a particular SNP could be explained by a direct effect on 
the protein function or reflect linkage disequilibrium with other polymorphisms within 
the same gene or nearby. Serum leptin binding activity (LBA) data are available from 
this cohort. The technique measures the ability of soluble leptin receptor, present in the 
individuals serum, to bind radioactively labelled leptin. Any differences in LBA
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associated with a certain allele may reflect functional differences in ligand binding or 
receptor dimerisation due to the fact that the SNPs code for amino acid changes in the 
extracellular domain of the receptor. As all the SNPs genotyped in this study are 
expressed in the leptin receptor, they will all be present in the soluble form of the 
receptor.
3.1.1 Aims of the study
Two LEPR SNPs were studied, LYS109ARG and LYS656ASN. The data were 
combined with information previously amassed for the GLN223ARG SNP. The aims 
of the study were to:
• genotype postmenopausal subjects for the two SNPs;
• seek associations between these SNPs and BMI, fat mass and leptin levels;
• analyse the potential effects of the amino acid changes on ligand binding via the 
LBA data;
• determine the extent of linkage disequilibrium between these SNPs and also the 
GLN223ARG SNP.
3.2 Study Design
Blood for genotyping studies was collected from a community-based cohort of 
Caucasian postmenopausal women, from the Sheffield area (by Professor R Eastell 
from the Northern General Hospital, as part of an osteoporosis epidemiological study 
funded by the Arthritis Research Campaign) (n=200). However, complete clinical data 
were only available for a sub-set of these women, and only these women were analysed 
for associations. Blood was spotted onto standard neonatal blood cards and dried
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overnight before storage at room temperature. Clinical details were recorded at the 
time of sample collection. Subjects gave informed consent and the studies had the 
approval of the North Sheffield Local Research Ethics Committee. The sub-group of 
women included in the study of leptin levels and LBA were selected as they were not 
undergoing hormone replacement therapy or using corticosteroids. Serum leptin levels 
had been measured by Allison Lee (at the University of Sheffield) using the Linco 
Research Co. RIA kit. Serum LBA had been measured by Naomi Quinton (at Sheffield 
Hallam University) by incubating serum samples, stripped of endogenous leptin, with 
iodinated leptin in the presence (to measure non-specific binding) or absence (to 
measure total binding) of 'cold' leptin. Radioactivity counts were determined using a 
gamma counter. The specific binding obtained was expressed as a percentage of the 
total [125I] -leptin counts per minute incubated in 50pl of serum 
Genotyping was carried out as described in chapter 2, sections 2.2.1 and 2.2.2. An A 
to G base change codes for the LYS to ARG amino acid substitution at codon 109 and 
a G to C base change codes for the LYS to ASN amino acid change at codon 656. The 
GLN223ARG SNP was not typed in this present study, instead it was typed at a prior 
date by by Naomi Quinton. In this SNP, an A to G base change codes for the GLN to 
ARG amino acid substitution at codon 223. Visualisation of the alleles for 
LYS 109ARG and LYS656ASN SNPs are shown in figure 3.1.
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3.2.1 Statistical Analysis
The distribution of genotypes was tested for deviation from Hardy-Weinburg 
equilibrium by %2 analysis (see chapter 2, section 2.9.2).
The continuous variable data (BMI, leptin levels, fat mass, lean mass and LBA) were 
analysed for normal distribution using SPSS software (see chapter 2, section 2.9.5). 
The data were not normally distributed due to the small number of study samples with 
with data values generally deviating from the tails of a normal distribution (see section 
2.9.6, figure 2.1). As the data deviated from a normal distribution, the Mann-Whitney 
U test was used to compare the difference in means between genotype groups for a 
given variable instead of the 2 sample t-test, which is used when the data is normally 
distributed. Furthermore, mean values were compared between individuals carrying 
and not carrying the most common allele. To do this, genotype groups including the 
most common allele (AA and AG for the LYS109ARG SNP, and GG and GC for the 
LYS656ASN SNP) were combined into one group and the mean value of a given 
variable for this combined group was compared to the mean value for the group not 
carrying the most common allele (GG and CC for the LYS 109 ARG and LYS656ASN 
SNPs respectively). This particular procedure has been repeatedly used in the literature 
including studies by Quinton and colleagues (2001). Mammes and colleagues (2001) 
and Hofistedt and colleagues (2002). Data were displayed graphically in a boxplot 
format using SPSS software (see chapter 2, section 2.9.7). Haplotype frequencies were 
determined using the EH program (Xie and Ott, 1993) and D and D’ constants were 
calculated using the 2LD program (Zhao, 2002) to gauge the degree of linkage 
disequilibrium between alleles for each SNP (see chapter 2, sections 2.9.3 and 2.9.4).
85
Figure 3.1: i) Picture o f the LYS109ARG SNP genotypes on a 3% agarose gel 
displaying, A. hyperladder IV DNA marker (Bioline), B. homozygous A 
genotype (70bp), C. homozygous G genotype (lOlbp) and D. heterozygous AG*, 
genotype,.
ii) Picture of the LYS656ASN genotypes on a 3% agarose gel displaying, A. 
hyperladder IV DNA marker (Bioline), B. homozygous G genotype (87 bp), C. 
homozygous C genotype (55bp) and D. heterozygous GC genotype (87 + 55bp)
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3.3 Results
3.3.1 LYS109ARG polymorphism
To determine allele and genotype frequencies, 184 subjects have been genotyped for 
the LYS109ARG SNP. The calculated allele frequencies (p = 0.74, q = 0.26) agree 
well with previous studies (see table 3.1). The distribution of homozygotes and 
heterozygotes observed, do not differ significantly from that expected of a population 
in Hardy-Weinberg equilibrium (see table 3.2).
All continuous variable data, which were grouped to a corresponding genotype, was 
analysed to determine whether it fitted a normal distribution. All such data were not 
normally distributed and so the non-parametric Mann-Whitney U test was carried out 
to compare the means for each variable between genotype groups (table 3.3). Boxplots 
of the different variables are shown in figures 3.2-3.6. For comparison, the data 
acquired by Quinton and colleagues (2001) for the GLN223ARG SNP in the same
cohort is displayed in table 3.4.
Allele Post­
menopausal 
women 
n=184 
(This study)
Lean British 
males 
(n=132) 
Gotoda et 
al, 1997
Obese British 
males 
(n=190) 
Gotoda et al, 1997
Caucasian males and 
females 
(n=190) 
Chagnon et a l ,2000
A 0.74 OJA 0.73 0.73
G 0.26 0.26 0.27 0.27
Table 3.1: Comparison of allele frequencies for the LYS109ARG SNP with published results
Observed genotype 
frequency
Expected genotype 
frequency
n n
Heterozygotes 73 71
Homozygous A o o 101
Homozygous G 11 12
Total 184 184
Table 3.2: Predicted genotype values from the Hardy-Weinberg equation for 
LYS 109ARG using the determined allele frequencies. The %2 p-value (1 degree of 
freedom) comparing the expected to observed genotype frequencies was 0.627.
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Genotype P value
AA AG GG
(AA+AG vGG) 0.017
BMI (kg/m2) 27.03 ± 0.52 1 26.15 ±0.73 23.16 ±0.88 (AAvGG) 0.008
N= n=54 n=31 n=7 (AAvAG) ns
0.014
Fat mass (g) 28587 ±1215 24714 ± 1227 18519 ±3753 0.009
N= n=46 n=32 n=6 0.035
ns
Lean mass (g) 36156 ±791 36381 ±908 33894 ± 1442 ns
N= n=46 n=32 n=6 ns
Serum leptin ns
concentration 20.76 ±1.88 18.31 ±2.10 25.27 ±2.83 ns
ng/ml N= n=40 n=33 n=7 ns
ns
Serum LBA (%) 10.41 ± 0.50 10.37 ± 0.54 11.53 ±2.36 ns
N= n=35 n=18 n=4 ns
Table 3.3: Mean levels of BMI, fat mass, lean mass, serum leptin levels and serum LBA 
for each genotype of the LYS109ARG SNP. P values were calculated by comparing non­
carriage of the A allele (AA+AG v GG), AA v GG and AA v AG genotypes using a 
Mann-Whitney U test.1 ± standard error of mean
Genotype P value
AA AG GG
BMI (kg/m2) 
N=
26.2 ± 0.07 1 
n=24
26.75 ± 0.7 
n=37
24.3 ± 0.88 
n=15
(AA + AG versus GG)0.009
Fat mass (g) 
N=
26393 ± 1325 
n=30
28859 ±1411 
n=43
22051± 1875 
n=15
0.006
Lean mass (g) 
N=
35990 ±1049 
n=30
36613 ± 1047 
n=43
36186 ±1138 
n=15
ns
Serum leptin 
concentration 
ng/ml N=
18.3 ±2 
n=26
23.8 ±2.5 
n=43
12.6 ±1.6 
n=15
0.0001
Serum LBA (%)
N=
10.5 ±0.50 
n=21
9.7 ± 0.5 
n=18
11.6± 0.9 
n=4
0.04
Table 3.4: Mean leve s of BMI, fat mass, lean mass, serum leptin levels and serum LBA
for each genotype of the GLN223ARG SNP (Quinton et al, 2001). P values were 
calculated by comparing non carriage of the A allele (AA + AG versus GG).
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Figure 3.2: Boxplot of BMI data grouped to AA, AG and GG genotypes of the 
LYS109ARG SNP. The mean of the GG homozygous group (non-carriage o f the A 
allele) is significantly lower than the mean of the combined AA/AG genotype groups 
(p = 0.017). The mean of the GG group is also significantly lower than the AA 
genotype group (p=0.008).
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Figure 3.3: Box plot displaying fat mass levels for individuals grouped to the 
AA, AG and GG genotypes for the LYS109ARG SNP. The mean of the GG 
homozygous group (non-carriage of the A allele) is significantly lower than 
the mean of the combined AA/AG genotype groups (p = 0.014). The mean of 
the GG group is significantly lower than the AA genotype group (p=0.009). 
The mean o f the GG group is also significantly lower than the AG genotype 
group (0.035).
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Figure 3.4: Box plot displaying lean mass levels for individuals grouped to
AA, AG and GG genotypes for the LYS109ARG SNP. There is no
significant difference in mean levels between groups.
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Figure 3.5: Box plot displaying leptin levels for individuals grouped to AA,
AG and GG genotypes for the LYS109ARG SNP. There is no significant
difference in mean levels between groups.
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Figure 3.6: Box plot displaying LB A for individuals grouped to AA, AG and GG
genotypes for the LYS109ARG SNP. There is no significant difference in mean
levels between groups.
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3.3.2 LYS656ASN polymorphism
To determine allele and genotype frequencies, 191 subjects have been genotyped for 
the LYS656ASN SNP. The calculated allele frequencies (p = 0.77, q = 0.23) agree 
with previous studies (see table 3.5). The observed balance of homozygous and 
heterozygous genotypes for this SNP did not differ significantly from that expected of 
a population in Hardy-Weinburg equilibrium (see table 3.6).
Mann-Whitney U tests were again used to compare mean values for each variable 
between genotype groups (table 3.7). Boxplots for each variable are shown in figures 
3.7-3.11.
Allele Post- 
Menopausal 
women 
n=191 
(This study)
Lean British
Males 
(n=132) 
Gotoda et al, 
1997
Obese British
Males 
(n=190) 
Gotoda et al, 
1997
Caucasian
Males 
(n=178) 
Chagnon et al, 
2000
G 0.77 0.84 0.82 0.82
C 0.23 0.16 0.18 0.18
Table 3.5: Comparison of allele frequencies for LYS656ASN with published results
Observed genotype 
frequency
Expected genotype 
frequency
n n
Heterozygotes 62 68
Homozygous G 116 113
Homozygous C 13 10
Total 191 191
Table 3.6: Predicted genotype results obtained from for Hardy-Weinburg equation for 
LYS656ASN using the determined allele frequencies. The p-value for the %2 analysis 
(1 degree of freedom) comparing the expected to the observed genotype frequencies 
was 0.242.
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Genotype P value
GG GC CC
(GG+GC v CC) ns
BMI (kg/m2) 26.04 ± 0.56 1 26.74 ±0.78 26.10 ±1.44 GG v CC ns
N= n=54 n=31 n=8 (GC v CC) ns
ns
Fat mass (g) 25602± 1063 27299± 1929 28785 ± 3676 ns
N= n=50 n=24 n=8 ns
ns
Lean mass (g) 36290 ±765 35724± 703 35631 ±2621 ns
N= n=50 n=24 n=8 ns
Serum leptin ns
concentration 17.68 ±1.50 20.90 ±2.54 25.27 ±9.22 ns
ng/ml N= n=52 n=22 n=5 ns
ns
Serum LBA (%) 10.08 ± 0.55 10.90 ±0.66 10.91 ± 1.02 ns
N= n=24 n=23 n=7 ns
Table 3.7: Mean levels of BMI, fat mass, lean mass, serum leptin levels and serum LBA 
for each genotype of the LYS656ASN SNP. P values were calculated by comparing non­
carriage of the G allele (GG+GC v CC), GG v CC and GC v CC genotypes using a Mann- 
Whitney U test. 1 ± standard error of mean
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Figure 3.7: Boxplot of BMI data grouped to GG,GC and CC genotypes of the 
LYS656ASN SNP. There is no significant difference in mean levels between 
groups.
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Figure 3.12: Graph displaying the fat mass of individuals with different combinations of the LYS109ARG and GLN223ARG genotypes 
(GLN223ARG genotype shown in bold and the horizontal bars represent the mean value for each group).
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Figure 3.8: Box plot displaying fat mass levels for individuals grouped to
GG, GC and CC genotypes for the LYS656ASN SNP. There is no
significant difference in mean levels between groups.
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Figure 3.9: Box plot displaying lean mass levels for individuals grouped to
GG, GC and CC genotypes for the LYS656ASN SNP. There is no significant
difference in mean levels between groups.
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Figure 3.10: Box plot displaying leptin levels for individuals grouped to GG, GC
and CC genotypes for the LYS656ASN SNP. There is no significant difference in
mean levels between groups.
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Figure 3.11: Box plot displaying LBA activity for individuals grouped to GG,
GC and CC genotypes for the LYS656ASN SNP. There is no significant
difference in mean levels between groups.
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3.4 Haplotype results
Other genetic studies have detected that LEPR SNPs are in linkage disequilibrium 
(Thompson et a l, 1997, Gotoda et a l, 1997).
Following genotyping for the LYS109ARG and LYS656ASN SNPs (in addition to the 
previously typed GLN223ARG), it is possible to determine whether alleles of the three 
SNPs are in linkage disequilibrium in this population. Firstly, the haplotype frequencies 
were calculated for individuals typed for all three SNPs using the EH software (see table 
3.8). Using the 2LD software, D' was subsequently calculated for the different pairwise 
SNP combinations (table 3.9). The largest value (0.64), indicating the most significant 
linkage disequilibrium, was obtained from the genotypes of the LYS109ARG and 
GLN223ARG SNPs. A %2 analysis of D between SNPs revealed that linkage 
disequilibrium between alleles of the LYS109ARG and GLN223ARG SNPs was 
statistically significant (p<0.00001), whilst the other pairwise combinations were not 
(table 3.10).
As described, the mean fat mass was seen to be statistically different for individuals 
homozygous for the G allele of the LYS109ARG SNP compared to the AG heterozygotes 
or the A homozygotes. The data were analysed in conjunction with the genotypes 
previously obtained for the GLN223ARG SNP for which an association with the G allele 
and fat mass was observed. The mean fat mass was lowest in individuals who were 
homozygous for the G allele in both SNPs compared to the other genotype combinations 
for the LYS109ARG and GLN223ARG SNPs (see figure 3.12).
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Haplotype 
LYS109ARG GLN223ARG LYS656ASN
Cohort
A A G 0.41
A A C 0.13
A G G 0.14
A G C 0.08
G A G 0.05
G A C 0
G G G 0.17
G G C 0.03
Table 3.8: Estimated haplotype frequencies determined for study cohort
SNP combination Df
109 + 223 0.64
109 + 656 0.34
223 + 656 0.03
Table 3.9: D' values calculated by pairwise analysis of SNPs by 2LD software
SNP combination p value
109 + 223 <0.00001
109 + 656 0.12
223 + 656 0.76
Table 3.10: P values for the D values which were calculated by pairwise analysis
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3.5 Discussion
Possible genetic associations with indicators of adiposity in a cohort of 
postmenopausal European Caucasian women were investigated. The availability of this 
cohort was advantageous as postmenopausal women may be less susceptible to 
hormonal influences. Sex hormones could modify leptin levels and adiposity in women 
who go through the reproductive cycle. Furthermore, a gender specific study may also 
clarify analysis. For example, Mammes and colleagues (2001) suggested a gender- 
gene interaction when they reported an association between the 'silent' SER343SER 
SNP and fat mass in the LEPR gene with Caucasian women only, from a mixed gender 
cohort. As this is a silent change they hypothesised that the SNP may be in association 
with a functional polymorphism lying in the regulatory region of the LEPR gene.
No associations were detected between the LYS656ASN SNP and the various, 
continuous variable data However, associations were detected for both fat mass and 
BMI with the G allele of the LYS109ARG SNP (which codes for the arginine amino 
acid). That associations were highlighted for both these indicators of adiposity was 
advantageous, as BMI measurements do not readily distinguish between fat and lean 
mass. Therefore fat mass is a more accurate measurement of adiposity.
Linkage disequilibrium analysis suggests that the LYS109ARG and GLN223ARG 
SNPs are in linkage disequilibrium
Quinton et al, (2001) highlighted positive associations with fat mass, BMI and leptin 
levels and the GLN223ARG SNP. Because linkage disequilibrium has been established 
between the two SNPs it is unclear which SNP is having an effect or whether both are 
having an effect to varying degrees although the multiple associations might suggest 
that the GLN223ARG is of prime importance. One strategy to help clarify this issue is 
to cany out functional studies. The LBA assay goes some way towards addressing
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this. LBA was significantly associated with GLN223ARG SNP in Quinton’s study but 
not with the LYS109ARG SNP in this study of the same cohort. The LYS to ARG 
amino acid substitution is a conservative substitution with the same overall charge 
being maintained which would presumably have a minimal affect on protein function. 
Nevertheless, the LBA data are not conclusive as the number of individuals analysed 
for LBA was less than the number of individuals with recorded BMI and fat mass data. 
For the LYS 109ARG SNP, fifty seven individuals were analysed for LBA whilst fat 
mass and BMI data were available for 84 and 92 individuals respectively. For the 
GLN223ARG SNP, LBA data were available for 60 individuals whilst fat mass and 
BMI data were available for 88 and 76 individuals respectively. Furthermore, other 
proteins in the serum (which could bind to leptin) may contribute to the LBA readings. 
Also, the amount of soluble leptin receptor was not quantified in the serum samples. It 
is possible, therefore, that the LBA data correlates with the GLN223ARG SNP 
because that SNP may be associated with higher levels of soluble receptor protein 
expression which would increase the LBA count, potentially masking any functional 
differences at the amino acid level.
Finally, conservative amino acid changes in the leptin receptor have been shown to 
create an effect. The GLN to PRO substitution at codon 269 (fa mutation) in the 
homologous rat leptin receptor protein maintains a neutral charge (at pH 6-7) but 
alters the signalling qualities of the receptor (Chua et al, 1996, Phillips et al., 1996). 
Clearly, association studies can contribute to our understanding of a condition but to 
augment and further clarify the situation, functional studies should be considered.
In vitro analysis of ligand binding and / or receptor dimerisation characteristics, of 
proteins expressing different combinations of the SNPs would be one way of gaining 
further insights into the issue.
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Chapter 4
Functional studies of the leptin receptor
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4.1 Introduction
In the mid 1990s, ground-breaking studies involving the identification and 
characterisation of entities implicated in obesity took place. This was an essential 
precedent to our current, and evolving, understanding of the way humans regulate 
food intake and energy expenditure.
Following the discoveiy of the mouse ob gene product, leptin, by Zhang et al, (1994) 
the next step was to identify high affinity leptin-binding sites that would effectively 
locate the leptin receptor. Tartaglia and colleagues (1995) achieved this by generating 
leptin-AP (alkaline phosphatase) fusion proteins which located binding sites in the 
choroid plexus tissue of the mouse brain. This enabled screening of a cDNA expression 
library of the tissue, again with leptin-AP fusion proteins and identification of a 5. lkb 
cDNA insert that codes for the leptin receptor in mice. The open reading frame 
encoded a single membrane-spanning protein with a mature extracellular domain 
predicted to contain 816 amino acids (minus a 22 amino acid secretion signal 
sequence). A 23 amino acid transmembrane domain and an intracellular domain of 34 
amino acids were also predicted. Afterwards, Chua and colleagues (1996) isolated 
clones coding for intracellular domains of varying length. Using the cDNA insert as a 
probe, a human cDNA homologue was identified and the predicted amino acid 
sequence was deduced to be 78% identical to that of the mouse form.
Subsequent work further characterised the properties of the leptin receptor. Lua and 
colleagues (1997) expressed and characterised both a full length and putative high 
affinity human soluble leptin receptor lacking the transmembrane and intracellular 
domains. The purified soluble protein product was sized at 130-150kDa as determined 
by Western blot analysis and Coomassie staining. As the native protein was predicted
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to be around 94kDa, the protein was assumed to be extensively glycosylated. 
Expression of the soluble form of the receptor in CHO cells and subsequent de- 
glycosylation studies highlighted a heavily N-glycosylated protein with minimal O- 
glycosylation (Haniu et al, 1998).
As any mutations in the receptor were a potential molecular basis for dysregulation of 
body weight, studies were conducted to detect mutations in the human LEPR gene 
which, in particular, caused obesity. Although few gross mutations were discovered 
(Clement et al, 1998), several SNPs were discovered, some of which code for amino 
acid substitutions throughout the protein (Gotoda et al, 1997, Thompson et al, 
1997). Of the amino acid substitutions that occur in the extracellular domain, one SNP 
codes for a LYS109ARG amino acid substitution, that is present in a cytokine 
homology domain of the protein. Another codes for the GLN223ARG substitution 
found within a loop region that is located between cytokine homology and fibronectin 
type III domains. Finally, a LYS656ASN amino acid change resides within a further 
fibronectin type III domain.
In genetic studies, these SNPs have been associated with traits of obesity. Specifically, 
the GLN223ARG SNP has been highlighted by Chagnon et al, 1999, Chagnon et al, 
2000, Yiannakouris et a l ,2001 and Quinton et al, 2001. The LYS109ARG SNP has 
been highlighted in this present study and the LYS656ASN SNP has been highlighted 
by Wauters et al, 2001. Due to the phenomenon of linkage disequilibrium, however, 
it is not clear-cut whether any positive associations found for one specific SNP are 
functionally significant or are actually due to another nearby SNP or a group of SNPs 
acting in unison. Quinton and colleagues (2001) measured leptin binding activity in 
serum from individuals (using a radiolabelled leptin ligand) who had been genotyped 
for the GLN223ARG SNP in the LEPR gene. Greater activity was associated with the
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ARG amino acid. However the contribution of other proteins in the serum cannot be 
discounted from the radioactivity count.
One potential way of tackling these issues is to engineer and then purify variant leptin 
receptor proteins, expressing different combinations of the SNPs, which would allow 
them to be analysed individually.
4.1.1 Aims of study
The aims of this study are:
1. to engineer variants of the leptin receptor protein that include different amino acids 
corresponding to SNPs in the coding region of the LEPR gene;
2. to characterise these protein variants;
3. to measure the ability of these variants to bind leptin via a radioactive leptin 
binding assay.
4.2 Study Design
4.2.1 PCR amplification and cloning of soluble LEPR
In the first instance, the coding DNA sequence for the soluble form of the human leptin 
receptor protein was obtained from HEK293 cells (human embryonic kidney cells) as 
previous work in the laboratory established that these cells express the protein 
(unpublished observations). RNA was obtained from these cells and RT-PCR carried 
out to obtain the cDNA for the soluble form of LEPR (See chapter 2, sections 2.4.1 
and 2.4.2). The PCR primers were designed to amplify a product of 2457bp. This 
contains sequence coding for codons 23 to 841 of the extracellular domain of the
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LEPR cDNA sequence with the forward primer containing additional sequence to 
generate a BamHI restriction enzyme site for ease of cloning. Figure 4.1 shows an 
agarose gel of the PCR reaction highlighting a single band of the predicted size 
representing the soluble LEPR cDNA whilst no DNA is seen in the lane containing a 
control sample lacking a cDNA template.
This DNA was subsequently cloned into the pGEM -T vector (Promega) (see chapter 
2, section 2.5.1). This vector is amenable to the cloning of PCR products because it is 
provided in a linearised form due to a restriction enzyme digest, after which single 
thymine base overhangs are added to the 5' positions. During PCR, Taq DNA 
polymerase adds adenine base overhangs when the enzyme reaches the end of a DNA 
fragment, so that PCR products have an unpaired adenine at the 3' ends. As a result, 
during a DNA ligation reaction, the adenine and thymine base overhangs of the PCR 
product (insert) and vector can form complementary base pairings. Once the PCR 
product has been ligated into the plasmid, subsequent digestions, to enable sub-cloning 
for example, are greatly facilitated because restriction enzymes work most efficiently 
when a sufficient length of DNA flanks the target restriction sequences. Therefore, in 
this scenario, it can be assured that the insert DNA sequence will have undergone 
complete digestion when compared to enzyme digestion of sites towards the termini of 
PCR fragments. A plasmid map of the pGEM-T vector and its multiple cloning site 
region is shown in figure 4.2. Figure 4.3 shows an agarose gel containing restriction 
digestions of recombinant pGEM-T vector. It displays the successful cloning of the 
LEPR cDNA insert into the pGEM-T vector, with lane B showing 2 bands 
representing the vector and insert respectively and lane C showing a band representing 
the linearised form of the vector + insert.
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Figure 4.1: Photograph of LEPR RT-PCR product on a 1% agarose gel containing, A: lkb DNA marker 
(Promega), B: LEPR RT-PCR product (2547bp) and C: negative control lacking a DNA template.
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Figure 4.2: Plasmid map of pGEM-T vector and DNA sequence o f its multiple 
cloning site. The red and green highlighted sequences display the restriction 
enzyme sites used to sub-clone the LEPR cDNA sequence into the pCMV Tag-2B 
vector. , .  _
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Figure 4.3: Photograph of recombinant pGEM-T vector on a 0.8% agarose gel containing, A: lkb 
DNA marker ( Promega), B: BamHl and Sail restriction enzyme digestion of recombinant pGEM- 
T vector and C: BamHl restriction enzyme digestion of recombinant pGEM-T vector (5.5kb).
Item D is a schematic representation of the BarnHl and Sail restriction enzyme digestion of the 
recombinant pGEM-T vector.
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The Bam HI restriction enzyme site present at the 5' end of the cloned LEPR cDNA 
insert and the Sal I restriction enzyme site present in the pGEM-T multiple cloning site 
region were used to sub-clone the insert into the pCMV-Tag 2B vector (see chapter 2, 
section 2.5.2). This is a eukaiyotic expression vector able to facilitate the expression of 
cloned inserts in mammalian cells. Figure 4.4 depicts a map of the plasmid alongside its 
multiple cloning site region. The plasmid contains an SV40 origin of replication that 
enables it to replicate in large copy numbers in COS-7 cells because they express the 
viral SV40 large T antigea A cytomegalovirus (CMV) promoter sequence to initiate 
translation is also present. Furthermore, the plasmid contains sequence coding for a 
FLAG tag (adjacent to the cloned insert) which is a hydrophobic sequence enabling the 
FLAG/insert fusion protein product to be affinity purified with monoclonal antibodies 
to the FLAG 'tag'.
Figure 4.5 shows an agarose gel containing restriction digestions of recombinant 
pCMV-Tag 2B vector DNA It demonstrates the successful sub-cloning of the LEPR 
cDNA insert into the pCMV-Tag 2B vector with lane B showing a band representing 
the linearised form of the vector + insert and lane C showing two bands representing 
the vector and insert respectively.
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Figure 4.4: Plasmid map of pCMV-Tag 2B expression vector and sequence of multiple 
cloning site region containing restriction sites, highlighted in red and blue, used to 
insert LEPR cDNA.
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BamHl
pCMV-Tag 2B LEPR insert
Figure 4.5: Photograph o f recombinant pCMV-Tag 2B on a 1.8% agarose gel displaying,
A:lkb DNA marker (Promega), B: BamHl and Sail restriction enzyme digestion of recombinant 
pCMV-Tag 2B vector and C: BamHl restriction enzyme digestion of recombinant 
pCMV-Tag 2B vector (6.8kb).
Item D is a schematic representation of the BamHl and Sail restriction enzyme digestion o f 
recombinant pCMV-Tag 2B.
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The recombinant plasmid DNA was sent to the Applied Biotechnology Centre, 
Imperial College London, for DNA sequencing (see chapter 2, section 2.5.8) to 
confirm that the DNA sequence was that of the human LEPR cDNA sequence and 
that the insert was cloned in-frame relative to the multiple cloning site of the plasmid. 
The insert DNA sequence was translated into amino acid sequence using DNASTAR 
Editseq software (version 4.05). The translated amino acid sequence is shown in figure 
4.6 alongside vector-encoded amino acids that would be expressed as part of the 
fusion protein and also with the different domains of the leptin receptor protein 
superimposed onto the amino acid sequence. The amino acid sequence is identical to 
that of codons 23 to 841 of the reference leptin receptor amino acid sequence (NCBI 
database accession number NP002294) with the exception that the arginine amino 
acid is present at codon 223 in the clone sequence compared to glutamine in the 
reference sequence, but this is simply a natural site of variation reflecting a SNP in the 
relevant position of the DNA sequence. The translated sequence demonstrates that the 
cloned insert is in fact the extracellular domain of the LEPR cDNA and that no 
mutations have been incorporated into the DNA sequence.
Figure 4.7 shows the DNA sequence across the pCMV-Tag 2B multiple cloning site / 
insert boundary and confirms that the insert is cloned in-frame in relation to the vector 
sequence and as such, the sequence will be expressed in the correct reading frame.
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Met A s p  Tvr Lvs A s p  A s p  A sp  A sp  L v s  Ser Pro Glv Glv Ser Asn Leu Ser Tyr
Pro lie Thr Pro Trp Arg Phe Lys Leu Ser Cys Met Pro Pro Asn Ser Thr Tyr Asp 
Tyr Phe Leu Leu Pro Ala Gly Leu Ser Lys Asn Thr Ser Asn Ser Asn Gly His T\
Glu Thr Ala Val Glu Pro Lys Phe Asn Ser Ser Gly Thr His Phe Ser Asn Leu Ser
Lys Thr Thr Phe His Cys Cys Phe Arg Ser Glu Gin Asp Arg Asn Cys Ser Leu Cys
Ala Asp Asn lie Glu Gly Lys Thr Phe Val Ser Thr Val Asn Ser Leu Val Phe Gin
Gin He Asp Ala Asn Trp Asn He Gin Cys Trp Leu Lys Gly Asp Leu Lys Leu Phe 
lie Cys Tyr Val Glu Ser Leu Phe Lys Asn Leu Phe Arg Asn Tyr Asn Tyr Lys Val 
His Leu Leu Tyr Val Leu Pro Glu Val Leu Glu Asp Ser Pro Leu Val Pro Gin Lys
Gly Ser Phe Gin Met Val His Cys Asn Cys Ser Val His Glu Cys Cys Glu Cys Leu
Val Pro Val Pro Thr Ala Lys Leu Asn Asp Thr Leu Leu Met Cvs Leu Lys He Thr 
Ser Gly Gly Val lie Phe Arg Ser Pro Leu Met Ser Val Gin Pro lie Asn Met Val Lys 
Pro Asp Pro Pro Leu Gly Leu His Met Glu He Thr Asp Asp Gly Asn Leu Lys He 
Ser Trp Ser Ser Pro Pro Leu Val Pro Phe Pro Leu Gin Tyr Gin Val Lys Tyr Ser Glu 
Asn Ser Thr Thr Val He Arg Glu Ala Asp Lys He Val Ser Ala Thr Ser Leu Leu Val 
Asp Ser lie Leu Pro Gly Ser Ser Tyr Glu Val Gin Val Arg Gly Lys Arg Leu Asp 
Gly Pro Gly lie Trp Ser Asp Trp Ser Thr Pro Arg Val Phe Thr Thr Gin Asp Val He 
Tyr Phe Pro Pro Lys He Leu Thr Ser Val Gly Ser Asn Val Ser Phe His Cys He Tyr 
Lys Lys Glu Asn Lys He Val Pro Ser Lys Glu He Val Trp Trp Met Asn Leu Ala 
Glu Lys He Pro Gin Ser Gin Tyr Asp Val Val Ser Asp His Val Ser Lys Val Thr Phe 
Phe Asn Leu Asn Glu Thr Lys Pro Arg Gly Lys Phe Thr Tyr Asp Ala Val Tyr Cys
Cys Asn Glu His Glu Cys His His Arg Tyr Ala Glu Leu Tvr Val He Asp Val Asn
He Asn He Ser Cys Glu Thr Asp Gly Tyr Leu Thr Lys Met Thr Cys Arg Trp Ser 
Thr Ser Thr He Gin Ser Leu Ala Glu Ser Thr Leu Gin Leu Arg Tyr His Arg Ser Ser 
Leu Tyr Cys Ser Asp He Pro Ser He His Pro He Ser Glu Pro Lys Asp Cys Tyr Leu 
Gin Ser Asp Gly Phe Tyr Glu Cys He Phe Gin Pro lie Phe Leu Leu Ser Gly Tyr Thr 
Met Trp He Arg He Asn His Ser Leu Gly Ser Leu Asp Ser Pro Pro Thr Cys Val Leu 
Pro Asp Ser Val Val Lys Pro Leu Pro Pro Ser Ser Val Lys Ala Glu He fh r  He Asn 
He Gly Leu Leu Lys lie Ser Trp Glu Lys Pro Val Phe Pro Glu Asn Asn Leu Gin 
Phe Gin lie Arg Tyr Gly Leu Ser Gly Lys Glu Val Gin Trp Lys Met Tyr Glu Val
Tyr Asp Ala Lys Ser Lys Ser Val Ser Leu Pro Val Pro Asp Leu Cys Ala Val Tyr
Ala Val Gin Val Arg Cys Lys Arg Leu Asp Gly Leu Gly Tyr Trp Ser Asn Trp Ser
Asn Pro Ala Tyr Thr Val Val Met Asp He Lys Val Pro Met Arg Gly Pro Glu Phe
Trp Arg He He Asn Gly Asp Thr Met Lys Lys Glu Lys Asn Val Thr Leu Leu Trp 
Lys Pro Leu Met Lys Asn Asp Ser Leu Cys Ser Val Gin Arg Tyr Val lie Asn His 
His Thr Ser Cys Asn Gly Thr Trp Ser Glu Asp Val Glv Asn His Thr Lys Phe Thr 
Phe Leu Trp Thr Glu Gin Ala His Thr Val Thr Val Leu Ala lie Asn Ser lie Gly Ala 
Ser Val Ala Asn Phe Asn Leu Thr Phe Ser Trp Pro Met Ser Lys Val Asn He Val 
Gin Ser Leu Ser Ala Tyr Pro Leu Asn Ser Ser Cys Val lie Val Ser Trp lie Leu Ser 
Pro Ser Asp Tyr Lys Leu Met Tyr Phe He He Glu Trp Lys Asn Leu Asn Glu Asp 
Gly Glu He Lys Trp Leu Arg He Ser Ser Ser Val Lys Lys Tyr Tyr He His Asp His 
Phe He Pro He Glu Lys Tyr Gin Phe Ser Leu Tyr Pro He Phe Met Glu Gly Val Gly 
Lys Pro Lys He He Asn Ser Phe Thr Gin Asp Asp He Glu Lys His Gin Ser Asp Ala 
Gl\ lie Thr Ser Ala Ala Ala Cvs Arg Ser Thr Ser Arg Glv Glv Pro Val Val Asp 
Leu Glu Glv Glv Pro Glv Thr
Figure 4.6: Protein sequence of translated LEPR cDNA clone presenting the domain regions 
as follows; CK domains in green, loop region in b lue, F3 domains in turquoise and the C2 
domain in pink. pCMV-Tag 2B vector encoded amino acids are highlighted in black, 
underlined font and the LYS109ARG, GLN223ARG and LYS656ASN variant amino acids 
are highlighted in red font.
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THRASN SER PRO ILELEU TYRBam HI site
Figure 4.7: DNA sequence chromatogram of recombinant pCMV-Tag 2B vector 
showing the BamHl restriction site present within the multiple cloning site of the vector 
immediately followed by an ASN codon . This is codon no.23 of the LEPR cDNA 
sequence and demonstrates that the cDNA sequence was cloned in-frame relative to the 
vector sequence.
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4.2.2 Site-directed mutagenesis
To enable expression of the extracellular protein variants coded for by the different 
combinations of the LYS109ARG and GLN223ARG SNPs in the DNA sequence, site- 
directed mutagenesis was utilised. Variants of the LYS656ASN SNP were not 
constructed as results in this thesis indicate that this SNP has not been associated with 
indicators of adiposity and was not determined to be in significant linkage 
disequilibrium with the other SNPs (see chapter 3). The method is described in chapter 
2, section 2.5.3. Essentially, it relies upon the annealing of two primers (in separate 
reactions for each SNP) to exactly the same sequence on opposite DNA strands across 
the region of the recombinant pCMV-Tag 2B plasmid which contains the desired site 
to be mutated. In the middle of the primer sequences, a single mismatched base is 
present at the desired site of mutation which, after DNA amplification, will result in the 
incorporation of this alternative base in the recombinant 'daughter1 plasmids. After 
amplification, the non amplified plasmid DNA (which is methylated) was digested by 
the enzyme Dpn I which preferentially targets methylated DNA leaving the amplified 
daughter plasmids (which are not methylated) available to be transformed into 
bacterial cells and spread onto antibiotic agar plates (to select for transformed 
bacteria). Plasmid DNA was purified from colonies which subsequently grew, and sent 
to the Applied Biotechnology Centre, Imperial College London for DNA sequencing 
to confirm that the site-directed mutagenesis reactions were successful.
This methodology allowed the generation of different combinations of the 
GLN223ARG and LYS109ARG SNPs. Figure 4.8 shows the A to G base change that 
was required to generate the LYS to ARG amino acid change in the protein sequence 
at codon 109. Figure 4.9 shows the G to A base change, which was required to
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generate the ARG to GLN amino acid substitution at codon 223. Following site- 
directed mutagenesis, the following combinations were generated;
1. LEPR insert in original parental recombinant plasmid containing sequence coding 
for the LYS amino acid at codon 109 and the ARG amino acid at codon 223.
2. LEPR insert in daughter plasmid which contains the sequence coding for the ARG 
amino acid at codon 109, after changing the DNA sequence for that codon from 
AAG to AGG, whilst maintaining the ARG amino acid at codon 223.
3. LEPR insert in daughter plasmid which contains the sequence coding for the GLN 
amino acid at codon 223, after changing the DNA sequence for that codon from 
CGG to CAG, whilst maintaining the LYS amino acid at codon 109.
Note that the combination of ARG at codon 109 and GLN at codon 223 remains to be 
created.
4.2.3 Recombinant LEPR production and protein analysis
Once the mutagenesis reactions were finished and confirmed by sequence analysis, 
each plasmid was separately transfected into COS-7 mammalian cells to enable 
expression of the protein variants (see chapter 2, section 2.7.5). Furthermore, as 
control experiments, the cells were transfected with the native pCMV-Tag 2B vector 
and flasks were also incubated in the absence of vector.
Following 72 hours incubation, proteins were affinity purified from the lysates using a 
FLAG tag immunoprecipitation kit (Sigma) (chapter 2, section 2.8.3 and 2.8.4).
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Figure 4.8: DNA sequence chromatogram confirming the A to G base change 
that codes for a LYS to ARG amino acid substitution at codon 109 of the LEPR 
cDNA sequence.
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GLN
Figure 4.9: DNA sequence chromatogram confirming the G to A base change 
that codes for an ARG to GLN amino acid substitution at codon 223 of the 
LEPR cDNA sequence.
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The protein products were visualised on a 4-15% SDS-PAGE gel (Figure 4.10), and 
the molecular weight of the purified protein was determined by constructing a standard 
log graph of the distance migrated in the gel by the SDS-PAGE protein standards 
(Bio-Rad) (figure 4.11). As such, the relative molecular mass of the protein was 
estimated to be 125-130kDa. No protein product was observed in cells transfected 
with the native vector only. Nor was any protein product observed in the cell media 
To confirm that the purified protein was in fact the human leptin receptor, it was 
analysed via a specific double monoclonal human leptin receptor ELISA (Abeam) (see 
chapter 2, section 2.8.5). Using the statistical software package, FigP, a standard curve 
was generated from the absorbances obtained for a series of soluble LEPR standards of 
known concentrations (see figure 4.12). From this graph, the software derived the 
concentration from the absorbances of the various purified LEPR protein variants. The 
samples were diluted 1 in 3 upon addition to the ELISA plate and each sample and 
standard was measured in duplicate (Table 4.1).
LEPR variant Average absorbance for 
diluted samples (450nm)
Neat sample 
concentration (U/ml)*
Blank sample 0.017 -
LYS109:ARG223 0.09 8.2
ARG109:ARG223 0.103 9
LYS 109.GLN223 0.093 8.3
Table 4.1: ELISA results for LEPR protein variants. * 1 unit equals 2ng recombinant 
leptin receptor standard.
Leptin receptor , was not detected in purified samples from cells transfected with the 
native pCMV-Tag 2B vector or in the media of cells transfected with the recombinant 
plasmid.
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45kDa
Figure 4.10: Photograph of silver-stained 4-15% SDS-PAGE gel displaying, A: High 
molecular weight protein standard (BioRad), B: affinity purified LYS109:ARG223 
recombinant leptin receptor protein variant from lysed COS-7 cells, C: PnGaseF treated 
LYS109:ARG223 leptin receptor protein, D: affinity purified control sample obtained 
from COS-7 cells transformed with native pCMV-Tag 2B plasmid only, E: affinity 
purified LYS109:ARG223 leptin receptor variant protein from COS-7 cell media, F: 
affinity purified ARG109:ARG223 leptin receptor protein variant from lysed COS-7 
cells and G: affinity purified LYS109:GLN223 leptin receptor protein variant from 
lysed COS-7 cells.
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Log graph of distance migrated by marker in SDS-PAGE gel
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Figure 4.11: Log graph of distance migrated by marker protein bands in 4-15% TRIS-HCL gel.
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Figure 4.12: Standard curve o f absorbances o f leptin receptor ELISA protein standards
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Recombinant expression of proteins in mammalian cells should contain similar post- 
translational modifications to the original protein of interest. Such modifications are 
important, in particular, protein glycosylation which is common on cell-surface receptors 
is known to facilitate ligand binding (Rudd et ah, 1999). To analyse the extent of 
glycosylation of the recombinant protein, a sample was digested with the enzyme 
PNGaseF that removes saccharides linked to asparagine amino acids in the protein 
sequence (see chapter 2, section 2.8.6). Figure 4.10 displays the deglycosylated protein in 
lane C. As determined from the log graph of the distance migrated by the protein 
standards in the SDS-PAGE gel, the deglycosylated protein was estimated to be 95-100 
kDa.
The expressed protein contains codons 23 to 841 and was engineered to lack the first 22 
amino acids of the primary sequence, which is assumed to be the signal sequence. This 
strategy was followed because, originally, an (unsuccessful) attempt was made to express 
the cDNA in bacterial cells which lack the cell machinery to cleave signal sequences. The 
signal sequence directs the protein through the endoplasmic reticulum and towards the 
cell membrane. Because of this, the remaining amino acid sequence was submitted to 
software which uses neural network algorithms to analyse the biochemical properties of 
amino acid strings embedded within the protein that may direct the protein to specific 
subcellular locations in the absence of the putative signal sequence. The software, 
TargetP version 1.01 (Emanuelsson et ah, 2000), and SignalP (Nielsen et ah, 1997) was 
used to search for such sequences. No specific sequences were detected however.
A method of measuring and comparing the leptin binding of the variant proteins is to 
subject them to the leptin-binding assay. This procedure is explained in chapter 2, section
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2.8.7, but essentially involves incubating the purified leptin receptor sample with I125 
leptin in the presence or absence of non-radioactive leptin. By subsequently measuring 
the radioactivity counts on a y-counter, the total binding of the ligand (sample containing 
radioactive leptin) minus the non-specific binding (sample containing radioactive and 
non-radioactive leptin) equals the specific binding of radioactive ligand to the receptor. 
Specific binding was measured for the LYS109/ARG223 and LYS109/GLN223 variants 
with 0.5 units (determined from ELISA results where 1 unit is equivalent to 2 ng of leptin 
receptor) of each variant present in each tube. The total and non-specific measurements 
were carried out in duplicate. Figure 4.13 shows the specific binding for both variants, 
alongside a positive (serum) control (to determine that the assay is working) and a blank 
control (lacking purified leptin receptor protein). Clearly, the samples are specifically 
binding the radioactive leptin (compared to the blank). These preliminary results suggest 
that there may be differences in ligand binding associated with the SNPs tested but the 
experiment would need to be repeated in multiples to statistically validate any results, as 
at the time there was insufficient sample to repeat the experiments.
Furthermore, due to time constraints towards the end of this body of work, and because 
more of this particular purified protein was used up during the SDS-PAGE analysis, the 
ARG109ARG223 protein was not available to be tested via the LB A assay and would 
therefore need to be tested for future experiments. Also, the ARG109GLN223 was not 
generated which would have enabled analysis of the LYS 109ARG mutation on leptin 
binding to the receptor.
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Figure 4.13: Graph displaying radioactive counts per minute emitted from I125 
leptin specifically bound to leptin receptor protein variants, serum sample and 
water sample (measurements were carried out in duplicate and the mean counts 
per minute plotted).
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4.3 Discussion
As a result of this study, a series of soluble human leptin receptor protein variants 
have been created. They are available as a set of tools to compare and contrast their 
properties. This would be of substantial scientific interest because several genetic 
studies have sought associations between SNPs in the leptin receptor cDNA sequence 
and indicators of adiposity. Some of these studies have highlighted an association or 
linkage with a particular SNP (Chagnon et al., 1999, Chagnon et al, 2000, 
Yiannakouris et al, 2001, Quinton et al, 2001) whilst others have not (Echwald et 
al, 1997, Matsuoka et al, 1997, Silver et al., 1997). A limitation of these studies is 
that it is difficult to distinguish which SNP is having an effect if linkage 
disequilibrium occurs. Also different population groups make up the sample cohort 
between studies. As a result, different environmental factors may contribute to 
varying degrees between studies depending upon population susceptibility. 
Furthermore, population admixture and stratification may confound results. One way 
of dissecting the issue would be to compare functional properties of purified leptin 
receptor variants such as the ability to dimerise or bind leptin using. in-vitro 
methodologies. Importantly, it would enable the comparison of specified 
combinations of SNPs expressed in each variant to potentially assign functionally 
significant effects to certain SNPs and not others. Using purified protein would also 
remove the affect of any systemic accessory proteins, which participate in the 
leptin:leptin receptor interface in vivo. ,
t.
Characterisation of the leptin receptor has been attempted by deletion studies of its 
extracellular domain (Fong et al., 1998, Sandowski et al., 2002). The extracellular 
domain contains two repeating CK-F3 domains separated by an amino acid loop 
sequence. Combined CK-F3 domains form ligand-binding sites in other cytokine
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receptors (Livnah et al, 1996, Wells and de Vos, 1996). By comparing binding of 
radiolabelled leptin to different deletion mutants of the extracellular domain, Fong 
suggested that the second CK-F3 is required for leptin binding and receptor 
activation. This region does not contain the LYS109ARG or GLN223ARG variants. 
However as more than one association study has identified lowered BMI in 
association with the ARG amino acid of the GLN223ARG variant (Chagnon et al, 
2000, Yiannakouris et al, 2001, Quinton et al, 2001), it is possible that this form has 
enhanced activity. One possible explanation may be that this variant enhances leptin 
binding or receptor activation and as such would not be detected by Fong’s 
methodology, which only generated mutants which resulted in reduced ligand binding 
compared to the full-length wild type receptor. Fong comments that the first CK.F3 
domain may not affect leptin binding in his experiments because the 'unusually long 
connecting loop may confer a very high degree of flexibility, preventing the formation 
of a stable leptin-binding site’. As the GLN223ARG variant is present in this loop and 
the ARG variant is associated with lowered indicators of adiposity, then this variant 
may stabilise the loop region, reducing the degree of flexibility and improving leptin 
binding and / or receptor activation properties. However, it must be noted that the 
preliminary results from the work presented here do not indicate enhanced leptin 
binding and if this is held true after more detailed analysis then an alternative 
explanation would be required to explain the association between this variant and 
lowered BMI.
/
/-Whilst'‘generating these protein variants, incidental observations were made of the
/molecular properties of the protein. The expressed protein lacked the first 22 amino 
acids that are a putative signal sequence (Tartaglia et al, 1995). This was so 
constructed because the protein was initially intended to be expressed in bacterial
iI
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cells which lack the protein machinery to cleave signal sequences from pro-peptides. 
Unfortunately the protein failed to express in a bacterial system and so was tested in a 
eukaryotic system. No protein was detected in the COS-7 cell media by SDS-PAGE 
or ELISA analysis but it was detected in the cell lysates. This suggests that the 
putative signal sequence is real. Of interest is the deglycosylation experiment which 
suggests that the protein is heavily N-glycosylated as a reduction in size from 
approximately 130kDa to 95kDa was observed after treatment with the enzyme 
PNGaseF. The protein size agrees well with expression of the leptin receptor from 
COS-7 cells by Liu et al (1997). They characterised a size of approximately 130kDa 
by Western blot analysis and Coomassie staining of the purified soluble receptor, and 
suggested that this was probably the glycosylated form of the receptor. Haniu et al, 
(1998) expressed the soluble leptin receptor in CHO cells and detected a purified 
protein of approximately 145kDa which was extensively N-glycosylated at about 36 
% of the total protein weight. In this study, the predicted molecular weight from 
amino acid sequence alone is 97kDa (93.5kDa leptin receptor + 4kDa vector-encoded 
amino add sequence). The reduction, from about 130kDa to this size following 
deglycosylation agrees with data produced by Haniu that the protein is extensively 
glycosylated, even in a different eukaryotic cell system Signal sequences are 
generally assumed to direct nascent proteins to the endoplasmic reticulum, where. N- 
glycosylation occurs, and subsequently to the Golgi apparatus where the attached
oligosaccharides are modified, before location to the cell surface and secretion out of
/.
the cell. Although the signal sequence is missing, it does not appear to have 
deleteriously affected protein glycosylation levels. It is possible that sorting signals 
embedded within the receptor amino add sequence may contribute to locating it to the 
ER. Software analysis of the receptor protein sequence did not detect any obvious
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sorting sequences. It may be that novel sorting sequences are present which carry out 
the procedure. It should be noted from the ELISA results that the overall level of 
recombinant protein expression is substantially lower than that commonly observed 
for transient expression in COS-7 cells (Warren and Shields, 1984; and Seed and 
Aruffo, 1987). It could be hypothesised, therefore that loss of the signal sequence 
reduces the amount of recombinant protein sorted to the ER but that the protein which 
does reach the ER is adequately glycosylated.
Certainly the observations in this study warrant further examination to characterise 
the phenomenon.
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Chapter 5
Investigation of polymorphisms in other 
relevant cytokine genes in relation to
adiposity
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5.1 Introduction
As research into eating disorders and obesity has progressed, the interaction of leptin 
with other members of the cytokine network has become apparent and specific 
relationships uncovered.
Although BMI correlates with leptin (Considine et al., 1996) and inversely correlates 
with leptin receptor levels (Ogier et al., 2002), individuals with an equivalent BMI 
have variable levels of these proteins. It is therefore important to find additional factors 
that might have an influence on this. The pleiotropic and overlapping nature of 
cytokine activity means that other cytokines deserve investigation regarding obesity in 
association with the leptin system as well as on their own merits. In this chapter, 
polymorphisms in other relevant cytokine genes have been investigated in addition to 
leptin receptor SNPs previously studied in this thesis.
As discussed in the introduction to this thesis, leptin is a satiety factor that is released 
into the blood stream from adipocytes and is able to cross the blood-brain barrier and 
bind specifically to receptors in the hypothalamus where it elicits signals to regulate 
food intake and energy expenditure.
Screening of the coding region of the LEP gene has yielded very few mutations that 
might contribute to obesity. As a result, studies of the 5' flanking region ensued.
In one study, several sequence variants were found, three of which were found to 
differ in allele frequencies between obese and non-obese women (W-D, Li et al,
1999). The most significant difference was observed for the G to A -2548 
polymorphism with the A allele reported to be associated with higher leptin levels in a 
study of men and women (Mammes et al, 1998). Mammes and colleagues (2000) 
went on to show that the G allele was associated with lowered leptin levels and
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overweight in men only. However, Le Stunff et al, (2000) published results which 
showed that in young, obese Caucasian girls, the A allele is associated with lower 
leptin levels between girls of comparable adiposity. More recently, Hoffstedt and 
colleagues (2002) observed that adipose tissue leptin mRNA levels were higher in AA 
homozygotes compared to GA/GG subjects in non-obese females.
Another relevant factor is tumour necrosis factor alpha (TNF-a). It was originally 
called cachexin because it induces cachexia (marked loss of weight and wasting) (for 
review Beutler and Cerami, 1989). Grunfeld et al, (1996) and Sarraf et al., (1997) 
have reported that TNF-a administration increases leptin levels in rodents. In humans, 
Zumbach et al, (1997) demonstrated that TNF-a infusion increases serum leptin levels 
in patients with solid tumours, whilst Mantzoros et al, (1997) have shown a positive 
association between TNF- a  and leptin levels with BMI in healthy controls and people 
with non-insulin dependent diabetes. Tumour necrosis factor alpha (TNF-a) belongs to 
the TNF family of cytokines. It acts predominately through two transmembrane 
receptors, TNF receptors 1 and 2 (TNFR1 and 2) which are found on a variety of cell 
types including fibroblasts, endothelial cells and adipocytes and are also present in 
soluble form. TNF-a is often referred to as the master pro-inflammatory cytokine with 
cell signalling leading to increased expression of other pro-inflammatory cytokines, 
such as IL-6 and IL-1.
Within the 5'-flanking region of the TNF-alpha gene, 308 nucleotides upstream from 
the transcription initiation start site, resides the TNF-alpha G-308 A SNP. The A allele 
appears to increase promoter activity and has been linked to several diseases, many of 
which are immune related (Abraham and Kroeger, 1999). With regard to obesity, the 
A allele is reported to be more frequent in individuals with a higher BMI (Brand et al,
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2001) suggesting a susceptibility locus for obesity. Also, Hoflstedt et al, (2000) 
reported an allele specific difference confined to women only, whereby the A allele was 
again associated with higher BMI and also fat mass.
A further cytokine that may be involved in weight regulation is the interleukin receptor 
antagonist (IL-lra). Leptin has been shown to induce expression and secretion of IL- 
lra from monocytes (Gabay et al., 2001). The molecular basis for this effect was 
subsequently investigated (Dreyer et al, 2002). It was discovered that the induction of 
IL-lra by leptin required the long form of the leptin receptor and activation of p42/44 
MAPKs which binds to a nuclear factor kappaB site of the ILRN promoter.
IL-lra levels are elevated in obese individuals, with a positive linear correlation with 
leptin levels, and are reduced after loss of body weight and lowered leptin levels 
resulting from surgery (Meier et al, 2002). EL-lra is secreted from many cell-types, 
but particularly macrophages in unison with IL-1 alpha (a) and IL-1 beta (P). These 
are released in response to injury or an immunological insult and promote 
inflammation. IL-lra binds to the IL-1 type 1 and type 2 receptors, as do IL-la and 
IL-lp, but unlike these two molecules, it does not elicit intracellular signalling events. 
As such, it is a competitive inhibitor of IL-1 activity, acting as an endogenous anti­
inflammatory agent.
The DL1RN gene contains a variable number tandem repeat (VNTR), with a core 
repeat sequence, 86bp in length. Five alleles have been reported (Lennard et al, 1992, 
Tarlow et al, 1993), with the 2 x 86bp repeat (known as IL1RN*2) implicated in 
severity of clinical course of various disorders, including systemic lupus erythematosus 
and ulcerative colitis (Blakemore et al, 1994 and Mansfield et al, 1994). It has been 
postulated that IL1RN*2 may correlate with a lowered level of production of IL-lra 
(Tarlow eta l, 1993, Blakemore etal., 1994).
Leptin regulates IL-lra and also IL-lra protein levels correlate with leptin levels. It is 
possible that a variation, in response to leptin, may be partly influenced by the VNTR 
alleles. As IL-lra inhibits IL-1 activity, which has cachexic properties, any potential 
variation in IL-lra response to leptin may consequently modulate the cachexic effects 
of IL-1. Alternatively, altered levels of IL-lra could adjust leptin levels via cytokine 
cross-talk involving positive and/or negative feedback pathways although no studies 
have reported that IL-lra can influence leptin levels.
The apparent clinical, molecular and cell biological observations that implicate the 
cytokines leptin, TNF-a and IL-lra with regulation of weight highlight the validity of 
analysing polymorphisms within their gene sequences to determine any associations 
with markers of adiposity. This was carried out in a cohort of Caucasian 
postmenopausal women from the Sheffield area who had previously been analysed for 
SNPs in the LEPR gene in relation to indicators of adiposity.
5.1.1 Study aims
Three polymorphisms were investigated in this study, the -2548 LEP promoter 
polymorphism, the G-308A TNF-alpha polymorphism and the IL1RN VNTR 
polymorphism
The aims of these studies were to:
• determine whether there is evidence for associations between these polymorphisms 
and markers of adiposity
• determine whether the leptin promoter polymorphism effects serum leptin levels (as 
previously reported in males) in a postmenopausal female study group;
• investigate whether the TNF-a promoter SNP and IL1RN VNTR influence serum 
leptin levels.
5.2 Study Design
The study design is the same as presented in chapter 3, section 3.2.
Genotyping was carried out as described in chapter 2, sections 2.2.3 and 2.2.4. The 
genotypes for the LEP G -2548 A SNP are shown in figure 5.1, in figure 5.2 for the 
TNF-alpha G-308A SNP and in figure 5.3 for the IL1RN VNTR
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Figure 5.1: Photograph of LEP -2548 SNP genotypes on a 3% nusieve agarose gel 
displaying A: 50bp DNA marker (Promega), B: AA genotype (241 bp), C: GA 
genotype and D: GG genotype (181bp).
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Figure 5.2: Photograph of TNF alpha G-308A SNPgenotypes on a 9% 
polyacrylamide gel displaying, A: 50bp DNA marker (Promega), B: the 
GG genotype (107bp), C: the AG genotype and D: the AA genotype 
(87bp).
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Figure 5.3: Photograph of the IL1RN VNTR genotypes on a 2% agarose 
gel displaying A: <])X174 HaeIII DNA marker (Promega), B: 4,4 repeat 
genotype (410bp), C: 4,5 repeat genotype, D: 2,2 repeat genotype 
(230bp), E: 2,4 repeat genotype and F: 2,5 repeat genotype. Note that the 
5 repeat is approximately 500bp.
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5.2.1 Statistical Analysis
Genotype results were analysed by the Hardy-Weinberg equation to determine if the 
distribution of heterozygotes and homozygotes fitted that expected of a population in 
Hardy-Weinberg equilibrium (see chapter 2, section 2.8.1). Continuous variable data 
were analysed using SPSS software to determine whether it was normally distributed 
(see chapter 2, section 2.8.6). Statistical comparison of the means of data grouped to 
each genotype for a particular SNP were analysed by a Mann-Whitney U test (see 
chapter 2, section 2.8.7). Data were displayed graphically using boxplots, plotted using 
SPSS software (see chapter 2, section 2.8.8).
5.3 Results
5.3.1 LEP  G -2548 A SNP
98 individuals were typed for this SNP. The observed genotypes were in Hardy- 
Weinberg equilibrium and allele frequencies of 0.51 and 0.49 were calculated for p and 
q (see table 5.1). Whilst this data indicates that the A allele is the most frequent allele 
in this cohort, due to the small sample size and the closeness in frequencies of the G 
and A alleles in other groups studied (table 5.1), the G allele is treated as the most 
common allele for statistical analysis. The continuous variable data were not normally 
distributed and the Mann-Whitney U test was used to compare the mean value for each 
variable between genotype groups (see table 5.2 and figures 5.4-5.8).
Allele Post­
menopausal 
women (n=98)
Le Stunff et al (2000) 
Obese Caucasian girls 
(n=93)
Mammes et al (1998) 
Overweight Caucasian men 
and women (n=l 17)
Hoffstedt et al (2002) 
non-obese Caucasian 
women
G 0.49 0.5 0.56 0.49
A 0.51 0.5 0.44 0.51
Table 5.1 : Comparison of allele frequencies for the LEP G -2548 A SNP with published results
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Observed genotype 
frequency
Expected genotype 
frequency
n n
Heterozygotes 53 49
Homozygous A 23 25
Homozygous G 22 24
Total 98 98
Table 5.2: Predicted genotype distribution obtained fromt le Hardy-Weinberg equation
for the ZjEP-2548 SNP using the determined allele frequencies. The p-value for the %2 
analysis of comparing the expected to the observed genotype frequencies was 0.42 (1 
degree of freedom).
Genotype P value
GG AG AA
(AAvGG) 0.012
BMI (kg/m2) 27.08 ±0.82 26.75 ± 0.56 25.28 ± 0.89 * (AAv AG/GG) 0.045
N= n=22 n=53 n=23 (AA v AG) NS
NS
Fat mass (g) 28368 ± 2083 26261± 1102 25095 ± 2052 NS
N= n=19 n=47 n=19 NS
NS
Lean mass (g) 35285 ± 1671 36545 ± 622 35937 ± 1082 NS
N= n=19 n=47 n=19 NS
Serum leptin 0.035
concentration ng/ml 20.90 ±10.61 20.05 ± 10.61 14.95 ±11.29 0.017
N= n=18 n=43 n=20 0.015
Normalised 0.07
serum leptin 0.79 ±0.081 0.74 ±0.045 0.57 ±0.059 0.014
(ng/ml per kg fat mass) 0.015
N= n=17 n=42 n=18
Table 5.3: Mean levels of BMI, fat mass, lean mass and serum leptin levels for each 
genotype of the LEP -2548 SNP. P values were calculated by comparing non-carriage 
of the G allele (GG/AG v AA genotype groups), AA v GG and AA v AG genotype 
groups using a Mann-Whitney U test * ± standard error of mean
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Figure 5.4: Boxplot of BMI levels grouped to the AA, AG and 
GG genotypes of the LEP -2548 SNP. Comparison of the mean 
value for the AA group with the AA/AG groups showed that it 
was significantly lower (p=0.045). This group was also 
significantly lower than the GG genotype group (p=0.012)
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Figure 5.5: Boxplot of fat mass levels grouped to the AA, AG and 
GG genotypes of the LEP -2548 SNP. There is no significant 
difference between the mean of each groups.
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Figure 5.6: Boxplot of lean mass levels grouped to the AA, AG and GG 
genotypes of the LEP -2548 SNP. There is no significant difference between 
the mean of each groups.
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Figure 5.7: Boxplot of serum leptin levels grouped to the AA, AG and GG 
genotypes of the LEP -2548 SNP. Comparison of the mean value o f the AA 
group with the combined other two groups showed that it was significantly 
lower (p=0.017). This group was also lower than the GG genotype group 
(p=0.035) and the AG group (p=0.015)
148
lep
tin
 l
eve
ls 
(ng
/m
l p
er 
kg 
fat 
m
as
s)
1.8
1.6
1.4
1.2 
1.0
.8
.6
.4
.2 
0.0
N = 18 42 17
AA AG GG
LEP  -2548 Genotypes
Figure 5.8: Boxplots of normalised serum leptin levels grouped to the AA, 
AG and GG genotypes of the LEP -2548 SNP. Comparison of the mean value 
of the AA group with the combined other two groups showed that it was 
significantly lower (p=0.014). This group was also significantly lower than 
the GG group (p=0.07) and the AG genotype group (0.015).
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5.3.2 TNF-alpha G-308A SNP
97 individuals were typed for the -308 polymorphism The balance of observed 
genotypes was as predicted by the Hardy-Weinberg equilibrium from the allele 
frequencies of 0.8 (p) and 0.2 (q) respectively (table 5.3). Mann-Whitney U analysis 
was used to compare the mean variable value between genotype groups (table 5.4 and 
figures 5.9-5.13).
Allele Post­
menopausal 
Caucasian women
n=97 
(This study)
Rasmussen et al 
(2000) 
Danish Caucasian 
men and women 
n=380
Fernandez-Real et al 
(1997)' 
Spannish Caucasian 
men and women 
n=38
Brand et al (2001)
German Caucasian 
men and women 
n =176
G 0.80 0.81 0.76 0.84
A 0.20 0.19 0.24 0.16
Table 5.4: Comparison of allele frequencies for the TNF-alpha G-308A SNP with published results
Observed genotype 
frequency
Expected genotype 
frequency
n . n
Heterozygotes 31 31
Homozygous A 4 4
Homozygous G 62 62
Total 97 97
Table 5.5: Predicted genotype distribution obtained fromt le Hardy-Weinberg equation
for the TNF-alpha G -308A SNP using the determined allele frequencies. The p-value 
for the %2 analysis of comparing the expected to the observed genotype frequencies 
was 0.96 (1 degree freedom).
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Genotype P value
GG AG AA
(AA v GG) NS
BMI (kg/m2) 26.75 ± 0.571 26.05 ± 0.65 28.4 ±2.29 (AA v GG/GA) NS
N= n=62 n=31 n=4 (AA v AG) NS
NS
Fat mass (g) 27216 ±1254 24219 ± 1274 28349± 3370 NS
N= n=51 n=29 n=4 NS
NS
Lean mass (g) 36742 ±514 34558 ±1314 39047 ±1138 NS
N= n=51 n=29 n=4 NS
Serum leptin NS
concentration 20.61 ± 1.85 15.57 ±1.77 20.15 ±3.56 NS
ng/ml N= n=49 n=27 n=4 NS
Normalised
Serum leptin 0.74 ± 0.047 0.63 ± 0.049 0.69 ± 0.057 NS
concentration NS
(ng/ml per kg fat mass) N= n=45 n=27 n=4 NS
Table 5.6: Mean levels of BMI, fat mass, lean mass and serum leptin levels for each 
genotype of the TNF alpha G -308A SNP. P values were calculated by comparing 
non-carriage of the G allele (AA v GG/AG genotype groups), AA v GG and AA v AG 
genotype groups using a Mann-Whitney U test. 1 ± standard error of mean.
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TNF-a -308 Genotypes
Figure 5.9: Boxplots of BMI mass levels grouped to GG, AG and AA
genotypes of the TNF-a -308 SNP. There is no significant difference between
the mean of each groups.
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Figure 5.10: Boxplots of fat mass levels grouped to GG, AG and AA
genotypes of the TNF-a -308 SNP. There is no significant difference between
the mean of each groups.
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Figure 5.11: Boxplots of lean mass levels grouped to GG, AG and AA
genotypes of the TNF-a -308 SNP. There is no significant difference between
the mean of each groups.
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TNF-a -308 Genotypes
Figure 5.12: Boxplots of serum leptin levels grouped to GG, AG 
and AA genotypes of the TNF-a -308 SNP. There is no significant 
difference between the mean of each groups.
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Figure 5.13: Boxplots of normalised serum leptin levels grouped to GG, 
AG and AA genotypes of the TNF-a -308 SNP. There is no significant 
difference between the mean of each groups.
15<f
5.3.3 IL1RN VNTR
To determine allele and genotype frequencies, 100 subjects have been genotyped for 
the IL1RN VNTR polymorphism There have been 5 alleles reported for this 
polymorphism, each comprising a different number of the 86-bp core repeat sequence. 
In this study only the 2,4 and 5 repeat alleles were observed. The frequencies for the 3 
alleles are p =0.3, q = 0.67 and r = 0.03 respectively for the 2, 4 and 5 repeats. Due to 
the relative rarity of the 5 repeat allele, the 4 and 5 repeats are considered as one allele 
in order to simplify statistical analysis of the continuous variable data via a biallelic 
format. Furthermore, as this particular strategy has been repeatedly reported in the 
literature, table 5.7 presents comparisons of carriage of the IL1RN 2 repeat versus 
non-carriage between this study and published results. The distribution of genotypes 
observed does not differ from those predicted from a population in Hardy-Weinberg 
equilibrium (see table 5.5). The Mann-Whitney U test was used to compare the mean 
value for each variable between genotype groups (see table 5.6 and figures 5.14-.5.18)
Allele Postmenopausal 
Caucasian women 
This study
(n=100)
Healthy Japanese 
men and women 
Watanabee et al 
(2002)
n= 74
American male and 
female Caucasians 
with Type 2 diabetes 
Marculescu et al 
(2002) 
n=250
Healthy Czech male 
and female Caucasians 
Vencovsky et al 
(2001)
n=168
carriage of 2 
repeat
0.45 0.068 0.27 0.16
non carriage 
of 2 repeat
0.55 0.932 0.73 0.84
Table 5.7: Comparison of carriage versus non-carriage of the IL1RN 2 repeat allele between this study 
and published results.
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Observed genotype 
frequency
Expected genotype 
frequency
n n
Heterozygotes 2* 33 41
Homozygous 2,2 12 8
Homozygous *,* 55 51
Total 100 100
Table 5.8: Predicted genotype distribution obtained from t le Hardy-Weinberg equation
for the IL1RN VNTR in the study group using the determined allele frequencies. The 
p-value for the %2 analysis of comparison between the expected and observed genotype 
frequencies was 0.06 (degrees of freedom =1). Note that * represents the 4 or 5 
repeats placed into a single group.
Genotype P value
* * 5 2,* 2,2
(2,2 v *,*) NS
BMI (kg/m2) 25.92 ± 0.611 26.9 ±0.58 26.36 ±0.87 (2,2 v 2,*/ *,*) NS
N= n=54 n=31 n=12 (2,2 v 2,*) NS
NS
Fat mass (g) 25166 ±1334 27183 ±1395 28910± 1878 NS
N= n=46 n=28 n=ll NS
NS
Lean mass (g) 35253 ± 884 37425 ± 770 36416 ±787 NS
N= n=46 n=28 n=ll NS
Serum leptin 0.011
concentration 15.54 ±1.2 21.67 ±2.73 25.83 ± 4.2 0.02
(ng/ml) N= n=43 n=27 n=ll NS
Normalised 0.006
serum leptin 0.63 ±0.037 0.75 ± 0.066 0.86 ±0.091 0.02
(ng/ml per kg fat mass) N= n=40 n=27 n=10 NS
Table 5.9: Mean levels of BMI, fat mass, lean mass and serum leptin levels for 
each genotype of the IL1RN VNTR. P values were calculated by comparing non­
carriage of the * allele (2,2 v 2,* / *,* genotype groups), 2,2 v *,* and 2,2 v 2*  
genotype groups.
*=4 or 5 repeat. 1 ± standard error of mean
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Figure 5.14: Boxplots of BMI data grouped to ELRN VNTR genotypes.
* represents the 4 or 5 repeat allele. There is no significant difference 
between the mean of each groups.
O
— i--------------------------------------------------------------------------1----------------------------------------------------------------1—
12 31 54
2,2 2 *
IL1RN VNTR Genotypes
159
Fa
t 
ma
ss 
(g)
60000
50000 -
40000 -
30000 -
20000
10000 -
IL1RN VNTR Genotypes
Figure 5.15: Boxplots of fat mass levels grouped to ILRN VNTR 
genotypes. * represents the 4 or 5 repeat allele. There is no significant 
difference between the mean of each groups.
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Figure 5.16: Boxplots of lean mass levels grouped to ILRN VNTR 
genotypes. * represents the 4 or 5 repeat allele. There is no significant 
difference between the mean of each groups.
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Figure 5.17: Boxplots of serum leptin levels grouped to the ELRN VNTR 
genotypes. * represents the 4 or 5 repeat allele. Comparison of the mean levels 
between the *,* and the combined other 2 groups genotype reveals that the mean 
levels are significantly lower in the *,* group (p=0.02). Also, the mean level is 
lower in the *,* group compared to the 2,2 genotype group (p=0.0l 1).
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Figure 5.18: Boxplots of normalised serum leptin levels grouped to the ILRN VNTR 
genotypes. * represents the 4 or 5 repeat allele. Comparison of the mean levels 
between the *,* and the combined other 2 groups reveals that the mean levels are 
significantly lower in the *,* group (p=0.02). Also, the mean levels are lower in the 
*,* group compared to the 2,2 genotype group (p=0.006).
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5.4 Discussion
The genetic basis underpinning weight regulation has been gradually teased apart since 
breakthrough discoveries in the mid-nineties. It has become clear that obesity in 
humans is most likely polygenic in the majority of cases. With this in mind, the activity 
of different candidate susceptibility genes, other than those involved in the leptinergic 
system, are currently being investigated. Cytokines are relevant candidates due to the 
overlapping, integrated actions of these proteins.
In this study, polymorphisms in the TNF-a, IL1RN and LEP genes have been analysed 
in relation to markers of adiposity. Of the three genes studied, only the LEP -2548 
promoter SNP showed more than one association, with the A allele associated with 
lower mean BMI, normalised and actual leptin levels. Although fat mass is generally 
assumed to be a more accurate indicator of adiposity, individuals with the A allele did 
not have significantly lower levels although the levels were lower arithmetically. 
Furthermore, a larger data set were available for BMI than for fat mass perhaps 
making it more accurate overall.
Associations with this SNP have been observed before. Mammes and colleagues 
(1998) demonstrated that the A allele was associated with higher leptin levels in a 
mixed sex cohort.
Subsequent to this, Mammes and colleagues (2000) showed that the G allele was more 
frequent in overweight individuals in a case-control mixed sex association study. 
Furthermore, carriage of the G allele was associated with lower leptin levels in men 
from the cohort. The results from this present study suggest an opposite effect.
It agrees, however, with a study by Le Stunff and colleagues (2000) who observed that 
obese Caucasian girls of similar adiposity had lower leptin levels associated with
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carriage of the A allele. It is tempting to speculate that the agreement between this 
present study and that carried out by Le Stunff is perhaps partly due to to the limited 
affect of sex hormones in both studies. A substantial proportion from Le Stunffs study 
would have been prepubscent due to their age ( mean of 11.5 years ± 2.9 years 
standard deviation). In our study all women were postmenopausal. The menstrual 
cycle is associated with fluctuations in leptin levels (Hardie et al, 1997, Quinton et al, 
1999). For this reason, both studies may not be confounded by this variation unlike the 
studies carried out by Mammes and colleagues.
No associations were uncovered for the TNF-alpha G -308A SNP. However the SNP 
was worthy of investigation due to reported associations with obesity (Hoflstedt et 
al, 2000, Brand et al, 2001) and particularly with insulin resistance in obesity (Dalziel 
et al, 2002, Wybranska et al, 2003).
Reasons why no associations were discovered in this study could include the relatively 
small cohort size, and also the possibility that the penetrance of risk alleles depends 
upon the genetic background present in the study group. Also, the prevalence of an 
environmental risk factor may differ between different groups being studied, affecting 
any observations (or lack of). These differences may partly explain conflicting results 
from association studies.
With the IL1RN VNTR, individuals lacking the two repeat allele had significantly 
lower mean levels of actual and normalised serum leptin levels. Leptin induces IL-lra 
expression and secretion from monocytes (Gabay et al, 2001). Although no studies 
have been reported of IL-lra modulating leptin expression and secretion, a cross-talk 
system may be operating.
As no associations were detected for BMI or adiposity, this association does not 
appear to extend to adiposity. However, roles for leptin in infection and immunity have
become apparent. Leptin is generally proinflammatoiy in action inducing in vitro 
secretion of IFNy and IL-2 from stimulated T-cells in human peripheral or umbilical 
cord blood, which predictes a shift to a T helper 1 proinflammatoiy environment 
(Martin et al, 2000). In monocytes, leptin stimulates TNF-a, IL-6 and IFNy in resting 
or endotoxin-stimulated peripheral blood mononuclear cell cultures (Zarkesh et al., 
2001). Therefore an intrinsic relationship with IL-lra (a major anti-inflammatory 
cytokine) might be expected to balance Ieptin’s proinflammatoiy effects.
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Chapter 6 
Case-Control Association study of 
LEPR SNPs in 
Anorexia Nervosa
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6.1 Introduction
Although described since Roman times, the incidence of the eating disorder, anorexia 
nervosa (AN) has markedly increased over the past 50 years. Its causes include 
sociocultural influences, individual risks linked to subjection to abuse, as well as 
biochemical and genetic components.
The DSM-IV diagnostic criteria for AN include a maintained body weight of less than 
85% of normal for age and height, intense fear of fatness, disturbed experience of 
body weight or shape and amenorrhoea for at least 3 consecutive cycles. The disorder 
can be sub-divided into restriction of food intake or binge/purge endophenotypes.
AN has been shown to have a heritable component, with increased prevalence of eating 
disorders amongst relatives of probands compared to controls (Gershon et al, 1984 
and Walters et al, 1985). Furthermore, concordance rates between monozygotic twins 
with AN has been estimated to be between 52-56% (Treasure and Holland, 1994). 
These observations indicate a genetic component.
Although substantial research has been carried out on the effects of the leptin system 
on obesity, relatively little work has been concerned with leptin alterations in anorexic 
individuals. As part of the "adipostat", leptin maintains the body's adiposity by 
reducing feeding and increasing energy expenditure in response to food intake. Any 
modifications in the leptin system may contribute to anorexia.
Several lines of experimental evidence point to a potential role for the leptin system in 
AN. Mantzoros et al, (1997) showed that body fat was lower in long term recovered 
AN individuals suggestive of an underlying genetic factor controlling body fat in these 
people. Whilst during recovery, leptin levels progressively increase to reach higher 
than expected levels for the body weight (Hebebrand et al, 1997).
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Krizova et al (2002) observed that soluble leptin receptor levels in anorexic women 
were significantly higher compared to healthy female controls and were not affected 
when measured 6 weeks into partial re-feeding. Such apparent modifications compared 
to healthy individuals suggest the possibility of an etiological role for the leptin system 
(For review see Brichard et al, 2003). In a recent genome-wide linkage study using 
families of European ancestry, Grice et al (2002) detected an anorexia nervosa 
susceptibility locus using marker D1S3721. The marker has been mapped to lp34.2. 
The leptin receptor is a plausible candidate gene that has been mapped to lp31.2, some 
distance from that marker on the same chromosome arm
Of particular relevance to this study, Quinton et al (2001) demonstrated a decrease in 
BMI and fat mass associated with the extracellular domain GLN223ARG leptin 
receptor SNP in a population-based association study. An adenine to guanine DNA 
base change substitutes the amino acid arginine for glutamine. This suggests the 
potential for altered ligand binding dependent on which allelic form is expressed. 
Indeed, preliminary evidence of lowered ligand-binding with the 223ARG SNP has 
been presented elsewhere in this thesis (chapter 4, figure 4.13).
As this polymorphism is associated with a decrease in BMI, it is a good candidate to 
test in anorectic populations who, by definition, have lowered BMI and fat mass levels. 
Furthermore, linkage disequilibrium with nearby polymorphisms in the LEPR gene has 
been established, in a Caucasian cohort elsewhere in this thesis, between the 
LYS109ARG and GLN223ARG SNPs but neither in LD with LYS656ASN (chapter 
3, table 3.10). For completeness, the LYS109ARG and LYS656ASN SNPs have also 
been investigated to determine whether a nearby SNP is actually having an effect or 
whether specific haplotypes are associated with AN.
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6.1.1 Aims of the study
Three leptin receptor SNPs, LYS109ARG, GLN223ARG and LYS656ASN, were 
studied. The aims of this study include;
• genotyping of female anorexic subjects and healthy female controls for the three 
SNPs.
• to determine if allele and / or haplotype frequencies, for the three SNPs, differ 
between the anorexic and control cohorts, and also between specific anorexic 
subtypes and the control cohort.
6.2 Study Design
Blood samples were collected from a cohort of British Caucasian patients with AN.
All subjects provided informed consent and ethical approval was granted for the study. 
Purified genomic DNA obtained from the blood samples was available for 175 
unrelated Caucasian female AN subjects (DSM-IV criteria) who attended the 
Yorkshire Centre for Eating Disorders. A sub-set of the anorexic patients were 
classified into restricting (n=64) and binge/purge (n=77) sub-types with the remaining 
patients unable to be so categorised at the time of assesement. The mean age of 
diagnosis for the entire cohort was 18.1 years, with a minimum mean body mass index 
of 13.73 kg/m2 (BMI data provided is the lowest BMI recorded during treatment).
The control cohort contained 145 unrelated unaffected Caucasian females. The mean 
age of the females was 30.28 years with an average BMI of 22.02 kg / m2. The latter 
were screened for a personal or immediate family history of an eating disorder.
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6.2.1 Analysis
Genotyping was carried out using a PCR-RFLP method as described in chapter 2, 
section 2.2.1 and 2.2.2. Visualisation of alleles for the GLN223ARG SNP is shown in 
figure 6.1.
Cases and controls were compared to check for associations with susceptibility to AN 
per se, and binge/purge and restricting sub-types were compared for specific 
associations with these endophenotypes. The distribution of genotypes was tested for 
deviation from Hardy-Weinberg equilibrium by %2 analysis. Comparison of allele 
frequencies between groups was also tested by %2 analysis. The frequencies of specific 
haplotypes in the control and patient samples was calculated using the EH software 
program as was the assignment of haplotypes with unknown phase via a permutation 
function present in the program. The FAS TEH software was employed to obtain a p- 
value via the %2 statistic, comparing the distribution of haplotype frequencies between 
case and control individuals and between binge/purge and restricting anorexia 
endophenotypes.
6.3 Results
A total of 175 anorexic samples and 145 control samples were genotyped for the 
LYS109ARG, GLN223ARG and LYS656ASN SNPs in order to determine allele, 
genotype and frequencies. The calculated allele frequencies for the anorexic cohort are 
shown in tables 6.1-3 alongside other published allele frequencies. There is good 
agreement between the allele frequencies in this study and previous studies. The 
observed balance of homozygous and heterozygous genotypes for each of the three
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SNPs, in the case and control cohorts, did not differ significantly from that expected 
of a population in Hardy-Weinberg equilibrium (tables 6.4 and 6.5). The allele 
frequencies and carriage rates of the three SNPs for both the anorexic and control 
groups are shown in table 6.6. x2 analysis of 2x2 contingency tables comparing allele 
frequencies and carriage rates between the cases and controls for each of the SNPs did 
not highlight any significant difference in frequencies. Furthermore, subdivision of 
the case cohort into restricting and binge/purging groups (table 6.5) did not highlight 
any significant differences either.
The EH computer program calculated haplotype frequencies for case, control, 
binge/purge and restricting types (table 6.7). Comparison of haplotype frequencies 
between groups was analysed using a x2 statistic by the FASTEH program. A p-value 
of 0.70 was obtained when comparing case versus control haplotypes. A p-value of 
0.45 was obtained comparing binge/purge to restricting types. In both instances, 
therefore, there was no significant difference in haplotype frequencies.
A B C
603bp>
310bp->>
Figure 6.1: Photograph of the GLN223ARG SNP genotypes on a 2.5% agarose gel 
containing, A: (j)X 174 Hae IH DNA marker, B: Heterozygous AG genotype, C: 
Homozygous G genotype (294 and 157bp), and D: homozygous A genotype (421 bp)
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Allele Anorexic
women
(this study)
Lean British 
males 
(n=132) 
Gotoda et al, 
1997
Obese British 
males 
(n=190) 
Gotoda et al, 
1997
Caucasian 
males and females 
(n=190) 
Chagnon et al, 
2000
A 0.75 0.74 0.73 0.73
G 0.25 0.26 0.27 0.27
Table 6.1: Comparison of LYS109ARG a lele frequencies for the anorexic cohort
with published results. The allele frequencies for the control women are given in 
table 6.6
Allele Anorexic
women
(this study)
Lean British 
males 
(n=T 32) 
Gotoda etal, 
1997
Obese British 
males 
(n=190) 
Gotoda et al, 
1997
Caucasian 
males and females 
(n=190) 
Chagnon eta l, 
2000
A 0.6 0.57 0.56 0.54
G 0.4 0.43 0.44 0.46
Table 6.2: Comparison of GLN223ARG allele frequencies for the anorexic cohort 
with published results. The allele frequencies for the control women are given in table 6.6
Allele Anorexic
women
(this study)
Lean British 
males 
(n=132) 
Gotoda etal, 
1997
Obese British 
males 
(n=190) 
Gotoda et al, 
1997
Caucasian 
males 
(n=190) 
Chagnon eta l, 
2000
G 0.86 0.84 0.82 0.82
C 0.14 0.16 0.18 0.18
Table 6.3: Comparison of LYS656ASN allele frequencies for the anorexic cohort 
with published results. The allele frequencies for the control women are given in table 6.6
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Observed genotype frequency Expected genotype frequency
LYS109ARG n n
Heterozygotes 68 64
Homozygous A 96 98
Homozygous G 9 11
Total 173 173
GLN223ARG n n
Heterozygotes 81 84
Homozygous A 65 63
Homozygous G 29 28
Total 175 175
LYS656ASN n n
Heterozygotes 41 42
Homozygous G 128 128
Homozygous C 4 3
Total 173 173
Table 6.4: Predicted genotype distributions obtained from the Hardy-Weinberg equation 
for the LYS109ARG, GLN223ARG, and LYS656ASN SNPs in the anorexic cohort 
using the determined allele frequencies. The p-value for the x2 analysis of comparing the 
expected to the observed genotype frequencies was 0.49, 0.66 and 0.74 for the 
LYS109ARG, GLN223ARG and LYS656ASN SNPs respectively (calculated to 1 df). 
Note that the total number of genotypes for each SNP differ due to failure of PCR 
amplification for some samples.
Observed genotype frequency Expected genotype frequency
LYS109ARG n n
Heterozygotes 48 46
Homozygous A 72 73
Homozygous G 6 7
Total 126 126
GLN223ARG n n
Heterozygotes 70 72
Homozygous A 46 45
Homozygous G 29 28
Total 145 145
LYS656ASN n n
Heterozygotes 33 31
Homozygous G 90 91
Homozygous C 2 3
Total 125 125
Table 6.5: Predicted genotype distributions obtained from the Hardy-Weinberg equation 
for the LYS109ARG, GLN223ARG, and LYS656ASN SNPs in the control cohort 
using the determined allele frequencies. The p-value for the %2 analysis of comparing the 
expected to the observed genotype frequencies was 0.58, 0.8 and 0.6 for the 
LYS109ARG, GLN223ARG and LYS656ASN SNPs respectively (calculated to 1 df). 
Note that the total number of genotypes between SNPs (for each group) may 
differ due to failure of PCR amplification for some DNA samples.
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Anorexic Cohort
Codon 109 n = 173 223 n =  175 656 n =  173
Allele A G A G G C
Allele 0.75 0.25 0.60 0.40 0.86 0.14
frequency
Carriage 0.95 0.45 0.83 0.63 0.98 0.26
Rate
Bingeing / purging group
Codon 109 VOc-'-IIe 223 n = 75 656 n = 77
Allele A G A G G C
Allele 0.76 0.24 0.6 0.44 0.86 0.14
frequency
Carriage 0.93 0.41 0.83 0.63 0.97 0.25
Rate
Restricting group
Codon 109 n=  61 223 n = 64 656 n =  61
Allele A G A G G C
Allele 0.78 0.28 0.58 0.42 0.85 0.15
frequency
Carriage 0.95 0.51 0.83 0.67 0.97 0.26
Rate
Control Cohort
Codon 109 n =  126 223 n=  145 656 n =  129
Allele A G A G G C
Allele 0.76 0.24 0.56 0.44 0.85 0.15
frequency
Carriage 0.95 0.43 0.80 0.68 0.98 0.28
Rate
Table 6.6: Allele frequencies and carriage rates for the anorexic, restricting, 
bingeing/purging and control cohorts with three LEPR SNPs. Note that differences in 
the total number of genotypes between SNPs (for each group) differ due to 
failure of PCR amplification from some DNA samples. Also, not all anorexic 
individuals were able to be classified as bingeing or restricting at time of recruitment.
Haplotype
LYS109ARG GLN223ARG LYS656ASN
control
cohort
anorexic
cohort
Bingeing/
purging
anorexics
restricting
anorexics
A A G 0.46 0.45 0.46 0.43
A A C 0.10 0.07 0.07 0.06
A G G 0.21 0.20 0.20 0.22
A G C 0.03 0.02 0.05 0
G A G 0.05 0.04 0.05 0.04
G A C 0 0.03 0.03 0.04
G G G 0.13 0.16 0.14 0.18
G G C 0.02 0.02 0 0.03
Table 6.7: Haplotype frequencies estimated for control/anorexia groups and bingeing/purging 
groups.
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6.4 Discussion
To date, there have been no published studies investigating associations between SNPs in 
the LEPR gene and AN. There has been one published study which investigated a 
polymorphism (G -1387A) in the region upstream of the LEP gene by comparing allele 
frequencies for the SNP between individuals with AN and healthy underweight people. 
No associations were uncovered (Hinney et a l, 1998).
The results from this case-control study suggest that there is no association with the SNPs 
studied of the LEPR gene and the eating disorder, anorexia nervosa, as a whole or with its 
specific restricting and binge/purge sub-types.
The difference in allele frequencies between the anorexic and control groups is not 
significant, whilst the frequencies in both groups agree well with published data on 
Caucasians. Furthermore, there is no significant difference in haplotype frequencies 
between cases and control or binge/purge and restricting endophenotypes.
Previous studies have shown that polymorphisms in the LEPR gene are in linkage 
disequilibrium (Thompson et a l, 1997, Gotoda et al., 1997). If  the SNPs studied are in 
linkage disequilibrium then certain haplotypes may be associated with anorexia and 
heritable. However the EH and FASTEH computer programs did not detect any particular 
haplotype which is associated with anorexia nervosa as a whole or more specifically 
within the binge/purge or restricting sub-types.
Although the anorexic cohort has a mean lower BMI than the control group, there are no 
associations between anorexia and the GLN223ARG SNP. Unfortunately, individual 
BMI values were not available to enable BMI analysis per genotype group for the control 
and test cohorts respectively.
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An association was found between BMI and the GLN223ARG SNP in postmenopausal 
women (Quinton et a l , 2001). A specific lowered BMI in older aged individuals (middle- 
aged men only) has also been previously reported by Chagnon et al (2000).
Bearing this in mind, it is possible that the SNPs in the leptin receptor may predispose to 
lower BMI but that confounding hormonal factors present in young women and not 
present in postmenopausal women may mask this. This may be the case for both the 
control and anorexic individuals. Also to consider, is that although the mean BMI data 
was available for the control and anorexic groups, unfortunately individuals’ BMI values 
were not available for this study, which would have enabled analysis o f associations of 
BMI with a particular genotype in either the cases or control groups.
Several association studies have been conducted testing various candidate genes for AN. 
Some, including studies on the 5-hydroxytryptophan (serotonin) receptor, have generated 
associations (Nacmias et a l, 1999), whilst others have not (Hinney et a l, 1997 and 
Campbell et al, 1998). As such, at the biological level, variation in the leptin receptor 
gene may not predispose to anorexia. Considering the undoubtedly complex gene-gene 
and gene environment interactions involved in the disorder (probably more 
heterogeneous in nature than a quantitative trait such as lowered BMI), there is a distinct 
possibility that more than one particular genetic background may predispose to AN and 
that several of these will be present in a cohort of anorexic individuals. Because of this, 
the frequency of any one kind may be lower and less easily detected.
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7.1 Discussion
The basic aim of this study was to characterise and expand upon our knowledge of the 
genetic and functional features of the leptin receptor. Firstly, genetic association 
studies were undertaken to examine the effect of leptin receptor SNPs on markers of 
adiposity in a postmenopausal European Caucasian and also an anorexic cohort. To 
complement this, genetic studies were also carried out using other relevant cytokine 
gene polymorphisms (including a SNP in the LEP gene). Secondly, recombinant 
protein expression and in vitro functional characterisation of the leptin receptor was 
undertaken.
Leptin is a cytokine predominately secreted from adipose tissue but also by other 
tissues including the stomach (Bado et al, 1998), skeletal muscle (Wang et al, 1998) 
and the brain (Weisner et al, 1999). It exerts its effects by crossing the blood-brain 
barrier and binding to the leptin receptor in the hypothalamus. The leptin receptor is 
expressed in various tissues of the body, including the placenta (Akerman et al, 2002, 
Hauguel-de Mouzon, 2003) and skeletal muscle (Wang et al, 1998). However, 
initially it was located to the hypothalamus in the brain (Tartaglia et al, 1995). Indeed, 
although the known roles of both proteins has expanded since their discoveries to 
include involvement in processes as apparently diverse as reproduction and immunity, 
the majority of work to date has concentrated on elucidating their role in notifying the 
brain of the body's level of adiposity.
The hypothalamus is the structure in the brain that controls food intake, energy 
expenditure and, consequently, body mass. An increase in body fat raises serum leptin 
concentrations, which results in increased signalling of the long form of the receptor in
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the hypothalamus leading to downstream events that contribute to a reduction in food 
intake and increases in thermogenesis and physical activity. BMI and fat mass have a 
positive linear correlation with leptin levels. In obese individuals, leptin levels are 
(excessively) high, suggesting that, at the molecular level, leptin resistance may occur, 
possibly through the saturable nature of leptin transport into the brain (Banks et al, 
2000, Maness et al, 2000).
In humans, mutations that significantly disrupt these proteins and cause monogenic 
obesity have only been discovered in a handfiil of families (Montague et al, 1997b, 
Clement et al, 1998). However, multifactorial obesity influenced by a variety of 
genetic and environmental factors, appears much more prevalent. Several SNPs exist in 
the leptin and leptin receptor genes that may influence the level of protein expression 
or alternatively, alter functional characteristics including ligand binding, receptor 
dimerisation and downstream signalling events.
Using DNA from a cohort of postmenopausal Caucasian women (used to avoid 
confounding cyclic effects of reproductive hormones on serum leptin levels and LB A), 
the SNPs, LYS109ARG and LYS656ASN were examined to see whether any 
associations were observed with indicators of adiposity. Previous work on the 
GLN223ARG SNP highlighted associations with several indicators of adiposity in this 
cohort (Quinton et al, 2001). In the present study, The LYS109ARG SNP was 
associated with fat mass and BMI. Linkage disequilibrium calculations determined that 
the LYS109ARG and GLN223ARG SNPs were in linkage disequilibrium. As the 
GLN223ARG SNP is also associated (more strongly) with indicators of adiposity and 
the two SNPs are in linkage disequilibrium, then it remains uncertain if the two SNPs 
are having separate effects, perhaps of varying potency, or if only one SNP is having 
an effect. Furthermore, they could also mark a third functional site for which these
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SNPs are acting as LD markers. For example, a functional mutation might exist 
between the two SNPs in exon 5, although nothing has been found in this region to 
date. No significant associations were observed with the LYS656ASN SNP.
Another study has suggested that either of these SNPs may affect adiposity, with the 
GLN223ARG SNP associated with BMI and fat mass and the LYS109ARG SNP 
linked to BMI and fat mass (Chagnon et al, 2000). Also, several studies have not 
highlighted an association with any SNPs in the LEPR gene and adiposity (Echwald et 
al., 1997, Matsuoka eta l, 1997, Silver et a l , 1997). There are several reasons for the 
conflicting data. If more than one SNP is present over a relatively small genetic 
distance and linkage disequilibrium exists over that region, then it is difficult to 
ascertain which allele of which particular SNP may influence susceptibility. 
Furthermore, it is difficult to recruit genetically isolated populations. This would be 
beneficial because phenomena such as population sub-structure, whereby unrecognised 
combinations of distinct genetic populations (each having distinct allele frequencies at 
a particular loci) coexist in one larger population, are common. As a result, apparently 
significant differences in allele frequencies at candidate loci may be detected between 
population strata (e.g. between cases and controls) and a spurious association 
assigned. However recent investigations suggest that this may be a less relevant factor 
than has sometimes been suggested (Ardlie et al, 2002).
Linkage studies are an alternative genetic approach to circumvent this problem. Co­
segregation studies are carried out in families and consequently limit genetic 
heterogeneity. However, these studies have classically been used for monogenic 
disorders and may be more difficult to apply in multifactorial disorders where, for 
example, a proportion of the susceptibility is due to a frequent allele variant of small
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effect. Also, it is possible that different markers may be linked to the same condition in 
different families.
In the approach described in this thesis, association was sought in a normal population 
(not an obese cohort). To transform the study into a case-control study, allowing 
comparison of allele frequencies between cases and controls, individuals would need to 
be classified by, for example, BMI. Due to the limited overall numbers present in the 
cohort, the power would be reduced if they were split into case and control groups. 
Such classifications are, to some extent, arbitrary whereby certain individuals can be 
classified as case or control depending on which variable is chosen for classification 
purposes.
Associations may reflect linkage disequilibrium with nearby markers (e.g. other SNPs 
in LEPR or a nearby gene) or may indicate a direct functional effect on the protein 
product. Functional analysis of variant leptin receptor proteins including different 
combinations of amino acid variants could clarify the situation of the relative effects of 
SNPs in the LEPR gene. To our knowledge, no such studies have been published.
A set of soluble leptin receptor protein variants were constructed, expressed and 
purified, each comprising different combinations of the GLN223ARG and 
LYS109ARG alleles. These may allow comparative analysis of ligand binding (by the 
leptin-binding assay) that could measure potential functional differences between 
variants. The actual basis for any differences may stem from an altered conformation of 
the receptor that would change its ligand-binding characteristics or affect the ability of 
receptors to dimerise with each other (which might subsequently be represented in the 
ability to bind leptin). The soluble form of the receptor may have a role in the 
sequestration of circulating leptin (reducing the amount of available leptin and so
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reducing activity) and / or a role in protecting leptin from degradating enzymes whilst 
in the circulation (a positive role in prolonging activity). Consequently, differential 
leptin binding by the variant soluble receptors may influence either of these processes. 
It is not clear, however which of these roles the soluble receptor is involved in and as 
such any effects of the variant receptors should be considered in light of either 
scenario. Future studies could involve incubating leptin with different degradating 
enzymes in the presence (or absence) of soluble leptin receptor to determine if leptin 
protection is occurring.
It is also possible that the SNPs may alter the intrinsic signalling properties of the 
membrane bound receptor, as the extracellular domain is identical for these isoforms 
and the soluble form An example of this is the GLN269PRO mutation in the fa  rat 
(White et al, 1997). In this rodent model of obesity, the amino acid substitution in the 
extracellular domain of the receptor appears to induce a conformational change that 
mimics that achieved upon ligand binding and imparts constitutive activation of 
STAT1 and -3 specifically. Contrastingly, significant impairment of ligand-induced 
activation of STAT5B is also observed in the fa  rat. Which of these defects is 
responsible for the fa  rat phenotype remains to be resolved.
One possible strategy to be considered for future work would be to heterologously 
express the full-length receptor expressing different combinations of the SNPs. Then, 
upon leptin administration to the cells expressing the different membrane-bound 
variants, the cell supernatants could be harvested and levels of specific phosphorylated 
STATs and JAKs (known to be activated by leptin signalling) could be quantitatively 
compared between the different cell cultures by western blotting and / or flow 
cytometry to assess any possible signalling differences (measured by differences in the 
level of phosphorylated STATs and JAKs).
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The preliminary results presented in this thesis suggest reduced binding to the 223ARG 
variant compared with the 223GLN variant. This is surprising as the ARG223 variant 
is associated with lower BMI. It might be expected that individuals who express the 
223ARG variant would have greater binding, relative to the GLN variant, suggestive 
of an improved signalling response to leptin leading to lower BMI. However, it should 
be noted that the leptin binding data are presented in this thesis as only preliminary 
results, which would need to be repeated for verification. As the binding data does not 
readily explain the observed lower BMI in individuals expressing the 223ARG variant, 
then one explanation is that affinity of leptin for the leptin receptor is not a 
contributory factor towards obesity and that leptin resistance lies in downstream events 
such as the JAK-STAT pathway. However, the indication of altered binding between 
variants would be worth following up especially when obesity is likely to be 
multifactorial in the majority of cases involving a combination of various genes (with 
the added complexity that different combined gene effects may be causal in different 
obese people) each contributing modestly towards the obese state. In such a complex 
scenario, a simplistic hypothesis that greater binding to certain variants of the leptin 
receptor leads to lowered BMI may not hold true.
Considering the effects of the SNPs on the soluble receptor, reduced binding to the 
223ARG variant could cause a reduction in sequestering of leptin (allowing more£‘bio­
active” leptin to be available, potentially increasing activity), and may possibly explain 
the lower BMI associated with the 223ARG variant. However, if the same binding 
affinity is seen with the membrane-bound form then this might off-set the potential for 
increased activity from less sequestration, due to less active signalling.
Alternatively, reduced binding to the 223ARG variant would lead to a reduction in its 
ability to protect leptin from degradation. This negative effect would be mirrored with
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the membrane-bound form, where reduced binding would be assumed to lead to less 
activity. As a result of these combined effects, a higher BMI would be expected which 
is not what is observed from the results obtained in this thesis.
Regardless of the ambiguous results regarding leptin binding and measures of 
adiposity, it should be noted that in the obese human state, leptin is present in excess 
and so variation in leptin sequestration and / or degradation may be of moderate 
importance when leptin is present in excess. Alternatively, if leptin is binding the 
membrane-bound receptor at saturable levels, but with poorer avidity with certain 
variants, then variants that bind with greater avidity may have a more prominent 
biological effect compared to differences in sequestration or protection from 
degradation. However, there are a proportion of obese individuals who have relatively 
low leptin levels for their fat mass. In these situations, the effects may become more 
prominent (Maffei et al, 1996)
Future studies of these engineered proteins should involve quantitative kinetic analysis 
requiring incubating each variant with increasing concentrations of radioactive leptin 
and measuring the binding counts for each leptin concentration. This would enable 
dissociation constants to be calculated for each variant providing a more accurate 
comparison of binding between variants. If leptin receptor variants do indeed have 
functional differences, then this work has the potential to direct therapeutic regimes 
against body weight dysfunction via the Ieptinergic system Therapeutic drugs may be 
tailored towards a particular receptor variant providing a targeted approach depending 
upon an individuals SNP genotype at the LEPR locus. Whilst obese people have an 
excess of leptin, it is arguable that increasing affinity of the leptin receptor for leptin, in 
individuals with high circulating levels of leptin would have little benefit. In which 
case, drugs aimed at improving leptin binding may be more beneficial for individuals
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who are modestly overweight or in the case of obese individuals who have been shown 
to have relatively low leptin levels for their BMI (Maffei et al, 1996).
Unfortunately due to time constraints towards the end of these studies, the 
ARG109ARG223 construct was not tested for its leptin binding, which could have 
been used to determine if there was any additive effect of the 109ARG on 223ARG 
compared with the 109LYS223GLN variant. Also due to lack of time, the 
109ARG223ARG construct was not created (this could have determined the effect of 
the 109ARG variant on the GLN223 background). Both of these issues would need to 
be addressed in future studies.
The leptin receptor expressed in this study lacked the putative signal sequence of the 
receptor (Tartaglia et al, 1995). The protein product was only found in the cell lysate. 
However, the receptor was extensively glycosylated, which is surprising for a protein 
lacking the signal sequence. Cell biology dogma indicates that signal binding protein 
(SBP) binds to the signal sequence of the nascent protein and locates it to the ER and 
Golgi apparatus where post-translational modifications are incorporated. No obvious 
signalling or sorting sequences were located in the remaining protein sequence. A 
possible explanation is that novel sequences are present. Alternatively, as the overall 
protein yield was substantially lower than that expected for expression in COS-7 cells, 
it is possible that the majority of the nascent protein was degraded in proteosome 
organelles. Any residual protein (perhaps in excess to that which could effectively be 
degraded by proteosomes) might be forced down alternative trafficking pathways, 
including those which incorporate post-translational modifications. To explore the 
cellular activity of the variant proteins, specific antibodies could be concurrently
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directed towards the receptor and different sub-cellular structures of the transfected 
COS cells to determine the cellular locations and trafficking of the protein.
Cytokines are a group of proteins that have overlapping and redundant modes of 
activity as demonstrated by the same signalling pathways being activated by different 
cytokines and also the ability of certain cytokines to signal via more than one receptor 
complex (see Paul, 1989 and Leonard, 1994 for review). In such a balanced, 
interconnected system, any cytokines that may be affected by, or affect leptin may in 
turn influence adiposity. For these reasons and the unique qualities of our post­
menopausal study cohort, investigation of SNPs in genes apart from LEPR was 
conducted. The obvious candidate to complement studies of the leptin receptor is the 
LEP gene. Of several SNPs that have been located in the leptin gene, the -2548 LEP 
promoter SNP has been associated with obesity in more than one study (Mammes et 
al, 1998, Li et al, 1999, Mammes et al., 2000). In this thesis, the results indicate that 
individuals homozygous for the A allele have lower mean leptin levels and BMI. This 
contradicts results from studies that suggest that the G allele is associated with lower 
leptin levels and BMI (Mammes et al, 1998, Mammes et a l, 2000). However it agrees 
with data from a study by Le Stunff and colleagues (2000) who observed that 
Caucasian obese girls of similar adiposity had lower leptin levels if they carried the A 
allele. Postmenopausal women and (a substantial proportion) of the young girls do not 
undergo menstruation. It is possible that the lack of hormonal variation associated with 
absence of menses present in these two groups could explain their similar outcomes. 
TNF-alpha is a pro-inflammatory cytokine. No significant associations were found 
between the -308 TNF alpha SNP and indicators of adiposity. However, associations 
have previously been reported with this SNP and obesity (Fernandez-Real et a l, 1997,
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Hofstedt et al, 2000, Brand et a l, 2001), as has lack of association (Waltson et al, 
1999, da Silva et al, 2000). The SNP may be exerting a biological effect that is 
clinically evident in some populations and not others due to additional factors present 
or absent in each population (e.g. differences in diet). Also to consider is the small size 
of the cohort that is being analysed and what affect this has on highlighting any 
associations. Clearly, the larger the study group, the more powerful the statistical 
analyses, and some associations that are seen as significant with smaller cohorts 
become non-significant with larger groups.
IL-lra is an important anti-inflammatory molecule that functions by competitively 
inhibiting IL-1 binding to receptors. IL-lra is produced in excess in many human 
chronic inflammatory and autoimmune diseases (Tarlow et a l, 1994, Blakemore et al, 
1994, Mansfield et al, 1994). This activity may not immediately suggest a role in 
obesity, via the leptinergic system However, Luheshi and colleagues (1997) 
demonstrated that IL-1 mediates leptin's actions on food intake and that injection of 
IL-lra into the cerebral ventricles of mice inhibited leptin-induced reduction in food 
intake. Also, IL-lra serum levels are increased in human obesity (Meier et a l, 2002) 
and positively correlated with leptin levels.
A two repeat allele of a VNTR polymorphism located within intron 2 of the IL1RN 
gene is associated with a variety of diseases (Blakemore et a l, 1994, Mansfield et al,
1994). This polymorphism was studied in the cohort of postmenopausal women, and 
although no associations were observed with markers of adiposity, the polymorphism 
was highly significantly associated with leptin levels.
It is tempting to speculate from these results that the response of IL-lra to leptin is 
modulated depending upon which VNTR alleles are present and that feedback 
mechanisms may subsequently alter leptin levels accordingly. Unfortunately, serum
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measurements for IL-lra were not available from this study to determine whether they 
correlated with the VNTR alleles. As no associations were seen with indicators such as 
BMI and fat mass, the association with leptin levels may be related to leptin's activity, 
in peripheral tissues, in inflammation and immunity processes (Heymsfield et a l, 1999, 
Zarkesh et al, 2001, Lord et a l, 2002). As IL-lra is implicitly involved with 
inflammatory responses and autoimmune activities then suggested processes stand out 
and the observed association may well be recording the interaction between IL-lra and 
leptin in these activities.
Clearly physiological homeostasis is affected by a lack of nutritional intake as well as 
an excess. At the opposite end of the body weight spectrum to obesity are the eating 
disorders, in particular anorexia nervosa, where in the worst cases the effects of 
starvation can lead to death. Characterised by emotional and physiological disturbances 
based around obsessionality and an altered objectivity of ones self, there is debate 
concerning the degree to which genetics predisposes to AN. Twin studies have 
provided conflicting results with one study indicating concordance, for anorexia, of 
about 67% between monozygotic twins (Holland and Treasure, 1989) and yet a higher 
concordance rate amongst dizygotic twins in another study (Walters and Kendler,
1995). Clearly, a higher concordance rate would be expected amongst monozygotic 
twins if a genetic predisposition were present. However, an equal shared environment 
(e.g. co-socialisation in adolescence) for twins, is an assumption in heritability 
estimates and may confound the results depending upon how accurate the assumption 
is. Nevertheless, AN clusters in families (Strober et a l, 1999) and although research is 
at an earlier stage than that devoted towards obesity, it is expanding rapidly.
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Whilst fewer animal models of anorexia exist than models of obesity, the amc mouse 
model is the primary example, which suffers from starvation and motor disturbances 
and has an altered distribution of NPY in the arcuate nucleus of the hypothalamus 
(Brobergeref <2/., 1997).
Several association studies in humans have looked at candidate genes which may be 
involved in anorexia, such as the 5-hydroxy tryptophan (serotonin) transporter gene 
and the estrogen receptor 2 gene, and have had varying results. For example, studies of 
the 5-hydroxy tryptophan transporter gene have reported both positive (Nacmias et al, 
1999) and negative associations (Hinney et al, 1997 and Campbell et a l, 1998). 
Groups have recorded lower leptin levels (Hebebrand et al, 1997) and increased 
leptin receptor levels (Krizova et a l, 2002) in anorexic individuals, compared to 
controls, which is maintained even after weight restoration suggesting an underlying 
biological dysregulation of the leptinergic system.
As recognised in this and other studies, alleles of SNPs in the leptin receptor are 
associated with variations in adiposity. When a particular allele is associated with 
lowered levels of fat mass or BMI, then a hypothesis is that anorexic populations, who 
by definition have very low measurements of adiposity, may have an increased 
prevalence of that allele. To our knowledge, no published studies have tested this 
hypothesis. A case-control association study was therefore undertaken to test the 
hypothesis. No statistically significant differences were observed between anorexics 
and controls, in allele frequencies for the LYS109ARG, GLN223ARG and 
LYS656ASN SNPs or a particular haplotype composed of alleles from these SNPs. 
With the potentially more pronounced emotional disturbances that afflict sufferers with 
eating disorders like AN, compared to obesity, the lack of an association with SNPs in 
the leptin receptor, which are perhaps too simplistically associated with measurements
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of adiposity alone, may be obvious. However, it should be acknowledged that the 
prevalence of an environmental risk factor for the disorder might differ between 
populations, leaving the door open to investigate other anorexic populations.
Future studies may employ a transmission disequilibrium test (TDT) whereby the 
frequency at which a candidate susceptibility gene is transmitted from parents to an 
affected sibling, is compared to transmission to non-affected offspring. This procedure 
circumvents the problem of population admixture or the need to provide control 
samples that are practically inpossible to match perfectly for all criteria wished for. 
The TDT approach was recently applied to polymorphisms in the 5-HT2A receptor 
with results suggesting no association with AN (Gorwood et a l, 2002).
If a genotype-phenotype correlation were detected from complementary genetic and 
functional studies as discussed in this thesis, it would be a significant achievement to 
tailor therapeutic regimes based on an individual’s SNP profile. This approach could be 
directed towards a whole range of conditions with a genetic component. As 
institutions grasp the exciting possibilities that should emanate from this area of 
research they are setting up large scale ‘biobank’ sample facilities (such as the 
Wellcome trust/ UK government initiative to collect DNA samples from 500,000 
people) that might give sufficient power to elucidate the genetic basis of complex 
diseases. The potential to unravel complex disease and develop new drugs as a result, 
leading to an improvement in the welfare of the sufferers, and the reduction in the 
health cost burden would be considerable.
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